Atlas · 1,116 treatments

Cancer treatments A to Z

Approved and investigational cancer drugs and modalities: what each one is and how it works, in a sentence or two.

Search treatments in the Atlas All 19,500+ records

A

A166phase-3: A166 is an experimental antibody-drug conjugate from Sichuan Kelun-Biotech Biopharmaceutical in phase 3 trials for HER2-positive breast cancer, aimed at HER2.Open in Atlas onco.cc
AAA817phase-3: AAA817 is an experimental radioligand therapy from Novartis Pharmaceuticals in phase 3 trials for prostate cancer, aimed at PSMA.Open in Atlas onco.cc
Abarelixwithdrawn: Abarelix was the first GnRH antagonist for prostate cancer, approved in the United States in 2003 for men who could not take agonists, but allergic reactions restricted it and it was withdrawn from the US market in 2005; it remained available in Germany.Open in Atlas onco.cc
ABBV-706phase-3: ABBV-706 is an experimental antibody-drug conjugate from AbbVie in phase 3 trials for non-small-cell lung cancer, with its target not yet stated publicly.Open in Atlas onco.cc
Abemaciclibapproved: Abemaciclib was the first CDK4/6 inhibitor approved after surgery for high-risk hormone-positive breast cancer.Open in Atlas onco.cc
Abexinostatphase-3: Abexinostat is an experimental small-molecule drug from Xynomic Pharmaceuticals in phase 3 trials for renal cell carcinoma, diffuse large B-cell lymphoma and follicular lymphoma, with its target not yet stated publicly.Open in Atlas onco.cc
Abiraterone acetateapproved: Abiraterone is a pill that shuts down testosterone production everywhere, including inside the tumour. Discovered at the Institute of Cancer Research, now generic and used from the first metastatic diagnosis.Open in Atlas onco.cc
ABSK061phase-2: ABSK061 is an experimental small-molecule drug from Abbisko Therapeutics in phase 2 trials for gastric & gastro-oesophageal junction cancer, bladder & urothelial cancer and non-small-cell lung cancer, aimed at HER2 and FGFR2.Open in Atlas onco.cc
ABT-301phase-2: ABT-301 is an experimental small-molecule drug from Anbogen Therapeutics in phase 2 trials for colorectal cancer, aimed at Histone deacetylases (HDAC).Open in Atlas onco.cc
Acalabrutinibapproved: Acalabrutinib is a cleaner BTK blocker with fewer heart and bleeding problems than ibrutinib. In February 2026 it became half of the first all-oral, fixed-duration CLL regimen.Open in Atlas onco.cc
Acasunlimabphase-3: Acasunlimab is an experimental bispecific antibody from Genmab in phase 3 trials for non-small-cell lung cancer, aimed at PD-L1.Open in Atlas onco.cc
Acitretinapproved: Acitretin is a vitamin A tablet licensed for severe psoriasis. In people who have had an organ transplant and keep developing skin cancers, it reduces the number of new squamous cell carcinomas while it is taken.Open in Atlas onco.cc
Actinium-225 DOTATATEphase-3: An alpha-particle version of Lutathera for neuroendocrine tumours that have stopped responding to the beta version.Open in Atlas onco.cc
Actinium-225 PSMA agentsphase-3: Alpha-emitting PSMA drugs that produce responses even after Pluvicto fails, held back mainly by isotope supply.Open in Atlas onco.cc
Adagloxad simoleninphase-3: Adagloxad simolenin is OBI Pharma's vaccine against the tumour sugar Globo H, in the phase 3 GLORIA trial as adjuvant treatment for triple-negative breast cancer that expresses the antigen.Open in Atlas onco.cc
Adagrasibapproved: Adagrasib was the second KRAS G12C inhibitor, with a long half-life and brain penetration, and is approved in lung and colorectal cancer.Open in Atlas onco.cc
Adavosertibphase-2: Adavosertib is an oral serine/threonine kinase inhibitor from AstraZeneca, in registered phase 2 trials for triple-negative breast cancer.Open in Atlas onco.cc
Adebrelimabapproved: Adebrelimab is Hengrui's PD-L1 antibody, approved in China for first-line extensive-stage small cell lung cancer on the CAPSTONE-1 trial.Open in Atlas onco.cc
ADG126phase-2: ADG126 is an experimental monoclonal antibody from Adagene in phase 2 trials for hepatocellular carcinoma, aimed at CTLA-4.Open in Atlas onco.cc
ADI-270phase-2: ADI-270 is an experimental CAR-T cell therapy from Adicet Therapeutics in phase 2 trials for renal cell carcinoma, aimed at CD70.Open in Atlas onco.cc
ADI-PEG20phase-3: ADI-PEG20 is an experimental investigational agent whose form is not stated in the registry from Polaris in phase 3 trials for hepatocellular carcinoma, with its target not yet stated publicly.Open in Atlas onco.cc
ADU-S100 (MIW815)withdrawn: ADU-S100 was the first STING agonist in the clinic. Injected directly into tumours, it produced almost no responses, alone or with checkpoint blockade.Open in Atlas onco.cc
Afamitresgene autoleucelapproved: Afamitresgene autoleucel was the first engineered T-cell receptor therapy approved for a solid tumour, synovial sarcoma.Open in Atlas onco.cc
Afatinibapproved: Afatinib (Gilotrif) is a second-generation pill that binds EGFR, HER2 and HER4 irreversibly, approved in 2013 for EGFR-mutant lung cancer. Its lasting value is activity against the uncommon EGFR mutations G719X, L861Q and S768I, approved in 2018, because os...Open in Atlas onco.cc
Afirma Genomic Sequencing Classifierestablished: A gene test on the needle sample from a thyroid lump that can safely call an 'uncertain' result benign and spare an operation.Open in Atlas onco.cc
Aglatimagene besadenovecphase-3: Aglatimagene besadenovec is an experimental gene therapy from Candel Therapeutics in phase 3 trials for non-small-cell lung cancer and prostate cancer, with its target not yet stated publicly.Open in Atlas onco.cc
AI-081phase-2: AI-081 is an experimental bispecific antibody from OncoC4 in phase 2 trials, aimed at PD-1 and VEGF / VEGFR.Open in Atlas onco.cc
AK117phase-3: AK117 is an experimental investigational agent whose form is not stated in the registry from Akeso in phase 3 trials for head and neck squamous cell carcinoma, colorectal cancer and non-small-cell lung cancer, with its target not yet stated publicly.Open in Atlas onco.cc
AK119phase-2: AK119 is an experimental monoclonal antibody from Akeso in phase 2 trials for colorectal cancer, aimed at CD73 / adenosine axis.Open in Atlas onco.cc
AK146D1phase-1: AK146D1 is Akeso's Nectin-4 × TROP2 bispecific ADC, combining the two most validated ADC addresses in one molecule.Open in Atlas onco.cc
AL2846phase-3: AL2846 is an experimental small-molecule drug from Chia Tai Tianqing Pharmaceutical in phase 3 trials for thyroid cancer, aimed at MET and RET.Open in Atlas onco.cc
AL8326phase-3: AL8326 is an experimental small-molecule drug from Advenchen Pharmaceuticals in phase 3 trials for small-cell lung cancer, non-small-cell lung cancer and renal cell carcinoma, with its target not yet stated publicly.Open in Atlas onco.cc
Aldesleukin (high-dose IL-2)approved: High-dose interleukin-2 was the first immunotherapy to cure a small fraction of patients with metastatic melanoma and kidney cancer, at the cost of ICU-level toxicity; today it mainly supports TIL therapy.Open in Atlas onco.cc
Aldoxorubicinphase-3: Aldoxorubicin is doxorubicin, the workhorse chemotherapy nicknamed the red devil, attached to a linker that hitches it to the body's own albumin so more reaches the tumour and less reaches the heart; it beat doxorubicin in a randomised phase 2 sarcoma trial...Open in Atlas onco.cc
Alectinibapproved: Alectinib is a well-tolerated ALK pill, standard first line for years and, since 2024, the first targeted therapy given after surgery for ALK-positive lung cancer.Open in Atlas onco.cc
Alemtuzumabapproved: Alemtuzumab (Campath) is an antibody that wipes out lymphocytes carrying the CD52 marker. It is approved for chronic lymphocytic leukaemia and is supplied in the US through a restricted distribution programme.Open in Atlas onco.cc
Algenpantucel-Lnegative: Algenpantucel-L was a whole-cell pancreatic cancer vaccine given after surgery; the phase 3 IMPRESS trial showed no survival benefit.Open in Atlas onco.cc
Alisertibphase-2: Alisertib is an oral serine/threonine kinase inhibitor from Puma Biotechnology, Inc., in registered phase 2 trials for small-cell lung cancer.Open in Atlas onco.cc
Alitretinoinestablished: Alitretinoin gel is a vitamin A derivative applied directly to Kaposi sarcoma skin lesions in people with AIDS, approved in the United States in 1999 as the first topical treatment for the disease.Open in Atlas onco.cc
ALLO-647phase-2: ALLO-647 is an experimental monoclonal antibody from Allogene Therapeutics in phase 2 trials for diffuse large B-cell lymphoma, aimed at CD52.Open in Atlas onco.cc
Allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldqapproved: Tregzi, formerly Orca-T, is a donor stem cell transplant sorted with high precision and given with regulatory T cells, so that patients with blood cancers keep the graft's anti-cancer effect while being protected from chronic graft-versus-host disease. The...Open in Atlas onco.cc
Alpelisibapproved: Alpelisib was the first PI3K drug for PIK3CA-mutant breast cancer (2019). It is effective, but high blood sugar and rash limited its use, and newer drugs are displacing it.Open in Atlas onco.cc
Altretamineestablished: Altretamine is an oral chemotherapy tablet approved in 1990 as a single agent for ovarian cancer that has persisted or come back after platinum-based treatment, now rarely used.Open in Atlas onco.cc
Amifostineapproved: Amifostine (Ethyol) is an infusion given just before chemotherapy or radiotherapy to shield the kidneys from cisplatin and the salivary glands from radiation, reducing dry mouth after head and neck treatment.Open in Atlas onco.cc
Aminoglutethimidehistoric: Aminoglutethimide produced a medical adrenalectomy for advanced breast and prostate cancer in the 1970s and 1980s, the ancestor of today's aromatase inhibitors, and was withdrawn once selective drugs arrived.Open in Atlas onco.cc
Aminolevulinic acid (topical, for photodynamic therapy)approved: Aminolevulinic acid is painted on sun-damaged skin and then activated with a lamp, destroying actinic keratoses before they can become skin cancer; in Europe the gel is also approved for superficial basal cell carcinoma.Open in Atlas onco.cc
Aminopterinhistoric: Aminopterin was the first drug to send childhood leukaemia into remission. In 1948 Sidney Farber reported temporary remissions in children with acute leukaemia, the birth of cancer chemotherapy; its safer cousin methotrexate replaced it within a decade.Open in Atlas onco.cc
Amivantamabapproved: A two-armed antibody that blocks EGFR and its escape partner MET, now first-line for EGFR-mutant lung cancer with lazertinib.Open in Atlas onco.cc
AMO959phase-2: AMO959 is a small-molecule inhibitor from Novartis Pharmaceuticals, in registered phase 2 trials for prostate cancer.Open in Atlas onco.cc
Amrubicinestablished: Amrubicin is a Japanese anthracycline approved there in 2002 for small cell and non-small cell lung cancer, a standard second-line option for small cell lung cancer in Japan that failed to beat topotecan in a Western phase 3 trial and now serves as the comp...Open in Atlas onco.cc
Amsacrineestablished: Amsacrine is an intravenous leukaemia drug, approved in Europe, Canada and Australia in the 1980s, used mainly for acute myeloid leukaemia that has relapsed or resisted anthracycline-based treatment.Open in Atlas onco.cc
AMT-116phase-2: AMT-116 is an antibody-drug conjugate from Multitude Therapeutics Inc., in registered phase 2 trials for non-small-cell lung cancer, small-cell lung cancer.Open in Atlas onco.cc
Anagrelideapproved: Anagrelide (Agrylin) is a capsule that lowers dangerously high platelet counts in essential thrombocythaemia and other myeloproliferative neoplasms, reducing the risk of clots and bleeding.Open in Atlas onco.cc
Anastrozoleapproved: Anastrozole is a daily tablet that stops the body making oestrogen after the menopause. It treats and prevents hormone-receptor-positive breast cancer and is an alternative to tamoxifen after surgery for ductal carcinoma in situ.Open in Atlas onco.cc
Anetumab ravtansinenegative: Anetumab ravtansine was the first antibody-drug conjugate tested in a randomised trial in mesothelioma, aimed at the mesothelin protein that nearly all mesotheliomas carry; it was no better than vinorelbine chemotherapy as second-line treatment, and is now...Open in Atlas onco.cc
Anitocabtagene autoleucelphase-3: Anitocabtagene autoleucel is a BCMA CAR-T whose binder is a small synthetic D-domain protein rather than an antibody fragment, a design chosen for low immunogenicity. In heavily pretreated myeloma it produced responses in 97% of patients with mostly low-gra...Open in Atlas onco.cc
Anlotinibapproved: Anlotinib is one of the most used cancer pills in China, first approved for lung cancer after other treatments have failed and then for several rarer tumours.Open in Atlas onco.cc
Anvumetostatphase-2: Anvumetostat is an experimental small-molecule drug from Amgen in phase 2 trials for non-small-cell lung cancer, aimed at PRMT5 (MTAP-deleted cancers).Open in Atlas onco.cc
Apalutamideapproved: An AR blocker approved for prostate cancer that has spread and for high-risk disease before it shows on scans.Open in Atlas onco.cc
Aprepitant (and fosaprepitant)approved: Aprepitant (Emend) was the first of a new class of anti-sickness drugs. Taken with a 5-HT3 blocker and dexamethasone, it prevents the delayed nausea and vomiting that follow strongly emetogenic chemotherapy such as cisplatin.Open in Atlas onco.cc
ARD103phase-2: ARD103 is a car-t cell therapy from ARCE Therapeutics, Inc., in registered phase 2 trials for acute myeloid leukaemia, myelodysplastic syndromes / neoplasms.Open in Atlas onco.cc
Arlocabtagene Autoleucelphase-3: Arlocabtagene Autoleucel is an experimental CAR-T cell therapy from Juno Therapeutics, a Bristol-Myers Squibb in phase 3 trials for multiple myeloma, aimed at GPRC5D.Open in Atlas onco.cc
Arsenic trioxideapproved: An ancient poison turned cure: with retinoic acid it cures more than 95% of acute promyelocytic leukaemia without conventional chemotherapy.Open in Atlas onco.cc
ArteraAI Breastapproved: An FDA-cleared AI test (May 2026) that reads breast cancer slides to estimate recurrence risk in early hormone-positive disease.Open in Atlas onco.cc
ArteraAI Prostateapproved: The first AI tool cleared by the FDA to predict both prognosis and treatment benefit from a routine biopsy slide, in prostate cancer.Open in Atlas onco.cc
ARX788phase-3: ARX788 is a HER2 ADC with a precisely placed, non-cleavable payload that beat lapatinib-capecitabine in China and showed activity in brain metastases.Open in Atlas onco.cc
ASC40phase-3: ASC40 is an experimental small-molecule drug from Ascletis Pharmaceuticals in phase 3 trials for glioma & glioblastoma, with its target not yet stated publicly.Open in Atlas onco.cc
Asciminibapproved: Asciminib is a BCR::ABL1 blocker that binds a different pocket from every other TKI, approved for all newly diagnosed chronic myeloid leukaemia in 2024 and now being tested in Ph-positive ALL.Open in Atlas onco.cc
ASP2138phase-3: ASP2138 is an experimental bispecific antibody from Astellas Pharma Global Development in phase 3 trials for gastric & gastro-oesophageal junction cancer, aimed at Claudin 18.2 and CD3.Open in Atlas onco.cc
ASP2998phase-1: An experimental drug that uses an antibody to deliver a cancer-killing drug and an immune activator to cells carrying TROP2. An early human study is recruiting; benefit and safety are still being tested.Open in Atlas onco.cc
Asparaginase (pegaspargase, calaspargase pegol, Erwinia asparaginase)approved: An enzyme that starves leukaemia cells of an amino acid they cannot make; a mainstay of childhood ALL therapy for 50 years, with new versions solving allergy and supply problems.Open in Atlas onco.cc
Aspirinestablished: Aspirin is not a cancer drug but sits in cancer care in two places: low doses prevent clots in polycythaemia vera and essential thrombocythaemia, and long-term use lowers colorectal cancer in people with Lynch syndrome, while a trial in the healthy elderly...Open in Atlas onco.cc
AT101phase-2: AT101 is an experimental CAR-T cell therapy from AbClon in phase 2 trials for hodgkin lymphoma, aimed at CD19.Open in Atlas onco.cc
Atebimetinibphase-3: Atebimetinib is an experimental small-molecule drug from Immuneering in phase 3 trials for pancreatic ductal adenocarcinoma, aimed at MEK1/2.Open in Atlas onco.cc
Atezolizumabapproved: A PD-L1 blocker used in lung, liver, and bladder cancer. In 2026 it became the first drug approved based on a blood test showing leftover cancer after bladder surgery.Open in Atlas onco.cc
Atigotatugphase-3: Atigotatug is an experimental monoclonal antibody from Bristol-Myers Squibb in phase 3 trials for non-small-cell lung cancer, with its target not yet stated publicly.Open in Atlas onco.cc
Atirmociclibphase-3: A next-generation pill that blocks only CDK4, not CDK6, to keep the benefit of today's drugs without the low blood counts.Open in Atlas onco.cc
Atrasentanwithdrawn: The other endothelin blocker. Adding it to chemotherapy for advanced prostate cancer changed nothing, and the trial was stopped for futility.Open in Atlas onco.cc
AU-007phase-2: AU-007 is a monoclonal antibody from Aulos Bioscience, Inc., in registered phase 2 trials for metastatic cancer, melanoma, non-small-cell lung cancer.Open in Atlas onco.cc
Aumolertinibapproved: Aumolertinib is Hansoh's third-generation lung cancer pill, the first China-developed drug of its class, approved for first-line EGFR-mutant lung cancer on the AENEAS trial.Open in Atlas onco.cc
Autogene cevumeranphase-2: Autogene cevumeran is BioNTech and Genentech's personalised mRNA vaccine encoding each patient's own tumour neoantigens. In a small phase 1 in resected pancreatic cancer, half of patients mounted T-cell responses and stayed free of recurrence far longer; ph...Open in Atlas onco.cc
Avapritinibapproved: Avapritinib is the first drug for GIST driven by the PDGFRA D842V mutation, which resists every other kinase inhibitor; it is also approved for systemic mastocytosis.Open in Atlas onco.cc
Avasopasem manganesephase-3: Avasopasem is Galera Therapeutics' radioprotector for the severe mouth ulcers of head and neck chemoradiation; its phase 3 trial met its main goal but the FDA asked for another study in 2023.Open in Atlas onco.cc
Avelumabapproved: Avelumab is a PD-L1 blocker given as maintenance after chemotherapy for advanced bladder cancer, which lengthened survival by about seven months.Open in Atlas onco.cc
Avutometinib + defactinibapproved: Avutometinib plus defactinib is the first treatment approved specifically for low-grade serous ovarian cancer, a slow-growing type driven by the RAS pathway.Open in Atlas onco.cc
AVZO-021phase-2: AVZO-021 is an experimental small-molecule drug from Avenzo Therapeutics in phase 2 trials for HR-positive / HER2-negative breast cancer, ovarian cancer and endometrial cancer, aimed at HER2.Open in Atlas onco.cc
AVZO-023phase-2: AVZO-023 is a small-molecule inhibitor from Avenzo Therapeutics, Inc., in registered phase 2 trials for metastatic cancer.Open in Atlas onco.cc
AVZO-103phase-1: AVZO-103 is an experimental antibody-drug conjugate being studied in people with advanced cancer. Its benefit and safety are still being evaluated.Open in Atlas onco.cc
Axatilimabapproved: Axatilimab targets an immune-cell signal used by macrophages. It is approved for chronic graft-versus-host disease and is being tested with olaparib in advanced breast cancer.Open in Atlas onco.cc
Axicabtagene ciloleucelapproved: A CD19 CAR-T that cures about 40% of patients with large B-cell lymphoma who had failed everything, and beat transplant in second line.Open in Atlas onco.cc
Axitinibapproved: Axitinib is a selective VEGF-receptor pill, now given mainly with pembrolizumab or avelumab as first-line kidney cancer treatment.Open in Atlas onco.cc
Azacitidineapproved: A gentle chemotherapy that switches silenced genes back on. With venetoclax it became the standard for older people with AML who cannot take intensive treatment.Open in Atlas onco.cc
AZD0120phase-3: AZD0120 is a car-t cell therapy from AstraZeneca, in registered phase 3 trials for multiple myeloma.Open in Atlas onco.cc
AZD0486phase-3: AZD0486 is an experimental bispecific antibody from AstraZeneca in phase 3 trials for diffuse large B-cell lymphoma, aimed at CD19 and CD3.Open in Atlas onco.cc
AZD3470phase-2: AZD3470 is an experimental small-molecule drug from AstraZeneca in phase 2 trials for hodgkin lymphoma and peripheral T-cell lymphomas, aimed at PRMT5 (MTAP-deleted cancers).Open in Atlas onco.cc
AZD4045phase-2: AZD4045 is an experimental CAR-T cell therapy from AstraZeneca in phase 2 trials for multiple myeloma, aimed at BCMA.Open in Atlas onco.cc
AZD4360phase-2: AZD4360 is an experimental antibody-drug conjugate from AstraZeneca in phase 2 trials for gastric & gastro-oesophageal junction cancer, biliary tract cancer and pancreatic ductal adenocarcinoma, aimed at Claudin 18.2.Open in Atlas onco.cc
AZD4512phase-2: AZD4512 is an experimental antibody-drug conjugate from AstraZeneca in phase 2 trials for hodgkin lymphoma, aimed at CD22.Open in Atlas onco.cc
AZD5335phase-3: AZD5335 is an experimental antibody-drug conjugate from AstraZeneca in phase 3 trials for ovarian cancer, with its target not yet stated publicly.Open in Atlas onco.cc
AZD5492phase-2: AZD5492 is an experimental T-cell engager from AstraZeneca in phase 2 trials, aimed at CD20.Open in Atlas onco.cc
AZD5863phase-2: AZD5863 is an experimental bispecific antibody from AstraZeneca in phase 2 trials for gastric & gastro-oesophageal junction cancer, pancreatic ductal adenocarcinoma and oesophageal cancer, aimed at Claudin 18.2 and CD3.Open in Atlas onco.cc
AZD6621phase-2: AZD6621 is an experimental T-cell engager from AstraZeneca in phase 2 trials for prostate cancer, aimed at CD3.Open in Atlas onco.cc
AZD7789phase-2: AZD7789 is an experimental bispecific antibody from AstraZeneca in phase 2 trials for non-small-cell lung cancer and gastric & gastro-oesophageal junction cancer, aimed at PD-1 and TIM-3.Open in Atlas onco.cc
AZD8421phase-2: AZD8421 is a small-molecule inhibitor from AstraZeneca, in registered phase 2 trials for ovarian cancer.Open in Atlas onco.cc
AZD9750phase-2: AZD9750 is an experimental protein degrader from AstraZeneca in phase 2 trials for prostate cancer, aimed at Androgen receptor.Open in Atlas onco.cc
AZD9793phase-2: AZD9793 is an experimental T-cell engager from AstraZeneca in phase 2 trials for hepatocellular carcinoma, aimed at Glypican-3.Open in Atlas onco.cc
Azenosertibphase-3: Azenosertib is an experimental small-molecule drug from K-, Beta in phase 3 trials for ovarian cancer, aimed at WEE1.Open in Atlas onco.cc

B

BA3071phase-2: BA3071 is an experimental monoclonal antibody from BioAtla in phase 2 trials for non-small-cell lung cancer and melanoma, aimed at CTLA-4.Open in Atlas onco.cc
Balstilimabphase-2: Balstilimab is a monoclonal antibody from Agenus Inc., in registered phase 2 trials for colorectal cancer.Open in Atlas onco.cc
BAT8008phase-1: BAT8008 is an experimental antibody-drug conjugate being studied in people with advanced cancer. Its benefit and safety are still being evaluated.Open in Atlas onco.cc
BCB-276phase-2: BCB-276 is an experimental CAR-T cell therapy from BrainChild Bio in phase 2 trials for glioma & glioblastoma, aimed at B7-H3.Open in Atlas onco.cc
BCD-100phase-3: BCD-100 is an experimental investigational agent whose form is not stated in the registry from Biocad in phase 3 trials for melanoma, with its target not yet stated publicly.Open in Atlas onco.cc
BCD-217phase-3: BCD-217 is an experimental investigational agent whose form is not stated in the registry from Biocad in phase 3 trials for melanoma, aimed at PD-1 and CTLA-4.Open in Atlas onco.cc
BCG033preclinical: BCG033 is an experimental drug designed to carry chemotherapy to cancer cells. Its published evidence is from laboratory and animal studies.Open in Atlas onco.cc
BDC-4182phase-2: BDC-4182 is an experimental monoclonal antibody from Bolt Biotherapeutics in phase 2 trials for gastric & gastro-oesophageal junction cancer, aimed at Claudin 18.2.Open in Atlas onco.cc
BEBT-209phase-3: BEBT-209 is an experimental small-molecule drug from BeBetter Med in phase 3 trials for triple-negative breast cancer and HR-positive / HER2-negative breast cancer, with its target not yet stated publicly.Open in Atlas onco.cc
Befotertinibphase-2: Befotertinib is an oral kinase inhibitor from Betta Pharmaceuticals Co., Ltd., in registered phase 2 trials for non-small-cell lung cancer.Open in Atlas onco.cc
Belantamab mafodotinapproved: A myeloma ADC that was withdrawn in 2022 then came back in 2025 after strong trials in earlier lines.Open in Atlas onco.cc
Belinostatapproved: Belinostat is an HDAC inhibitor for relapsed peripheral T-cell lymphoma; about a quarter of patients respond, and it can be used in patients with low platelets.Open in Atlas onco.cc
Belumosudilapproved: Belumosudil is a pill for chronic graft-versus-host disease, the long-term immune complication of donor stem-cell transplants used to cure blood cancers.Open in Atlas onco.cc
Belzutifanapproved: Belzutifan is the first HIF-2α inhibitor, born from Nobel-winning biology, and is now approved after kidney cancer surgery with pembrolizumab.Open in Atlas onco.cc
Bemarituzumabphase-3: Bemarituzumab is an antibody against FGFR2b, a growth receptor overproduced in about a third of stomach cancers. It improved survival early in its phase 3 trial, but the gain faded with longer follow-up.Open in Atlas onco.cc
Bempegaldesleukinnegative: Bempegaldesleukin was a re-engineered interleukin-2 meant to be a safer version of a famous old immunotherapy. It added nothing to nivolumab in three phase 3 trials.Open in Atlas onco.cc
Bendamustineapproved: An East German chemotherapy rediscovered in the 2000s that became the backbone partner for rituximab in follicular, mantle cell and Waldenström lymphomas.Open in Atlas onco.cc
Benmelstobartapproved: Benmelstobart is Chia Tai Tianqing's PD-L1 antibody, approved in China in 2024 for extensive-stage small-cell lung cancer in combination with anlotinib and chemotherapy.Open in Atlas onco.cc
Bevacizumabapproved: Bevacizumab is a humanised antibody that soaks up VEGF-A, the signal tumours use to grow new blood vessels. Approved in 2004, it partners chemotherapy in colorectal, ovarian, cervical, lung, kidney and liver cancer and glioblastoma, and adds to trifluridine...Open in Atlas onco.cc
Bevacizumab (glioblastoma use)approved: A blood-vessel-blocking antibody that shrinks glioblastoma on scans and reduces swelling, but has never been shown to help patients live longer.Open in Atlas onco.cc
Bexaroteneapproved: Bexarotene (Targretin) is a vitamin A-like capsule and gel for the skin disease of cutaneous T-cell lymphoma when other treatments have stopped working.Open in Atlas onco.cc
Bexmarilimabphase-2: Bexmarilimab is a monoclonal antibody from Faron Pharmaceuticals Ltd, in registered phase 2 trials for acute myeloid leukaemia, chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, myelodysplastic syndromes / neoplasms.Open in Atlas onco.cc
Bexobrutidegphase-3: Bexobrutideg is an experimental protein degrader from Nurix Therapeutics in phase 3 trials for chronic lymphocytic leukaemia, aimed at BTK (Bruton tyrosine kinase).Open in Atlas onco.cc
Bezuclastinibphase-3: Bezuclastinib is an experimental small-molecule drug from Cogent Biosciences in phase 3 trials for gastrointestinal stromal tumour, aimed at KIT and MET.Open in Atlas onco.cc
BGB-16673phase-3: Instead of blocking BTK, this pill destroys it, so it works even when the enzyme has mutated to escape every inhibitor.Open in Atlas onco.cc
BGB-43395phase-3: BGB-43395 is an experimental small-molecule drug from BeOne Medicines in phase 3 trials for HR-positive / HER2-negative breast cancer, with its target not yet stated publicly.Open in Atlas onco.cc
BHV-1510phase-1: BHV-1510 is an experimental chemotherapy-delivering antibody being studied alone and with immunotherapy. Early response findings need confirmation in larger trials.Open in Atlas onco.cc
Bicalutamideapproved: The old antiandrogen pill used to block the testosterone flare from GnRH agonists and in combined androgen blockade; superseded by enzalutamide-class drugs.Open in Atlas onco.cc
Binimetinibapproved: Binimetinib is the MEK inhibitor partnered with encorafenib; blocking the next step in the same relay stops the tumour rerouting around the BRAF block.Open in Atlas onco.cc
BIO-106phase-2: BIO-106 is an experimental antibody-drug conjugate from BiOneCure Therapeutics in phase 2 trials, aimed at TROP2.Open in Atlas onco.cc
Bleomycinapproved: Bleomycin is the 'B' in BEP for testicular cancer and ABVD for Hodgkin lymphoma; its unique danger is scarring of the lungs, so lung function is monitored and it is often dropped when safe.Open in Atlas onco.cc
Bleximenibphase-3: Bleximenib is an experimental small-molecule drug from Janssen Research & Development in phase 3 trials for acute myeloid leukaemia, with its target not yet stated publicly.Open in Atlas onco.cc
Blinatumomabapproved: Blinatumomab was the first T-cell engager (2014), and is now given to children and adults with leukaemia even when in remission, because it improves survival.Open in Atlas onco.cc
BMS-986365phase-3: BMS-986365 is an experimental protein degrader from Celgene in phase 3 trials for prostate cancer, aimed at Androgen receptor.Open in Atlas onco.cc
BNT113phase-3: BNT113 is an experimental investigational agent whose form is not stated in the registry from BioNTech SE in phase 3 trials for head and neck squamous cell carcinoma, with its target not yet stated publicly.Open in Atlas onco.cc
BNT324phase-3: BNT324 is an experimental antibody-drug conjugate from BioNTech SE in phase 3 trials for prostate cancer and non-small-cell lung cancer, aimed at B7-H3.Open in Atlas onco.cc
Bomedemstatphase-3: Bomedemstat is an experimental small-molecule drug from Merck Sharp & Dohme in phase 3 trials for myeloproliferative neoplasms, with its target not yet stated publicly.Open in Atlas onco.cc
Bortezomibapproved: Bortezomib was the first proteasome inhibitor: it jams the cell's protein-recycling machine, which antibody-factory plasma cells cannot tolerate.Open in Atlas onco.cc
Boserolimabphase-2: Boserolimab is a monoclonal antibody from Merck Sharp & Dohme LLC, in registered phase 2 trials for non-small-cell lung cancer.Open in Atlas onco.cc
Bosutinibapproved: Bosutinib is a CML pill with less cardiovascular and pleural toxicity than its rivals; its main side effect is diarrhoea.Open in Atlas onco.cc
Botensilimabphase-2: Botensilimab is an experimental monoclonal antibody from Agenus in phase 2 trials for colorectal cancer, aimed at CTLA-4.Open in Atlas onco.cc
BRACAnalysis CDxapproved: The inherited BRCA test that decides who can have PARP inhibitor pills for ovarian, breast, pancreatic and prostate cancer.Open in Atlas onco.cc
Breast Cancer Indexestablished: The only test designed to tell a woman who has finished five years of hormone therapy whether another five years is worth the side effects.Open in Atlas onco.cc
Brenetafuspphase-3: Brenetafusp is a soluble T-cell receptor bispecific, tebentafusp's successor, that recognises a PRAME peptide on HLA-A*02:01 and drags T cells onto the tumour. A phase 3 with nivolumab in first-line melanoma is enrolling, but only patients carrying HLA-A*02...Open in Atlas onco.cc
Brentuximab vedotinapproved: The ADC that made the modern field credible (2011), for Hodgkin lymphoma and CD30+ lymphomas.Open in Atlas onco.cc
Brexucabtagene autoleucelapproved: Brexucabtagene autoleucel is the CAR-T therapy for mantle cell lymphoma and adult acute lymphoblastic leukaemia, giving long remissions after BTK inhibitors fail.Open in Atlas onco.cc
Brigatinibapproved: Brigatinib is an ALK pill with strong brain activity, approved first after crizotinib and then first line after beating it in ALTA-1L.Open in Atlas onco.cc
Brigimadlinphase-3: Brigimadlin is a tablet that frees the p53 'guardian' protein from MDM2, the protein that liposarcomas make in excess to keep p53 switched off. It is being compared with doxorubicin as first treatment for dedifferentiated liposarcoma in a phase 2/3 trial.Open in Atlas onco.cc
Bromocriptineapproved: Bromocriptine was the first pill that could shrink a pituitary tumour. From the 1970s it turned prolactinomas from a surgical disease into one usually controlled with tablets, and it is still used where cabergoline is unavailable or unsuitable.Open in Atlas onco.cc
Budigalimabphase-3: Budigalimab is an experimental investigational agent whose form is not stated in the registry from AbbVie in phase 3 trials for hepatocellular carcinoma, non-small-cell lung cancer and bladder & urothelial cancer, with its target not yet stated publicly.Open in Atlas onco.cc
Burosumabapproved: Crysvita is an antibody for a rare bone-softening condition in which the body leaks phosphate. Some small tumours cause it by making too much of a hormone called FGF23; when the tumour cannot be found or removed, Crysvita blocks the hormone.Open in Atlas onco.cc
Buserelinestablished: Buserelin is one of the original GnRH agonists, approved in Europe and Canada in the 1980s for advanced prostate cancer and also used in endometriosis and fertility treatment; it is not sold in the United States.Open in Atlas onco.cc
Busulfanapproved: Busulfan is one of the oldest cancer drugs. As a tablet it controlled chronic myeloid leukaemia before imatinib; as an infusion it is used to clear the bone marrow before a stem cell transplant.Open in Atlas onco.cc

C

Cabazitaxelapproved: A second taxane that works after docetaxel and beat a second hormone pill head-to-head (CARD).Open in Atlas onco.cc
Cabergolineapproved: Cabergoline is a tablet taken once or twice a week that shrinks prolactin-secreting pituitary tumours and normalises hormone levels in most patients, so surgery is reserved for the few whose tumours resist or who cannot tolerate it.Open in Atlas onco.cc
Cabozantinibapproved: A pill that blocks both blood-vessel growth and the MET escape pathway, used in kidney, liver, thyroid and, since 2025, neuroendocrine cancers.Open in Atlas onco.cc
Cadonilimabapproved: A Chinese two-armed antibody that blocks PD-1 and CTLA-4 together, approved in China for cervical cancer and extending survival even in PD-L1-negative tumours.Open in Atlas onco.cc
Calderasibphase-3: Calderasib is an experimental small-molecule drug from Merck Sharp & Dohme in phase 3 trials for non-small-cell lung cancer and colorectal cancer, aimed at KRAS.Open in Atlas onco.cc
CAM2029 (octreotide subcutaneous depot)phase-3: CAM2029 is Camurus's monthly octreotide depot that patients can inject themselves, positive in the phase 3 SORENTO trial for gastroenteropancreatic neuroendocrine tumours against the standard depot formulations.Open in Atlas onco.cc
Camizestrantapproved: Camizestrant is an oral oestrogen-receptor degrader approved in September 2026 for a new kind of decision: switching treatment when a blood test shows resistance developing, before the cancer visibly grows.Open in Atlas onco.cc
Camonsertibphase-2: Camonsertib is an oral serine/threonine kinase inhibitor from Hoffmann-La Roche, in registered phase 2 trials for metastatic cancer.Open in Atlas onco.cc
Camrelizumabapproved: Camrelizumab is Jiangsu Hengrui's humanised PD-1 antibody, approved in China for oesophageal, liver and lung cancer but not in the US, where its liver cancer combination with rivoceranib drew complete response letters in 2024 and 2025 over manufacturing and...Open in Atlas onco.cc
Camrelizumab + rivoceranibapproved: A Chinese immunotherapy-plus-anti-angiogenic pill combination that clearly beat sorafenib in liver cancer, yet remains unapproved in the US after three manufacturing-related rejections.Open in Atlas onco.cc
CAN020preclinical: CAN020 is an experimental drug designed to carry chemotherapy to cancer cells. Its published evidence is from laboratory and animal studies.Open in Atlas onco.cc
Cancerguardemerging: Exact Sciences' multi-cancer blood test, sold since 2025 as a lab test that has not been through FDA approval.Open in Atlas onco.cc
Capecitabineapproved: Capecitabine (Xeloda) is a tablet form of the chemotherapy fluorouracil. It is a backbone of treatment for bowel cancer and a standard option in advanced breast cancer.Open in Atlas onco.cc
Capecitabine + temozolomide (CAPTEM)established: CAPTEM (capecitabine plus temozolomide) is an all-oral chemotherapy pair that shrinks pancreatic neuroendocrine tumours in about a third of patients.Open in Atlas onco.cc
Capivasertibapproved: Capivasertib (Truqap) is the first AKT inhibitor, for breast cancer with PI3K-pathway mutations and, since 2026, for prostate cancer with PTEN loss.Open in Atlas onco.cc
Capmatinibapproved: Capmatinib is a targeted pill for the small group of lung cancers driven by a MET exon 14 skipping mutation, found by tumour sequencing.Open in Atlas onco.cc
Capmatinib & tepotinibapproved: Capmatinib and tepotinib are two pills for the roughly 3% of lung cancers with a MET exon 14 skipping mutation.Open in Atlas onco.cc
CAPOX (capecitabine, oxaliplatin)standard-of-care: CAPOX pairs the oral fluoropyrimidine capecitabine with intravenous oxaliplatin as a pill-based alternative to FOLFOX. For low-risk stage III colon cancer three months after surgery works as well as six and halves nerve damage; it is also standard in gastri...Open in Atlas onco.cc
Carboplatinapproved: Carboplatin is a platinum chemotherapy that crosslinks DNA; it is part of the standard pre-surgery regimen for triple-negative breast cancer.Open in Atlas onco.cc
Carfilzomibapproved: Carfilzomib is a second-generation proteasome inhibitor with less nerve damage but more heart and blood-pressure effects.Open in Atlas onco.cc
Carmustineapproved: Carmustine is a chemotherapy that reaches the brain. It is given by infusion for brain tumours, lymphoma and myeloma, and as a slow-release wafer left in the cavity after a brain tumour is removed.Open in Atlas onco.cc
Carotuximabnegative: Carotuximab was an antibody against endoglin, a protein on growing blood vessels and on angiosarcoma cells. Added to pazopanib in the phase 3 TAPPAS trial it did not help, and the trial was stopped in 2019.Open in Atlas onco.cc
CART84phase-2: CART84 is an experimental CAR-T cell therapy from Gyala Therapeutics in phase 2 trials for acute myeloid leukaemia, aimed at CD3.Open in Atlas onco.cc
CATB-101preclinical: CATB-101 is an experimental drug designed to carry chemotherapy to cancer cells. Its published evidence is from laboratory and animal studies.Open in Atlas onco.cc
Catumaxomabapproved: Catumaxomab (Korjuny) is an antibody infused into the abdominal cavity to control malignant ascites, the build-up of fluid caused by cancers such as ovarian and stomach cancer, in people whose other treatments have stopped working.Open in Atlas onco.cc
CBB-120preclinical: CBB-120 is an experimental drug designed to carry chemotherapy to cancer cells. Its published evidence is from laboratory and animal studies.Open in Atlas onco.cc
CD19 t-haNKphase-2: CD19 t-haNK is an experimental cell therapy whose type is not stated from ImmunityBio in phase 2 trials for hodgkin lymphoma, aimed at CD19.Open in Atlas onco.cc
Cediranibphase-2: Cediranib is a tablet that blocks the blood-vessel growth signal VEGF. In alveolar soft part sarcoma, a rare very vascular sarcoma that ignores chemotherapy, a randomised trial showed it shrinks tumours and delays progression, although it was never licensed.Open in Atlas onco.cc
Celecoxibapproved: Celecoxib is a common anti-inflammatory painkiller. In oncology it is paired with low-dose oral methotrexate as a cheap 'metronomic' treatment for advanced head and neck cancer, a regimen from Tata Memorial in Mumbai that beat intravenous cisplatin in a ran...Open in Atlas onco.cc
Cemiplimabapproved: A PD-1 blocker that is the standard for advanced skin squamous cell carcinoma, and in 2025 became the first adjuvant immunotherapy for it.Open in Atlas onco.cc
Ceralasertibphase-3: Ceralasertib is an experimental small-molecule drug from AstraZeneca in phase 3 trials for non-small-cell lung cancer, melanoma and triple-negative breast cancer, aimed at ATR.Open in Atlas onco.cc
Ceritinibapproved: Ceritinib is a second-generation ALK pill for lung cancer, effective after crizotinib but with gastrointestinal toxicity that limited uptake.Open in Atlas onco.cc
CERVAVAC (quadrivalent HPV vaccine, India)approved: India's first home-made HPV vaccine, protecting against the two virus types that cause most cervical cancers and the two that cause genital warts, at a price meant for a national programme.Open in Atlas onco.cc
Cetrelimabphase-3: Cetrelimab is an experimental investigational agent whose form is not stated in the registry from Janssen Research & Development in phase 3 trials for bladder & urothelial cancer, prostate cancer and non-small-cell lung cancer, with its target not yet state...Open in Atlas onco.cc
Cetuximabapproved: Cetuximab is a chimeric antibody that blocks the EGFR growth receptor. It is used with FOLFIRI or FOLFOX in RAS wild-type, left-sided bowel cancer, with encorafenib in BRAF V600E disease, with KRAS G12C inhibitors, and with radiation or chemotherapy in head...Open in Atlas onco.cc
Cetuximab sarotalocanapproved: Cetuximab sarotalocan is an EGFR antibody carrying a light-activated dye: after infusion, a red laser is shone on the tumour and the cells burst. It has been approved in Japan since 2020.Open in Atlas onco.cc
Cevostamabphase-3: Cevostamab is an experimental investigational agent whose form is not stated in the registry from Hoffmann-La Roche in phase 3 trials for multiple myeloma, with its target not yet stated publicly.Open in Atlas onco.cc
CGT4859phase-2: CGT4859 is an experimental small-molecule drug from Cogent Biosciences in phase 2 trials for biliary tract cancer, aimed at FGFR2.Open in Atlas onco.cc
Chiauranibphase-3: Chiauranib is an experimental small-molecule drug from Chipscreen Biosciences in phase 3 trials for ovarian cancer, aimed at VEGF / VEGFR and KIT.Open in Atlas onco.cc
Chlorambucilapproved: Chlorambucil (Leukeran) is a gentle oral chemotherapy tablet used for decades in chronic lymphocytic leukaemia and low-grade lymphomas, mainly in older patients.Open in Atlas onco.cc
Choline C-11established: Choline C-11 was the first PET tracer approved in the United States, in 2012, to find where prostate cancer has come back when PSA rises after treatment; PSMA tracers have now largely replaced it.Open in Atlas onco.cc
Ciltacabtagene autoleucelapproved: Ciltacabtagene autoleucel is a one-time BCMA CAR-T for myeloma that, in CARTITUDE-4, cut the risk of death by about 45% compared with standard regimens.Open in Atlas onco.cc
Cinacalcetestablished: Cinacalcet is a tablet that quiets overactive parathyroid tissue, approved in 2004 and labelled for the dangerous high calcium levels of parathyroid carcinoma, a rare cancer where surgery often cannot remove all the hormone-producing tissue.Open in Atlas onco.cc
Cinrebafusp alfaphase-2: Cinrebafusp alfa is an experimental fusion protein from Pieris Pharmaceuticals in phase 2 trials for gastric & gastro-oesophageal junction cancer, aimed at HER2.Open in Atlas onco.cc
Cisplatinapproved: Cisplatin is the original platinum chemotherapy, discovered by accident in 1965; it cures testicular cancer and makes radiation work better in cervical and head and neck cancer.Open in Atlas onco.cc
Cladribineapproved: A one-week infusion that puts most people with hairy cell leukaemia into remission for years; also used in multiple sclerosis in tablet form.Open in Atlas onco.cc
Clifutinibphase-3: Clifutinib is an experimental small-molecule drug from Sunshine Lake Pharma in phase 3 trials for acute myeloid leukaemia, with its target not yet stated publicly.Open in Atlas onco.cc
Clofarabineapproved: Clofarabine (Clolar) is an infusion for children and young adults whose acute lymphoblastic leukaemia has come back after at least two other treatments.Open in Atlas onco.cc
clonoSEQapproved: A DNA test that counts leftover leukaemia, myeloma or lymphoma cells down to one in a million, used to decide whether treatment has really worked.Open in Atlas onco.cc
cobas EGFR Mutation Test v2approved: The lung cancer gene test that became the first blood-based companion diagnostic the FDA ever approved.Open in Atlas onco.cc
Cobimetinibapproved: Cobimetinib is the MEK partner for vemurafenib, and the first drug approved for histiocytic neoplasms.Open in Atlas onco.cc
Cobolimabphase-3: Cobolimab is an experimental investigational agent whose form is not stated in the registry from GlaxoSmithKline in phase 3 trials for non-small-cell lung cancer, melanoma and hodgkin lymphoma, with its target not yet stated publicly.Open in Atlas onco.cc
Cologuardapproved: A home stool test done every three years that looks for cancer DNA and hidden blood; a positive result means you need a colonoscopy.Open in Atlas onco.cc
Cologuard Plusapproved: The updated Cologuard, approved in 2024, which keeps the high cancer detection rate while causing fewer false alarms.Open in Atlas onco.cc
Copanlisibwithdrawn: Copanlisib is an intravenous PI3K inhibitor for relapsed follicular lymphoma, approved in 2017 and withdrawn in 2023 when its confirmatory trial failed.Open in Atlas onco.cc
Cosibelimabapproved: Cosibelimab is a PD-L1 antibody approved in December 2024 for advanced cutaneous squamous cell carcinoma, offering a third immunotherapy choice.Open in Atlas onco.cc
CPX-351 (liposomal daunorubicin-cytarabine)approved: The two old chemotherapy drugs packed together into tiny fat bubbles at a fixed ratio, which doubled five-year survival in older adults with high-risk AML.Open in Atlas onco.cc
CRB-701phase-2: CRB-701 is an experimental antibody-drug conjugate from Corbus Pharmaceuticals in phase 2 trials, aimed at Nectin-4.Open in Atlas onco.cc
CRC01phase-2: CRC01 is an experimental CAR-T cell therapy from Curocell in phase 2 trials for diffuse large B-cell lymphoma, follicular lymphoma and acute lymphoblastic leukaemia, aimed at CD19.Open in Atlas onco.cc
Cretostimogene grenadenorepvecphase-3: Cretostimogene is a virus engineered to multiply only in bladder cancer cells with a broken RB pathway, instilled into the bladder. It cleared carcinoma in situ in 75% of BCG-unresponsive patients.Open in Atlas onco.cc
Crisantaspase (recombinant Erwinia asparaginase)approved: Enrylaze is a replacement asparaginase for children and adults with acute lymphoblastic leukaemia or lymphoblastic lymphoma whose bodies have reacted against, or quietly neutralised, the usual E. coli asparaginase. It keeps the asparagine-starving part of t...Open in Atlas onco.cc
Crizotinibapproved: Crizotinib was the first ALK inhibitor, approved four years after ALK fusions were found in lung cancer; it was also the first drug for ROS1 lung cancer and for ALK-positive lymphoma and inflammatory myofibroblastic tumour in children.Open in Atlas onco.cc
CT3001phase-2: CT3001 is a small-molecule inhibitor from Crossignal Therapeutics, Inc., in registered phase 2 trials for colorectal cancer, pancreatic ductal adenocarcinoma.Open in Atlas onco.cc
CTPH-03preclinical: CTPH-03 is an experimental drug designed to carry chemotherapy to cancer cells. Its published evidence is from laboratory and animal studies.Open in Atlas onco.cc
CTX112phase-2: CTX112 is an experimental CAR-T cell therapy from CRISPR Therapeutics in phase 2 trials for hodgkin lymphoma, chronic lymphocytic leukaemia and follicular lymphoma, aimed at CD19.Open in Atlas onco.cc
Cusatuzumabphase-2: Cusatuzumab is an experimental monoclonal antibody from OncoVerity in phase 2 trials for acute myeloid leukaemia, aimed at CD70.Open in Atlas onco.cc
Custirsenwithdrawn: A drug designed to switch off a protein that helps cancer cells survive chemotherapy. Two large trials found it added nothing.Open in Atlas onco.cc
Cxbladderestablished: A urine test that can rule out bladder cancer in people with blood in their urine, so fewer need a camera examination of the bladder.Open in Atlas onco.cc
Cyclophosphamideapproved: Cyclophosphamide is an alkylating chemotherapy that damages DNA in dividing cells. It is part of CHOP for lymphoma, AC for breast cancer and VAC for childhood sarcomas, clears lymphocytes before CAR-T and prevents graft-versus-host disease after transplant;...Open in Atlas onco.cc
CYH33phase-2: CYH33 is a small-molecule inhibitor from Haihe Biopharma Co., Ltd., in registered phase 2 trials for ovarian cancer.Open in Atlas onco.cc
Cytarabineapproved: Cytarabine is the core chemotherapy for acute myeloid leukaemia, given with an anthracycline as the classic 7+3 induction and at high doses for consolidation; it is also injected into the spinal fluid to treat or prevent leukaemia in the brain.Open in Atlas onco.cc
Cytarabine + anthracycline ('7+3')standard-of-care: The intensive chemotherapy that has induced remission in fit AML patients since 1973: seven days of one drug, three of another. Still the backbone that targeted drugs are added to.Open in Atlas onco.cc

D

D-0502phase-3: D-0502 is an experimental small-molecule drug from InventisBio in phase 3 trials for HR-positive / HER2-negative breast cancer, with its target not yet stated publicly.Open in Atlas onco.cc
D07001phase-3: D07001 is an experimental small-molecule drug from InnoPharmax in phase 3 trials for biliary tract cancer, with its target not yet stated publicly.Open in Atlas onco.cc
Dabrafenibapproved: Dabrafenib (Tafinlar) is a capsule that switches off the faulty BRAF protein driving some melanomas, lung, thyroid and other cancers. It is almost always paired with trametinib.Open in Atlas onco.cc
Dabrafenib + trametinibapproved: Dabrafenib plus trametinib is the BRAF-plus-MEK pill combination, approved for BRAF V600E lung cancer and, since 2022, for any solid tumour with that mutation.Open in Atlas onco.cc
Dacarbazineapproved: Dacarbazine is an older chemotherapy infusion. It was the standard treatment for advanced melanoma for decades and is the D in the ABVD regimen that cures most Hodgkin lymphoma.Open in Atlas onco.cc
Dacomitinibapproved: A second-generation EGFR pill that beat gefitinib on survival in EGFR-mutant lung cancer but was quickly overshadowed by osimertinib.Open in Atlas onco.cc
Dactinomycin (actinomycin D)approved: The first antibiotic used as an anticancer drug (1954) and still the core of chemotherapy for Wilms tumour, rhabdomyosarcoma and gestational trophoblastic disease.Open in Atlas onco.cc
Dalpiciclibapproved: Dalpiciclib is Hengrui's CDK4/6 inhibitor, the first China-developed drug of the class, approved for hormone-driven advanced breast cancer on the DAWNA trials.Open in Atlas onco.cc
Danazolestablished: Danazol is an old hormone tablet, licensed for endometriosis, that can raise haemoglobin and platelets in myelofibrosis and bone marrow failure. It was the comparison treatment that momelotinib beat in the MOMENTUM trial.Open in Atlas onco.cc
Daratumumabapproved: The CD38 antibody that turned triplets into quadruplets: adding it to standard induction roughly halves the risk of myeloma progressing.Open in Atlas onco.cc
Daraxonrasibapproved: The first drug that blocks all active RAS variants, approved by the FDA in August 2026 for metastatic pancreatic cancer, where KRAS drives 90% of tumours.Open in Atlas onco.cc
Darbepoetin alfaapproved: Darbepoetin alfa (Aranesp) is a longer-acting version of erythropoietin given every one to three weeks to treat anaemia caused by chemotherapy, reducing transfusions but with the same warnings about clots and tumour growth as epoetin.Open in Atlas onco.cc
Darolutamideapproved: Darolutamide is an AR blocker that barely enters the brain, so it causes fewer falls and cognitive side effects; it is approved with and without chemotherapy.Open in Atlas onco.cc
Daromunphase-3: Daromun is a pair of antibody-linked immune messengers injected straight into melanoma deposits before surgery. In a phase 3 trial it lowered the chance of the melanoma coming back after the operation compared with surgery alone.Open in Atlas onco.cc
Darovasertibphase-3: Darovasertib is an experimental small-molecule drug from IDEAYA Biosciences in phase 3 trials for uveal melanoma and melanoma, with its target not yet stated publicly.Open in Atlas onco.cc
Dasatinibapproved: Dasatinib is a second-generation BCR::ABL1 pill that, combined with the immunotherapy blinatumomab, can put Ph-positive ALL into deep remission with no chemotherapy at all.Open in Atlas onco.cc
Datopotamab deruxtecanapproved: Datopotamab deruxtecan delivers chemotherapy to cells bearing TROP2. Its FDA approvals cover specific advanced breast-cancer and EGFR-mutated lung-cancer settings.Open in Atlas onco.cc
Daunorubicinapproved: Daunorubicin is the anthracycline most often combined with cytarabine to bring acute myeloid leukaemia into remission; it is also part of induction for acute lymphoblastic leukaemia.Open in Atlas onco.cc
DB-1305 / BNT325phase-1: DB-1305 / BNT325 is an experimental antibody-drug conjugate being studied in people with advanced cancer. Its benefit and safety are still being evaluated.Open in Atlas onco.cc
DCVax-Lphase-3: A personalised vaccine made from the patient's own immune cells and tumour. Its 20-year-old phase 3 trial reported longer survival, but the way the result was analysed has divided the field.Open in Atlas onco.cc
Decipher Prostateestablished: A 22-gene test on the biopsy or surgical specimen that predicts spread and death, used to decide on surveillance or adding hormone therapy.Open in Atlas onco.cc
Decitabineapproved: Decitabine (Dacogen) is an infusion that loosens the chemical silencing of genes in myelodysplastic syndromes and acute myeloid leukaemia, helping the bone marrow work again. An oral version combined with cedazuridine has its own record.Open in Atlas onco.cc
Decitabine + cedazuridine (oral)approved: Oral decitabine-cedazuridine is a pill version of the hypomethylating chemotherapy that, since May 2026, lets older AML patients take their whole venetoclax regimen at home.Open in Atlas onco.cc
Defibrotideapproved: Defibrotide (Defitelio) is the only approved treatment for hepatic veno-occlusive disease, a life-threatening liver complication of high-dose chemotherapy before stem cell transplant, in patients whose kidneys or lungs are also failing.Open in Atlas onco.cc
Degarelixapproved: An injectable hormone blocker for prostate cancer that lowers testosterone within days without the initial surge caused by agonists.Open in Atlas onco.cc
Denileukin diftitoxapproved: Denileukin diftitox (Lymphir) is an infusion that uses the interleukin-2 signal as a homing device to deliver a bacterial toxin into cutaneous T-cell lymphoma cells. It was withdrawn in 2014 and returned in an improved form in 2024.Open in Atlas onco.cc
Denosumabapproved: Denosumab is an injection under the skin that blocks the signal driving bone breakdown. As Xgeva it prevents fractures and other bone complications in people whose cancer has spread to bone or who have myeloma; as Prolia it treats osteoporosis, including bo...Open in Atlas onco.cc
Depatuxizumab mafodotinnegative: Depatuxizumab mafodotin carried a cell-killing payload to glioblastomas with extra copies of the EGFR gene. It caused serious eye problems and, in the phase 3 INTELLANCE-1 trial, did not help patients live longer, so development stopped in 2019.Open in Atlas onco.cc
Devimistatnegative: Devimistat tried to starve pancreatic cancer cells of their energy supply alongside chemotherapy; the phase 3 AVENGER 500 trial found no survival gain.Open in Atlas onco.cc
Dexamethasoneapproved: Dexamethasone is a long-acting glucocorticoid steroid that kills lymphoid cancer cells directly, which is why it sits in nearly every myeloma regimen and in childhood leukaemia and lymphoma protocols. It is also the standard drug for preventing chemotherapy...Open in Atlas onco.cc
Dexrazoxaneapproved: Dexrazoxane protects the heart from the cumulative damage of doxorubicin in women with metastatic breast cancer who need to keep receiving it, and, as Totect, limits tissue destruction when an anthracycline leaks out of a vein.Open in Atlas onco.cc
Diazoxideestablished: Diazoxide is a medicine that stops insulin-producing tumours releasing insulin. It is used to control dangerous low blood sugar from an insulinoma while the patient is prepared for surgery or when the tumour cannot be removed.Open in Atlas onco.cc
Diethylstilbestrolhistoric: Diethylstilbestrol was the first hormonal treatment for prostate cancer, standard from the 1940s, and was also given for breast cancer, before its cardiovascular harms and the cancers it caused in the daughters of women who took it in pregnancy ended its use.Open in Atlas onco.cc
Dinutuximab (ch14.18) / dinutuximab betaapproved: The antibody that raised cure rates in high-risk childhood neuroblastoma by about 20 points when given after transplant with immune boosters and retinoid.Open in Atlas onco.cc
Disitamab vedotinapproved: Disitamab vedotin is a Chinese HER2 ADC approved for gastric and bladder cancer, now in global trials with Pfizer.Open in Atlas onco.cc
Divarasibphase-3: Divarasib is Roche's KRAS G12C pill, the first to beat the two approved KRAS drugs head-to-head (July 2026).Open in Atlas onco.cc
DJI136phase-2: DJI136 is an experimental CAR-T cell therapy from Novartis Pharmaceuticals in phase 2 trials for non-small-cell lung cancer, aimed at DLL3.Open in Atlas onco.cc
DOC1021phase-2: DOC1021 is a cancer vaccine from Diakonos Oncology Corporation, in registered phase 2 trials for glioma & glioblastoma, melanoma.Open in Atlas onco.cc
Docetaxelapproved: The first chemotherapy to extend life in prostate cancer (2004), now part of triplet therapy at first metastatic diagnosis.Open in Atlas onco.cc
Dolasetronestablished: Dolasetron is one of the serotonin-blocking antiemetics that transformed chemotherapy in the 1990s, approved in 1997 to prevent nausea and vomiting; its intravenous form lost its chemotherapy indication in 2010 because of heart rhythm effects.Open in Atlas onco.cc
Domvanalimabphase-3: Domvanalimab is an experimental monoclonal antibody from Gilead Sciences in phase 3 trials for non-small-cell lung cancer, bladder & urothelial cancer and head and neck squamous cell carcinoma, with its target not yet stated publicly.Open in Atlas onco.cc
Donafenibapproved: Donafenib is a Chinese redesign of sorafenib that lived longer than the original in a head-to-head liver cancer trial and is approved in China as a first-line option.Open in Atlas onco.cc
Dordaviproneapproved: Dordaviprone is the first drug ever approved for a childhood and young-adult brain tumour that had none, diffuse midline glioma with the H3 K27M mutation (August 2025).Open in Atlas onco.cc
Dorocubicel (UM171-expanded cord blood)approved: Zemcelpro is a laboratory-expanded umbilical cord blood transplant for adults with blood cancers who need a donor stem cell transplant but have no suitable matched donor; expanding the cells lets a single small cord blood unit be enough.Open in Atlas onco.cc
Dostarlimabapproved: Dostarlimab is a PD-1 blocker famous for making rectal cancer disappear without surgery in every patient with a mismatch-repair-deficient tumour.Open in Atlas onco.cc
Doxifluridineestablished: Doxifluridine is an oral fluorouracil prodrug approved in Japan in 1987 and used in China and Korea for stomach, bowel and breast cancers; capecitabine, which the body turns into doxifluridine, later carried the same idea to the rest of the world.Open in Atlas onco.cc
Doxorubicinapproved: The red chemotherapy drug from a soil bacterium that is still the backbone of treatment for sarcoma, lymphoma and breast cancer, limited by cumulative heart damage.Open in Atlas onco.cc
DR-01phase-2: DR-01 is a monoclonal antibody from Dren Bio, in registered phase 2 trials for peripheral T-cell lymphomas.Open in Atlas onco.cc
Dronabinolestablished: Dronabinol is synthetic THC in a capsule, approved in 1985 for chemotherapy nausea and vomiting that other antiemetics have failed to control, and later for appetite loss in AIDS; it sits well behind the 5-HT3 and NK1 antagonists in today's guidelines.Open in Atlas onco.cc
DSB2455phase-1: DSB2455 is an experimental pill being studied to block a DNA-repair enzyme in cancer cells.Open in Atlas onco.cc
Durvalumabapproved: A PD-L1 blocker that became standard after chemoradiation for stage III lung cancer, and now in bladder, biliary, and gastric cancers.Open in Atlas onco.cc
Duvelisibapproved: A dual PI3K inhibitor for relapsed CLL whose survival data raised FDA concern; use is now limited to late lines.Open in Atlas onco.cc
DZD8586phase-3: DZD8586 is an experimental small-molecule drug from Dizal Pharmaceuticals in phase 3 trials for chronic lymphocytic leukaemia and diffuse large B-cell lymphoma, with its target not yet stated publicly.Open in Atlas onco.cc

E

E-EDV-D682phase-2: E-EDV-D682 is an experimental EDV nanocell (bacterial minicell) drug conjugate from Engeneic Pty in phase 2 trials for pancreatic ductal adenocarcinoma, aimed at EGFR.Open in Atlas onco.cc
EB-CAR30-NKphase-2: EB-CAR30-NK is an experimental CAR-NK cell therapy from Beijing Biotech in phase 2 trials for thymoma and thymic carcinoma, aimed at CD30.Open in Atlas onco.cc
EB-MF-CAR-NK-01phase-2: EB-MF-CAR-NK-01 is an experimental bispecific antibody from Beijing Biotech in phase 2 trials for mesothelioma, aimed at Mesothelin and FAP.Open in Atlas onco.cc
EB-NK-301phase-1: EB-NK-301 is an experimental donor-derived immune-cell therapy aimed at TROP2. Its registered trial combines phase 1 and phase 2 testing; no clinical benefit is established.Open in Atlas onco.cc
Efbemalenograstim alfaapproved: Efbemalenograstim alfa (Ryzneuta) is a once-per-cycle white cell booster, an alternative to pegfilgrastim, that reduces the risk of febrile infections after chemotherapy.Open in Atlas onco.cc
Eflapegrastimapproved: Eflapegrastim is a once-per-cycle white cell growth factor approved in the United States in 2022 to prevent infections when chemotherapy for solid tumours knocks down neutrophils, an alternative to pegfilgrastim.Open in Atlas onco.cc
Eflornithine (DFMO)approved: Eflornithine (DFMO) is an old sleeping-sickness drug repurposed as the first oral maintenance therapy for high-risk neuroblastoma, approved in December 2023 to reduce relapse after immunotherapy.Open in Atlas onco.cc
EIK1001phase-3: EIK1001 is an experimental investigational agent whose form is not stated in the registry from Eikon Therapeutics in phase 3 trials for melanoma and non-small-cell lung cancer, with its target not yet stated publicly.Open in Atlas onco.cc
EIK1004phase-2: EIK1004 is an experimental pill being studied to block a DNA-repair enzyme in cancer cells.Open in Atlas onco.cc
EIK1005phase-2: EIK1005 is a small-molecule inhibitor from Eikon Therapeutics, in registered phase 2 trials for colorectal cancer, endometrial cancer.Open in Atlas onco.cc
Elacestrantapproved: Elacestrant was the first oral oestrogen-receptor degrader (2023), for ESR1-mutant breast cancer detected by blood test.Open in Atlas onco.cc
Elenestinibphase-3: Elenestinib is an experimental small-molecule drug from Blueprint Medicines in phase 3 trials for systemic mastocytosis, with its target not yet stated publicly.Open in Atlas onco.cc
ELI-002 7Pphase-2: A ready-made vaccine against the seven commonest KRAS mutations, given after pancreatic cancer surgery. Its phase 2 missed the main goal in 2026 but showed signs of activity.Open in Atlas onco.cc
Elironrasibphase-2: A next-generation KRAS G12C drug that hits the active form of the protein, from the same company as daraxonrasib.Open in Atlas onco.cc
Elotuzumabapproved: An immune-stimulating antibody for myeloma that works only in combination, adding benefit to lenalidomide or pomalidomide.Open in Atlas onco.cc
Elraglusibphase-2: Elraglusib blocks a kinase that helps pancreatic cancer resist chemotherapy; in a randomised phase 2 it lengthened survival when added to gemcitabine and nab-paclitaxel, and a phase 3 is planned.Open in Atlas onco.cc
Elranatamabapproved: Elranatamab is Pfizer's BCMA bispecific, given under the skin every week then every two weeks, for myeloma after four prior lines.Open in Atlas onco.cc
Elriterceptphase-3: Elritercept is Keros and Takeda's ligand trap for the anaemia of myelodysplastic syndromes, a relative of luspatercept, in phase 3 trials.Open in Atlas onco.cc
Eltrombopagestablished: Eltrombopag is a daily tablet that raises platelet counts by stimulating the bone marrow; it is approved for immune thrombocytopenia and severe aplastic anaemia, and haematologists also use it when low platelets complicate blood cancers and their treatment.Open in Atlas onco.cc
Emactuzumabphase-3: Emactuzumab is an experimental monoclonal antibody from SynOx Therapeutics in phase 3 trials for tenosynovial giant cell tumour, aimed at CSF1R.Open in Atlas onco.cc
Emapalumabestablished: Emapalumab switches off interferon gamma, the signal behind the runaway immune activation of haemophagocytic lymphohistiocytosis (HLH), a condition that can also be triggered by lymphoma and by CAR-T therapy.Open in Atlas onco.cc
Emavusertibphase-2: Emavusertib is an oral serine/threonine kinase inhibitor from Curis, Inc., in registered phase 2 trials for chronic lymphocytic leukaemia, brain and spinal cord tumours.Open in Atlas onco.cc
Enasidenibapproved: Enasidenib is the IDH2 counterpart of ivosidenib, approved in the US for relapsed disease but never approved in Europe after it failed to extend survival in a confirmatory trial.Open in Atlas onco.cc
ENB003phase-2: ENB003 is a small-molecule antagonist from ENB Therapeutics, Inc, in registered phase 2 trials for melanoma.Open in Atlas onco.cc
Encorafenibapproved: Encorafenib is a BRAF inhibitor that, with cetuximab and chemotherapy, became first-line standard for BRAF-mutant colorectal cancer in 2026.Open in Atlas onco.cc
EndoPredictestablished: A 12-gene test that combines gene activity with tumour size and lymph nodes to say whether hormone therapy alone is enough, and whether to continue it beyond five years.Open in Atlas onco.cc
Enfortumab vedotinapproved: Enfortumab vedotin is an ADC against Nectin-4 that, combined with pembrolizumab, nearly doubled survival in advanced bladder cancer.Open in Atlas onco.cc
Englumafusp alfaphase-2: Englumafusp alfa is an experimental fusion protein from Hoffmann-La Roche in phase 2 trials for hodgkin lymphoma, aimed at CD19.Open in Atlas onco.cc
Ensartinibapproved: A Chinese-developed ALK pill approved in the US in December 2024 for first-line ALK-positive lung cancer.Open in Atlas onco.cc
Entrectinibapproved: Entrectinib (Rozlytrek) is a pill for NTRK-fusion cancers and ROS1 lung cancer that reaches brain metastases.Open in Atlas onco.cc
ENV-501phase-2: ENV-501 is an experimental antibody-drug conjugate from Hummingbird Bioscience in phase 2 trials for melanoma, non-small-cell lung cancer and HR-positive / HER2-negative breast cancer, aimed at HER3.Open in Atlas onco.cc
Envafolimabapproved: Envafolimab is the first PD-L1 antibody given as a quick injection under the skin rather than an infusion, approved in China for advanced tumours with mismatch-repair deficiency.Open in Atlas onco.cc
Enzalutamideapproved: Enzalutamide is a second-generation androgen-receptor blocker that stops the receptor binding testosterone, entering the nucleus and switching on genes. It is approved at every stage of advanced prostate cancer, from rising PSA after surgery to castration-r...Open in Atlas onco.cc
EP0031phase-2: EP0031 is an experimental small-molecule drug from Ellipses Pharma in phase 2 trials for non-small-cell lung cancer, aimed at RET.Open in Atlas onco.cc
EP0062phase-2: EP0062 is an experimental small-molecule drug from Ellipses Pharma in phase 2 trials for HR-positive / HER2-negative breast cancer, aimed at Androgen receptor.Open in Atlas onco.cc
Epacadostatnegative: An enzyme blocker meant to stop tumours starving T cells of tryptophan. Its 2018 phase 3 failure ended an entire class overnight.Open in Atlas onco.cc
Epcoritamabapproved: Epcoritamab is an under-the-skin injection that pulls T cells onto lymphoma cells; it is approved for relapsed large B-cell and follicular lymphoma, and moving toward first line.Open in Atlas onco.cc
Epirubicinapproved: Epirubicin (Ellence) is a close relative of doxorubicin used mainly after breast cancer surgery when lymph nodes are involved, and in stomach cancer regimens; it is a little kinder to the heart.Open in Atlas onco.cc
Epoetin alfaapproved: Epoetin alfa is a manufactured version of the kidney hormone that tells the bone marrow to make red blood cells. In cancer it treats anaemia caused by chemotherapy and reduces the need for transfusions, but it is used cautiously because it can shorten survi...Open in Atlas onco.cc
Epoetin thetaapproved: Epoetin theta is a made-to-order version of erythropoietin, the hormone that tells the marrow to make red blood cells. It is used to treat the anaemia of chemotherapy in people with non-myeloid cancers, sparing some transfusions.Open in Atlas onco.cc
Eprenetapoptnegative: Eprenetapopt (APR-246) was a drug meant to refold mutant p53, the most common broken protein in cancer. Its phase 3 in blood cancer failed in 2020.Open in Atlas onco.cc
Equecabtagene autoleucelapproved: Equecabtagene autoleucel is a BCMA CAR-T from IASO Bio and Innovent, approved in China in June 2023 for multiple myeloma that has returned after at least three lines of treatment. In the FUMANBA-1 trial about 96% of infused patients responded, most with dee...Open in Atlas onco.cc
Erdafitinibapproved: The first targeted pill for bladder cancer, for the roughly 20% of tumours with FGFR3 alterations, used after immunotherapy.Open in Atlas onco.cc
Eribulinapproved: A sea-sponge-derived chemotherapy that extended survival in heavily pretreated breast cancer and in liposarcoma, where almost nothing else had.Open in Atlas onco.cc
Erlotinibapproved: Erlotinib was one of the first EGFR pills for lung cancer; it was approved before anyone knew EGFR mutations predicted who would respond, then redefined by them.Open in Atlas onco.cc
Eryaspasenegative: Eryaspase packed a leukaemia enzyme into red blood cells to starve pancreatic cancer of an amino acid; the phase 3 TRYbeCA-1 trial missed its survival goal.Open in Atlas onco.cc
ESG401phase-3: ESG401 is an experimental drug that delivers chemotherapy to cells bearing TROP2. Early breast-cancer response results are being followed by larger trials.Open in Atlas onco.cc
Estramustineestablished: Estramustine is an oral prostate cancer drug that combines an oestrogen with an alkylating agent, approved in the United States in 1981 for metastatic disease and later combined with taxanes, though its clotting risk has pushed it out of routine use.Open in Atlas onco.cc
Ethiodized oilestablished: Lipiodol is an iodine-rich oil injected into the liver's artery that lodges in liver tumours; it lets radiologists see them on CT and is the vehicle that carries chemotherapy into the tumour in conventional chemoembolisation for liver cancer.Open in Atlas onco.cc
Etoposideapproved: Etoposide is a chemotherapy from the mayapple plant, essential to curing testicular cancer (BEP), treating small-cell lung cancer, lymphomas, childhood sarcomas and leukaemias, and used in transplant conditioning.Open in Atlas onco.cc
Everolimusapproved: An mTOR-blocking pill that doubled progression-free time with exemestane in 2012 and is now paired with the oral SERD giredestrant.Open in Atlas onco.cc
Evexomostatphase-2: Evexomostat is a small-molecule inhibitor from SynDevRx, Inc., in registered phase 2 trials for metastatic cancer.Open in Atlas onco.cc
EVM14phase-2: EVM14 is a cancer vaccine from Everest Medicines (Beijing) Co., Ltd., in registered phase 2 trials for metastatic cancer.Open in Atlas onco.cc
Evofosfamidenegative: Evofosfamide was the most advanced hypoxia-activated drug, designed to kill the oxygen-starved tumour cells radiotherapy and chemotherapy miss, but it failed both of its phase 3 trials in 2015.Open in Atlas onco.cc
Evorpaceptphase-3: Evorpacept is an experimental immune checkpoint modulator from ALX Oncology in phase 3 trials for gastric & gastro-oesophageal junction cancer, HR-positive / HER2-negative breast cancer and HER2-positive breast cancer, with its target not yet stated publicly.Open in Atlas onco.cc
Exemestaneapproved: Exemestane is a steroidal aromatase inhibitor, the partner of everolimus and the agent tested with ovarian suppression in young women.Open in Atlas onco.cc

F

F182112phase-3: F182112 is an experimental investigational agent whose form is not stated in the registry from Shandong New Time Pharmaceutical in phase 3 trials for multiple myeloma, with its target not yet stated publicly.Open in Atlas onco.cc
FAP-2286 (177Lu / 68Ga)phase-2: A FAP-targeted theranostic pair: one version images almost any solid tumour, the other treats it with radiation.Open in Atlas onco.cc
Farletuzumab ecteribulinphase-2: Farletuzumab ecteribulin is an antibody-drug conjugate from Eisai Inc., in registered phase 2 trials for metastatic cancer.Open in Atlas onco.cc
Farletuzumab-exatecanphase-2: Farletuzumab-exatecan is an experimental antibody-drug conjugate from CSPC Megalith Biopharmaceutical in phase 2 trials, aimed at Folate receptor alpha.Open in Atlas onco.cc
Favezelimabphase-3: Favezelimab is Merck's LAG-3 antibody, tested with pembrolizumab in phase 3 trials in colorectal cancer and classical Hodgkin lymphoma; the colorectal trial did not succeed.Open in Atlas onco.cc
FDA018-ADCphase-3: FDA018-ADC, also called F0024, is an experimental drug that carries chemotherapy to TROP2-bearing cells. Early response results do not establish a benefit over standard treatment.Open in Atlas onco.cc
Fedratinibapproved: A second JAK inhibitor for myelofibrosis that works after ruxolitinib fails; it carries a boxed warning for a rare brain toxicity (Wernicke encephalopathy) so thiamine is checked.Open in Atlas onco.cc
Feladilimabphase-2: Feladilimab is a monoclonal antibody from GlaxoSmithKline, in registered phase 2 trials for multiple myeloma.Open in Atlas onco.cc
Fenbendazole (veterinary anthelmintic)preclinical: Fenbendazole is a dog and livestock dewormer that is sold online as a cancer cure. It has never been approved for people, no trial has tested it in cancer, and doctors have reported severe liver injury in patients who took it.Open in Atlas onco.cc
Fentanyl (transmucosal, for breakthrough cancer pain)approved: These are fast-acting forms of the opioid fentanyl, taken as a tablet against the cheek or as a nasal spray, for sudden flares of pain in people whose cancer pain is otherwise controlled by a regular opioid. They are only for patients already tolerant to op...Open in Atlas onco.cc
Fianlimabphase-3: Fianlimab is Regeneron's LAG-3 blocking antibody, paired with the PD-1 blocker cemiplimab. A 60% phase 1 response rate in untreated melanoma prompted phase 3 trials, but the metastatic trial against pembrolizumab missed its progression endpoint in 2026.Open in Atlas onco.cc
Ficerafusp alfaphase-3: Ficerafusp alfa is an EGFR antibody fused to a TGF-beta sponge, designed to remove the immune-suppressing signal that keeps HPV-negative throat cancers cold.Open in Atlas onco.cc
Ficlatuzumabphase-3: Ficlatuzumab is an experimental monoclonal antibody from AVEO Pharmaceuticals in phase 3 trials for head and neck squamous cell carcinoma, with its target not yet stated publicly.Open in Atlas onco.cc
Filgrastim (G-CSF)approved: Filgrastim (Neupogen and its biosimilars) is a daily injection that speeds the recovery of infection-fighting white cells after chemotherapy, lets doctors give chemotherapy on schedule and mobilises stem cells for transplant.Open in Atlas onco.cc
Flonoltinibphase-2: Flonoltinib is an oral kinase inhibitor from Chengdu Zenitar Biomedical Technology Co., Ltd, in registered phase 2 trials for myeloproliferative neoplasms.Open in Atlas onco.cc
Florastamin F-18phase-3: Florastamin is FutureChem's fluorine-18 PSMA PET tracer from South Korea, in phase 3 trials for staging high-risk and recurrent prostate cancer alongside the established PSMA agents.Open in Atlas onco.cc
FLOT (5-FU, leucovorin, oxaliplatin, docetaxel)standard-of-care: FLOT is the four-drug chemotherapy given before and after surgery for stomach cancer in the West; since 2025 immunotherapy is added to it.Open in Atlas onco.cc
Flotufolastat F-18approved: Flotufolastat is a third PSMA PET tracer, with a radiohybrid chemistry designed to be reused for therapy.Open in Atlas onco.cc
Floxuridineestablished: Floxuridine is a cousin of fluorouracil pumped directly into the liver's artery to treat bowel cancer that has spread to the liver, delivering a very high local dose with little reaching the rest of the body.Open in Atlas onco.cc
Fluciclovine F-18approved: Fluciclovine F-18 was the first PET tracer approved for finding recurrent prostate cancer after treatment (2016), and has been largely superseded since 2020 by PSMA PET.Open in Atlas onco.cc
Fludarabineapproved: Fludarabine is a chemotherapy infusion for chronic lymphocytic leukaemia. It anchored the FCR regimen that was the first to give long remissions, and today it is used above all to prepare patients for CAR-T cells and transplants.Open in Atlas onco.cc
Fludeoxyglucose F-18 (FDG)approved: The radioactive sugar used in almost every cancer PET scan, approved in the 1990s and made fresh each day by regional cyclotrons.Open in Atlas onco.cc
Flumatinibapproved: Flumatinib is Hansoh Pharma's second-generation BCR-ABL inhibitor, approved in China in 2019 for newly diagnosed chronic-phase chronic myeloid leukaemia.Open in Atlas onco.cc
Fluoroestradiol F-18 (FES PET)approved: A PET scan that shows which breast cancer deposits still have oestrogen receptors, helping decide whether hormone therapy will work when biopsy is impractical.Open in Atlas onco.cc
Fluorouracil (5-FU)approved: The 1957 chemotherapy that remains the backbone of treatment for bowel, stomach, pancreatic, anal, head and neck and breast cancers, and as a cream for skin precancers.Open in Atlas onco.cc
Fluoxymesteronehistoric: Fluoxymesterone is an oral male hormone approved in 1956 and once used to palliate advanced breast cancer in women, an approach abandoned when better tolerated antioestrogens and aromatase inhibitors arrived.Open in Atlas onco.cc
Flutamideapproved: Flutamide was the first tablet to block testosterone at the prostate cancer cell. It is taken with an injection that stops testosterone production, but newer drugs have largely replaced it.Open in Atlas onco.cc
Fluzoparibphase-2: Fluzoparib is an oral parp inhibitor from Risen (Suzhou) Pharma Tech Co., Ltd., in registered phase 2 trials for metastatic cancer.Open in Atlas onco.cc
FOLFIRI (5-FU, leucovorin, irinotecan)standard-of-care: FOLFIRI is the other backbone bowel-cancer chemotherapy, swapping oxaliplatin for irinotecan. Used first or second line and, since 2026, with the BRAF combination.Open in Atlas onco.cc
FOLFIRINOX / mFOLFIRINOXstandard-of-care: FOLFIRINOX is a four-drug chemotherapy combination that, in 2011, became the first treatment to meaningfully extend life in metastatic pancreatic cancer; it is now the standard before and after surgery.Open in Atlas onco.cc
FOLFOX (5-FU, leucovorin, oxaliplatin)standard-of-care: FOLFOX is the workhorse chemotherapy combination for bowel cancer, used after surgery to cure and in advanced disease as the backbone that targeted drugs are added to.Open in Atlas onco.cc
FOLFOXIRI (5-FU, leucovorin, oxaliplatin, irinotecan)established: All three of the active bowel cancer chemotherapy drugs given together instead of two. It shrinks more tumours than a doublet and is chosen when shrinking the tumour is what matters, usually with bevacizumab.Open in Atlas onco.cc
Formestanehistoric: Formestane, launched in Europe in 1993, was the first selective aromatase inhibitor for advanced breast cancer, given by injection every two weeks; oral exemestane and the non-steroidal inhibitors made it redundant within a few years.Open in Atlas onco.cc
Fostamatinibestablished: Fostamatinib is a tablet that blocks the enzyme SYK so the spleen stops destroying antibody-coated platelets; it is approved for chronic immune thrombocytopenia and was first trialled as a lymphoma drug.Open in Atlas onco.cc
FoundationOne CDx / Liquid CDxapproved: The FDA-approved tissue (324 genes) and blood genomic tests that serve as companion diagnostics for dozens of drugs.Open in Atlas onco.cc
FPI-2265phase-2: FPI-2265 is an experimental radioligand therapy from Fusion Pharmaceuticals in phase 2 trials for prostate cancer, aimed at PSMA.Open in Atlas onco.cc
Fruquintinibapproved: A Chinese-discovered pill that blocks the blood-vessel receptors, approved in 2023 for bowel cancer after all standard treatments.Open in Atlas onco.cc
Fulvestrantapproved: Fulvestrant is a monthly intramuscular injection that degrades the oestrogen receptor rather than blocking it, the endocrine backbone paired with CDK4/6, PI3K and AKT inhibitors once aromatase inhibitors fail. Slow uptake and incomplete receptor degradation...Open in Atlas onco.cc
Fulzerasibapproved: Fulzerasib was the first KRAS G12C-blocking pill approved in China, for lung cancers carrying that mutation after earlier treatment.Open in Atlas onco.cc
Furmonertinibapproved: Furmonertinib is a Chinese lung cancer pill of the same class as osimertinib, which more than doubled the time before cancer grew compared with gefitinib in the FURLONG trial.Open in Atlas onco.cc
Futibatinibapproved: Futibatinib is a covalent FGFR inhibitor for FGFR2-fusion bile duct cancer, with the highest response rate of the first-generation drugs.Open in Atlas onco.cc

G

Galeteronewithdrawn: An experimental prostate cancer tablet meant to work in men whose cancer makes a broken form of the androgen receptor. The trial designed to prove it collapsed.Open in Atlas onco.cc
Galleriphase-3: A blood test screening for more than 50 cancers at once, before the FDA in September 2026.Open in Atlas onco.cc
Gallium-68 DOTATATE (and Cu-64 DOTATATE)approved: The PET scan for neuroendocrine tumours that finds far more disease than older scans and confirms eligibility for lutetium radioligand therapy (the theranostic pair).Open in Atlas onco.cc
Gallium-68 gozetotide (PSMA-11)approved: Gallium-68 PSMA-11 was the first PSMA PET tracer approved in the US (2020), and is made on site from a generator or cyclotron.Open in Atlas onco.cc
Garsorasibapproved: Garsorasib is InventisBio's KRAS G12C-blocking pill, approved in China in 2024 for previously treated lung cancer with that mutation.Open in Atlas onco.cc
GC012Fphase-2: GC012F is an experimental CAR-T cell therapy from Gracell Biotechnologies (Shanghai) in phase 2 trials for multiple myeloma, aimed at CD19 and BCMA.Open in Atlas onco.cc
GC101 TILphase-2: GC101 TIL is an experimental tumour-infiltrating lymphocyte therapy from Shanghai Juncell Therapeutics in phase 2 trials for melanoma, aimed at PD-1 and BRAF.Open in Atlas onco.cc
Gecacitinibphase-2: Gecacitinib is an oral kinase inhibitor from Suzhou Zelgen Biopharmaceuticals Co.,Ltd, in registered phase 2 trials for cervical cancer.Open in Atlas onco.cc
Gedatolisibapproved: An intravenous drug that blocks the whole PI3K/mTOR pathway, approved in July 2026 for hormone-positive breast cancer.Open in Atlas onco.cc
Gefitinibapproved: The lung-cancer pill whose dramatic responses in a few patients led to the discovery of EGFR mutations in 2004.Open in Atlas onco.cc
Gemcitabineapproved: A versatile chemotherapy used in pancreatic, bladder, lung, ovarian, breast and biliary cancers, in nasopharyngeal cancer, and as a bladder instillation.Open in Atlas onco.cc
Gemcitabine + cisplatinstandard-of-care: Gemcitabine plus cisplatin has been the chemotherapy backbone for bile duct cancer since 2010 and is now given with immunotherapy.Open in Atlas onco.cc
Gemcitabine + nab-paclitaxelstandard-of-care: Gemcitabine plus nab-paclitaxel is the gentler of the two standard chemotherapy backbones for pancreatic cancer, and the base on which most new drugs are being tested.Open in Atlas onco.cc
Gemcitabine intravesical system (TAR-200)approved: TAR-200 is a small pretzel-shaped device placed in the bladder that releases gemcitabine for three weeks at a time. It was approved in 2025 for early bladder cancer that no longer responds to BCG.Open in Atlas onco.cc
Gemtuzumab ozogamicinapproved: Gemtuzumab ozogamicin (Mylotarg) is an anti-CD33 antibody linked to the DNA-cutting payload calicheamicin, the first ADC approved, in 2000 for relapsed acute myeloid leukaemia. An unstable linker and no benefit in a confirmatory trial led to withdrawal in 2...Open in Atlas onco.cc
GFH375phase-3: GFH375 is an experimental small-molecule drug from Genfleet Therapeutics (Shanghai) in phase 3 trials for pancreatic ductal adenocarcinoma and non-small-cell lung cancer, aimed at KRAS.Open in Atlas onco.cc
GI-6301negative: GI-6301 was a vaccine made from yeast carrying brachyury, the protein that chordomas depend on. Given with radiotherapy in a randomised trial it did not improve tumour responses.Open in Atlas onco.cc
Gilteritinibapproved: A single pill that beats salvage chemotherapy for relapsed FLT3-mutated AML, and the backbone of the triplets now being tested in frontline disease.Open in Atlas onco.cc
Giredestrantphase-3: Giredestrant is Roche's oral SERD: it failed to beat an aromatase inhibitor in first-line metastatic disease but succeeded after surgery and after CDK4/6 failure.Open in Atlas onco.cc
Givinostatphase-3: Givinostat is an experimental small-molecule drug from Italfarmaco in phase 3 trials for myeloproliferative neoplasms, with its target not yet stated publicly.Open in Atlas onco.cc
Glasdegibapproved: Glasdegib is a hedgehog-pathway pill that, with low-dose chemotherapy, extends survival in older AML patients who cannot have intensive treatment; it has largely been displaced by venetoclax combinations.Open in Atlas onco.cc
Glecirasibapproved: Glecirasib is Jacobio's KRAS G12C inhibitor, approved in China in 2024 for previously treated non-small cell lung cancer with that mutation, and in a phase 3 trial against docetaxel.Open in Atlas onco.cc
Glofitamabapproved: Glofitamab is a fixed-duration bispecific for large B-cell lymphoma, with OS benefit when combined with chemotherapy.Open in Atlas onco.cc
GLSI-100phase-3: GLSI-100 is an experimental cancer vaccine from Greenwich LifeSciences in phase 3 trials for HR-positive / HER2-negative breast cancer, aimed at HER2.Open in Atlas onco.cc
Glucarpidaseapproved: Glucarpidase (Voraxaze) is a single emergency injection that chops up methotrexate in the blood when a patient's kidneys have failed to clear a high dose, preventing potentially fatal toxicity.Open in Atlas onco.cc
Glumetinibapproved: Glumetinib is a Chinese MET inhibitor approved in 2023 for lung cancers with MET exon 14 skipping, one of three such drugs approved in China and now in a phase 3 trial in gastric cancer.Open in Atlas onco.cc
Golcadomidephase-3: Golcadomide is a next-generation lenalidomide-like pill that degrades two lymphoma transcription factors far more potently, now in phase 3 with R-CHOP.Open in Atlas onco.cc
Golidocitinibapproved: Golidocitinib is Dizal's JAK1 inhibitor, approved in China in 2024 as the first JAK inhibitor for relapsed peripheral T-cell lymphoma, a cancer with few options after first-line chemotherapy.Open in Atlas onco.cc
Goserelin / leuprolide (ovarian function suppression)approved: Monthly or 3-monthly injections that switch off the ovaries, letting premenopausal women use aromatase inhibitors and lowering recurrence in higher-risk cases.Open in Atlas onco.cc
Gotistobartphase-3: Gotistobart is an experimental monoclonal antibody from OncoC4 in phase 3 trials for non-small-cell lung cancer, melanoma and head and neck squamous cell carcinoma, aimed at CTLA-4.Open in Atlas onco.cc
GQ1005phase-3: GQ1005 is an experimental antibody-drug conjugate from GeneQuantum Healthcare (Suzhou) in phase 3 trials for HER2-positive breast cancer, aimed at HER2.Open in Atlas onco.cc
GR1803phase-3: GR1803 is an experimental investigational agent whose form is not stated in the registry from Genrix (Shanghai) Biopharmaceutical in phase 3 trials for multiple myeloma, with its target not yet stated publicly.Open in Atlas onco.cc
Granisetronapproved: Granisetron is an anti-sickness medicine for chemotherapy given as a tablet, an injection, a week-long skin patch (Sancuso) or a slow-release injection that lasts several days (Sustol).Open in Atlas onco.cc
GRT-C901phase-3: GRT-C901 is an experimental cancer vaccine from Seattle Project in phase 3 trials for colorectal cancer, with its target not yet stated publicly.Open in Atlas onco.cc
GRT-R902phase-3: GRT-R902 is an experimental cancer vaccine from Seattle Project in phase 3 trials for colorectal cancer, with its target not yet stated publicly.Open in Atlas onco.cc
GS-0201phase-1: GS-0201 is an experimental pill being studied to block a DNA-repair enzyme in cancer cells.Open in Atlas onco.cc
GSK2256098phase-2: GSK2256098 is a tablet that blocks an enzyme called FAK, which meningiomas missing the NF2 gene rely on. In the Alliance A071401 trial it slowed progression in recurrent NF2-mutant meningiomas, one of the first positive results for a targeted drug in this t...Open in Atlas onco.cc
Guardant Revealestablished: A blood test for leftover cancer after surgery that needs no tumour sample, so results come faster than tumour-informed tests.Open in Atlas onco.cc
Guardant360 CDxapproved: A blood test that reads a tumour's mutations without a tissue biopsy and is the FDA-approved gateway to several targeted drugs.Open in Atlas onco.cc

H

H101 oncolytic adenovirusapproved: Oncorine is Shanghai Sunway Biotech's oncolytic adenovirus, approved in China in 2005 for nasopharyngeal carcinoma with chemotherapy, the first oncolytic virus approved anywhere in the world.Open in Atlas onco.cc
HB-200phase-2: HB-200 is a vaccine built from two harmless engineered viruses that teach the immune system to attack the HPV16 proteins inside cervical and throat cancers. It has been tested with pembrolizumab in HPV16-positive head and neck cancer.Open in Atlas onco.cc
HB0036phase-2: HB0036 is an experimental investigational agent whose form is not stated in the registry from Shanghai Huaota Biopharmaceutical in phase 2 trials for non-small-cell lung cancer, aimed at PD-L1 and TIGIT.Open in Atlas onco.cc
HB1801phase-3: HB1801 is an experimental investigational agent whose form is not stated in the registry from Shanghai JMT-Bio in phase 3 trials for HER2-positive breast cancer, with its target not yet stated publicly.Open in Atlas onco.cc
HDM2017phase-2: HDM2017 is an experimental investigational agent whose form is not stated in the registry from Hangzhou Zhongmei Huadong Pharmaceutical in phase 2 trials for colorectal cancer, aimed at MET.Open in Atlas onco.cc
HER2 IHC and ISH companion assays (HercepTest, PATHWAY 4B5, HER2 Dual ISH)approved: The tests that grade a breast or stomach cancer's HER2 level, from the original trastuzumab test in 1998 to the new 'HER2-low' and 'ultralow' cut-offs.Open in Atlas onco.cc
Hexaminolevulinateestablished: Hexaminolevulinate makes bladder tumours fluoresce red under blue light so the urologist can see and remove flat and tiny cancers that white-light cystoscopy misses.Open in Atlas onco.cc
Histamine dihydrochlorideapproved: Ceplene is a twice-daily injection of histamine given alongside low-dose interleukin-2 as maintenance treatment for adults with acute myeloid leukaemia in first remission, to help immune cells prevent relapse. It is authorised in Europe only.Open in Atlas onco.cc
Histrelinestablished: Histrelin is a GnRH agonist delivered by a small implant under the skin of the arm that lasts a whole year, approved in the United States as Vantas for palliative treatment of advanced prostate cancer and as Supprelin for early puberty in children.Open in Atlas onco.cc
HLX11phase-3: HLX11 is an experimental monoclonal antibody from Shanghai Henlius Biotech in phase 3 trials for HR-positive / HER2-negative breast cancer and HER2-positive breast cancer, aimed at HER2.Open in Atlas onco.cc
HLX22phase-3: HLX22 is an experimental monoclonal antibody from Shanghai Henlius Biotech in phase 3 trials for gastric & gastro-oesophageal junction cancer and HR-positive / HER2-negative breast cancer, aimed at HER2.Open in Atlas onco.cc
HLX26phase-2: HLX26 is an experimental monoclonal antibody from Shanghai Henlius Biotech in phase 2 trials for non-small-cell lung cancer, aimed at LAG-3.Open in Atlas onco.cc
HLX43phase-3: HLX43 is an experimental antibody-drug conjugate from Shanghai Henlius Biotech in phase 3 trials for non-small-cell lung cancer, cervical cancer and ovarian cancer, aimed at PD-L1 and EGFR.Open in Atlas onco.cc
HMBD-001phase-2: HMBD-001 is an experimental monoclonal antibody from Hummingbird Bioscience in phase 2 trials for non-small-cell lung cancer, head and neck squamous cell carcinoma and oesophageal cancer, aimed at HER3 and EGFR.Open in Atlas onco.cc
HMPL-306phase-3: HMPL-306 is an experimental small-molecule drug from Hutchmed in phase 3 trials for acute myeloid leukaemia, aimed at IDH1 / IDH2.Open in Atlas onco.cc
HMPL-453phase-3: HMPL-453 is an experimental small-molecule drug from Hutchmed in phase 3 trials for biliary tract cancer, aimed at FGFR2.Open in Atlas onco.cc
HMPL-760phase-3: HMPL-760 is an experimental small-molecule drug from Hutchmed in phase 3 trials for diffuse large B-cell lymphoma, with its target not yet stated publicly.Open in Atlas onco.cc
HPV bivalent vaccine (types 16 and 18)approved: Cervarix is a vaccine against HPV types 16 and 18, the two types that cause most cervical cancers, authorised in the EU in 2007 and the US in 2009 after the 18,000-woman PATRICIA trial showed near-complete protection against type-specific precancer. GSK wit...Open in Atlas onco.cc
HPV quadrivalent vaccine (types 6, 11, 16 and 18)approved: Gardasil was the first HPV vaccine, licensed in 2006 to prevent cervical and other genital cancers and genital warts. It has been replaced in most countries by the nine-type version, Gardasil 9.Open in Atlas onco.cc
HR070803phase-3: HR070803 is an experimental small-molecule drug from Jiangsu HengRui Medicine in phase 3 trials for colorectal cancer, with its target not yet stated publicly.Open in Atlas onco.cc
HRS-1167phase-2: HRS-1167 is an experimental pill being studied to block a DNA-repair enzyme in cancer cells.Open in Atlas onco.cc
HRS-4357phase-3: HRS-4357 is an experimental investigational agent whose form is not stated in the registry from Jiangsu HengRui Medicine in phase 3 trials for prostate cancer, aimed at PSMA.Open in Atlas onco.cc
HRS-8080phase-3: HRS-8080 is an experimental small-molecule drug from Shandong Suncadia Medicine in phase 3 trials for HR-positive / HER2-negative breast cancer, with its target not yet stated publicly.Open in Atlas onco.cc
HS-10502phase-1: HS-10502 is an experimental pill being studied to block a DNA-repair enzyme in cancer cells.Open in Atlas onco.cc
HS-20089phase-3: HS-20089 is an experimental antibody-drug conjugate from Hansoh BioMedical R&D in phase 3 trials for ovarian cancer and endometrial cancer, with its target not yet stated publicly.Open in Atlas onco.cc
HS-20093phase-3: HS-20093 is an experimental investigational agent whose form is not stated in the registry from Hansoh BioMedical R&D in phase 3 trials for osteosarcoma, non-small-cell lung cancer and sarcomas, with its target not yet stated publicly.Open in Atlas onco.cc
HS-20117phase-3: HS-20117 is an experimental bispecific antibody from Hansoh BioMedical R&D in phase 3 trials for non-small-cell lung cancer, aimed at EGFR and MET.Open in Atlas onco.cc
HST-1011phase-2: HST-1011 is a small-molecule inhibitor from HotSpot Therapeutics, Inc, in registered phase 2 trials for metastatic cancer.Open in Atlas onco.cc
Human normal immunoglobulin (IVIg)approved: Intravenous immunoglobulin is pooled antibody from many blood donors. People with chronic lymphocytic leukaemia or myeloma whose own antibody levels have collapsed, and who keep getting bacterial infections despite antibiotics, receive it as replacement.Open in Atlas onco.cc
Hydroxyurea (hydroxycarbamide)approved: Hydroxyurea is a cheap, decades-old pill that lowers high blood counts in polycythaemia vera and essential thrombocythaemia and is also the main drug for sickle cell disease.Open in Atlas onco.cc

I

IAH0968phase-3: IAH0968 is an experimental small-molecule drug from SUNHO（China）BioPharmaceutical CO. in phase 3 trials for gastric & gastro-oesophageal junction cancer, aimed at HER2.Open in Atlas onco.cc
Ibandronic acidapproved: Ibandronic acid (Bondronat) is a bisphosphonate available in Europe as a monthly infusion or daily tablet to prevent fractures and other bone complications in women with breast cancer that has spread to bone, and to treat cancer-related high calcium.Open in Atlas onco.cc
Iberdomideapproved: Iberdomide is a far more potent successor to lenalidomide, now in phase 3 as post-transplant maintenance and in relapsed disease.Open in Atlas onco.cc
IBI130phase-1: IBI130 is an experimental antibody-drug conjugate being studied in people with advanced cancer. Its benefit and safety are still being evaluated.Open in Atlas onco.cc
IBI3014phase-1: IBI3014 is an experimental antibody-drug conjugate being studied in people with advanced cancer. Its benefit and safety are still being evaluated.Open in Atlas onco.cc
IBI310phase-3: IBI310 is an experimental investigational agent whose form is not stated in the registry from Innovent Biopharmaceutical Technology (Hangzhou) in phase 3 trials for hepatocellular carcinoma, with its target not yet stated publicly.Open in Atlas onco.cc
IBI343phase-3: IBI343 is an experimental investigational agent whose form is not stated in the registry from Innovent Biologics (Suzhou) in phase 3 trials for pancreatic ductal adenocarcinoma, aimed at Claudin 18.2.Open in Atlas onco.cc
IBI354phase-3: IBI354 is an experimental antibody-drug conjugate from Innovent Biologics (Suzhou) in phase 3 trials for HER2-positive breast cancer and ovarian cancer, aimed at HER2.Open in Atlas onco.cc
IBI363phase-2: IBI363 is an experimental fusion protein from Innovent Biologics (Suzhou) in phase 2 trials for melanoma, non-small-cell lung cancer and colorectal cancer, aimed at PD-1.Open in Atlas onco.cc
Ibritumomab tiuxetanapproved: Zevalin is an antibody carrying a radioactive isotope that seeks out CD20 on lymphoma cells. It treats follicular lymphoma that has relapsed and is given as a one-off consolidation after chemotherapy.Open in Atlas onco.cc
Ibrutinibapproved: The pill that ended chemotherapy for most CLL. It blocks the survival signal B cells depend on, and it was the first drug to beat chemoimmunotherapy in nearly every CLL setting.Open in Atlas onco.cc
Icotinibapproved: Icotinib, approved in 2011, was the first cancer drug invented and developed in China, and it showed that a domestic lung cancer pill could match a Western one head to head.Open in Atlas onco.cc
ICP-248phase-3: ICP-248 is an experimental small-molecule drug from Beijing InnoCare Pharma Tech in phase 3 trials for mantle cell lymphoma and chronic lymphocytic leukaemia, with its target not yet stated publicly.Open in Atlas onco.cc
Idarubicinapproved: Idarubicin is an anthracycline chemotherapy approved in 1990 for adult acute myeloid leukaemia, given with cytarabine in 3+7 induction and FLAG-Ida salvage and in acute promyelocytic leukaemia protocols. Randomised trials showed more complete remissions tha...Open in Atlas onco.cc
Idecabtagene vicleucelapproved: Idecabtagene vicleucel was the first myeloma CAR-T (2021) and is now approved after two prior lines based on KarMMa-3.Open in Atlas onco.cc
Idelalisibapproved: Idelalisib was the first PI3K inhibitor for blood cancers; it is effective in CLL with rituximab but so toxic (colitis, hepatitis, pneumonitis, infections) that the class has largely been abandoned.Open in Atlas onco.cc
IDRX-42phase-3: IDRX-42 is an experimental small-molecule drug from GlaxoSmithKline in phase 3 trials for gastrointestinal stromal tumour, with its target not yet stated publicly.Open in Atlas onco.cc
Ifinatamab deruxtecanphase-3: Ifinatamab deruxtecan is a B7-H3 ADC showing some of the best response rates ever seen in relapsed small-cell lung cancer.Open in Atlas onco.cc
Ifosfamideapproved: Ifosfamide is an alkylating chemotherapy partnered with doxorubicin in sarcoma and with etoposide in Ewing sarcoma, given with a bladder-protecting drug.Open in Atlas onco.cc
Ifupinostatphase-3: Ifupinostat is an experimental investigational agent whose form is not stated in the registry from BeBetter Med in phase 3 trials for diffuse large B-cell lymphoma, with its target not yet stated publicly.Open in Atlas onco.cc
Illuccix (kit for Ga-68 gozetotide)approved: Telix's ready-to-label kit that lets any nuclear medicine department make the gallium PSMA scan for prostate cancer.Open in Atlas onco.cc
IMA203phase-3: IMA203 is an experimental TCR-T cell therapy from Immatics US in phase 3 trials for melanoma, aimed at PRAME.Open in Atlas onco.cc
Imatinibapproved: The drug that started the targeted therapy era in 2001, turning chronic myeloid leukaemia into a manageable condition with near-normal life expectancy.Open in Atlas onco.cc
Imetelstatapproved: Imetelstat is a lipid-linked oligonucleotide that binds the RNA template of telomerase, the enzyme cancer cells use to stay immortal, and it is the first telomerase inhibitor approved for any cancer. In lower-risk myelodysplastic syndromes it freed 40% of t...Open in Atlas onco.cc
Imiquimodapproved: Imiquimod (Aldara) is a cream that provokes the skin's own immune system to clear superficial basal cell carcinomas and the sun-damage patches (actinic keratoses) that can turn into skin cancer.Open in Atlas onco.cc
Imlunestrantapproved: Imlunestrant is Lilly's oral oestrogen-receptor degrader, approved in 2025 for ESR1-mutant breast cancer and shown to work with abemaciclib regardless of mutation.Open in Atlas onco.cc
IMP1734phase-2: EIK1003, formerly IMP1734, is an experimental pill that blocks the PARP1 DNA-repair enzyme.Open in Atlas onco.cc
IN10018phase-3: IN10018 is an experimental small-molecule drug from InxMed (Shanghai) in phase 3 trials for non-small-cell lung cancer, pancreatic ductal adenocarcinoma and ovarian cancer, with its target not yet stated publicly.Open in Atlas onco.cc
Inaticabtagene autoleucelapproved: Inati-cel is a Chinese CAR-T for adults with acute lymphoblastic leukaemia that has come back or stopped responding, approved in 2023.Open in Atlas onco.cc
Inavolisibapproved: Inavolisib is a PI3K drug that also destroys the mutant protein, approved in 2024 with palbociclib and fulvestrant for PIK3CA-mutant breast cancer.Open in Atlas onco.cc
INBRX-106phase-3: INBRX-106 is an experimental monoclonal antibody from Inhibrx Biosciences in phase 3 trials for head and neck squamous cell carcinoma, with its target not yet stated publicly.Open in Atlas onco.cc
INCA033989phase-1: INCA033989 is an antibody that recognises only the mutant form of calreticulin found in about a quarter of essential thrombocythaemia and myelofibrosis patients. Unlike existing drugs, which control counts, it targets the diseased clone itself and is in fir...Open in Atlas onco.cc
INCA33890phase-3: INCA33890 is an experimental investigational agent whose form is not stated in the registry from Incyte in phase 3 trials for colorectal cancer, with its target not yet stated publicly.Open in Atlas onco.cc
INCB123667phase-3: INCB123667 is an experimental small-molecule drug from Incyte in phase 3 trials for ovarian cancer, with its target not yet stated publicly.Open in Atlas onco.cc
INCB161734phase-3: INCB161734 is an experimental small-molecule drug from Incyte in phase 3 trials for pancreatic ductal adenocarcinoma, aimed at KRAS.Open in Atlas onco.cc
Inetetamabapproved: Inetetamab is 3SBio's HER2 antibody, approved in China in 2020 with vinorelbine for HER2-positive metastatic breast cancer.Open in Atlas onco.cc
Infigratinibwithdrawn: Infigratinib is an FGFR inhibitor pill given accelerated approval in the United States in 2021 for bile duct cancer with an FGFR2 fusion, then withdrawn in 2024 when its confirmatory trial could not enrol; it is now being developed for achondroplasia instead.Open in Atlas onco.cc
Iniparibnegative: Billed as the first PARP inhibitor for triple-negative breast cancer, it failed its phase 3 in 2011. It turned out not to inhibit PARP at all.Open in Atlas onco.cc
Inlexisertibphase-2: Inlexisertib is an oral serine/threonine kinase inhibitor from Deciphera Pharmaceuticals, LLC, in registered phase 2 trials for metastatic cancer.Open in Atlas onco.cc
INO-5401phase-2: INO-5401 is an experimental cancer vaccine from Inovio Pharmaceuticals in phase 2 trials for glioma & glioblastoma, aimed at PSMA.Open in Atlas onco.cc
Inotuzumab ozogamicinapproved: Inotuzumab ozogamicin is an antibody carrying a DNA-cutting toxin to CD22 on leukaemia cells. It gets far more relapsed ALL patients into remission than chemotherapy and bridges them to transplant.Open in Atlas onco.cc
INT230-6phase-3: INT230-6 is an experimental investigational agent whose form is not stated in the registry from Intensity Therapeutics in phase 3 trials for sarcomas, with its target not yet stated publicly.Open in Atlas onco.cc
Interferon alfa-2a/2bhistoric: Interferon alfa was the first biologic cancer drug (1986). It treated hairy cell leukaemia, CML, melanoma, kidney cancer and Kaposi sarcoma, and has been replaced almost everywhere by better-tolerated agents.Open in Atlas onco.cc
Intismeran autogenephase-3: A custom mRNA vaccine encoding up to 34 of a patient's own tumour mutations. In August 2026 it became the first personalised cancer vaccine to win a phase 3 trial.Open in Atlas onco.cc
Intravesical BCGstandard-of-care: A weakened tuberculosis vaccine put directly into the bladder. Since 1976 it has been the most effective treatment for early bladder cancer, and it remains in chronic short supply.Open in Atlas onco.cc
IO102-IO103phase-3: IO102-IO103 is an experimental peptide (immunotherapeutic vaccine) from IO Biotech in phase 3 trials for melanoma and head and neck squamous cell carcinoma, aimed at PD-L1.Open in Atlas onco.cc
Iomab-Bphase-3: Iomab-B is Actinium's radioactive antibody that clears the bone marrow before a transplant for older patients with active relapsed acute myeloid leukaemia; the phase 3 SIERRA trial met its primary endpoint but the FDA asked for another study.Open in Atlas onco.cc
Iparomlimab and tuvonralimabapproved: QL1706 is Qilu Pharmaceutical's PD-1 plus CTLA-4 antibody mixture, approved in China in 2024 for recurrent or metastatic cervical cancer after platinum chemotherapy.Open in Atlas onco.cc
Ipatasertibphase-3: Ipatasertib is an experimental small-molecule drug from Hoffmann-La Roche in phase 3 trials for HR-positive / HER2-negative breast cancer and ovarian cancer, aimed at AKT.Open in Atlas onco.cc
IPG1094phase-2: IPG1094 is a small-molecule inhibitor from Nanjing Immunophage Biotech Co., Ltd, in registered phase 2 trials for metastatic cancer.Open in Atlas onco.cc
Ipilimumabapproved: Ipilimumab was the first checkpoint inhibitor (2011), and proved the immune system could be unleashed against cancer.Open in Atlas onco.cc
Irinotecan (and liposomal irinotecan)approved: Irinotecan is a topoisomerase-blocking chemotherapy central to bowel and pancreatic cancer regimens (FOLFIRI, FOLFIRINOX, NALIRIFOX) and to salvage therapy in childhood sarcomas; it carries the same warhead as the deruxtecan ADC payloads.Open in Atlas onco.cc
Iruplinalkibapproved: Iruplinalkib is Qilu Pharmaceutical's second-generation ALK inhibitor, approved in China in 2023 for ALK-positive non-small-cell lung cancer after crizotinib and in 2024 as first-line treatment.Open in Atlas onco.cc
Isatuximabapproved: Isatuximab is Sanofi's CD38 antibody, approved in frontline transplant-ineligible myeloma (IMROZ) and, from July 2026, as an under-the-skin injection.Open in Atlas onco.cc
ISB 2001phase-1: An Indian-discovered antibody that grips two targets on myeloma cells at once while pulling in T cells to kill them, licensed to AbbVie in 2025 in the biggest deal yet for an Indian cancer drug.Open in Atlas onco.cc
Isotretinoinapproved: Isotretinoin, the acne drug, is given to children with high-risk neuroblastoma for six months after transplant to nudge any surviving cancer cells into growing up into harmless nerve cells. A 1999 trial showed it improved survival and it has been part of st...Open in Atlas onco.cc
Ivermectinphase-2: Ivermectin is a worm and parasite medicine that is being tested as an add-on to immunotherapy in two small early trials. No trial has shown that it treats any cancer, and people who have dosed themselves outside a trial have ended up in hospital with seizur...Open in Atlas onco.cc
Ivonescimabapproved: A Chinese bispecific that beat Keytruda head-to-head on progression-free survival in lung cancer, the first drug ever to do so.Open in Atlas onco.cc
Ivosidenibapproved: The first drug to block a mutant metabolic enzyme in cancer. With azacitidine it tripled survival in IDH1-mutated AML that could not take intensive chemotherapy.Open in Atlas onco.cc
Ivospeminphase-3: Ivospemin is an experimental small-molecule drug from Panbela Therapeutics in phase 3 trials for pancreatic ductal adenocarcinoma, with its target not yet stated publicly.Open in Atlas onco.cc
Ixabepiloneapproved: Ixabepilone (Ixempra) is a chemotherapy infusion for breast cancer that has stopped responding to anthracyclines, taxanes and capecitabine.Open in Atlas onco.cc
Ixazomibapproved: Ixazomib (Ninlaro) is the first oral proteasome inhibitor for multiple myeloma, enabling an all-oral triplet with lenalidomide and dexamethasone.Open in Atlas onco.cc
Izalontamab brengitecanphase-3: Izalontamab brengitecan is the first bispecific ADC to succeed in a phase 3 trial, hitting two growth receptors at once in triple-negative breast cancer.Open in Atlas onco.cc

J

JBI-802phase-2: JBI-802 is a small-molecule inhibitor from Jubilant Therapeutics Inc., in registered phase 2 trials for myeloproliferative neoplasms, chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms.Open in Atlas onco.cc
JDQ443phase-3: JDQ443 is an experimental small-molecule drug from Novartis Pharmaceuticals in phase 3 trials for non-small-cell lung cancer and colorectal cancer, aimed at KRAS.Open in Atlas onco.cc
JK08phase-2: JK08 is an experimental fusion protein or cytokine from Salubris Biotherapeutics in phase 2 trials for melanoma, colorectal cancer and non-small-cell lung cancer, aimed at CTLA-4.Open in Atlas onco.cc
JMT101phase-3: JMT101 is an experimental monoclonal antibody from Shanghai JMT-Bio in phase 3 trials for non-small-cell lung cancer, aimed at EGFR.Open in Atlas onco.cc
JMT203phase-2: JMT203 is a monoclonal antibody from Shanghai JMT-Bio Inc., in registered phase 2 trials for non-small-cell lung cancer, pancreatic ductal adenocarcinoma, colorectal cancer.Open in Atlas onco.cc
JNJ-79635322phase-3: JNJ-79635322 is an experimental investigational agent whose form is not stated in the registry from Janssen Research & Development in phase 3 trials for multiple myeloma, with its target not yet stated publicly.Open in Atlas onco.cc
JNJ-87189401phase-3: JNJ-87189401 is an experimental costimulatory agent from Janssen Research & Development in phase 3 trials for prostate cancer, aimed at PSMA.Open in Atlas onco.cc
JNJ-90014496phase-2: JNJ-90014496 is an experimental CAR-T cell therapy from Janssen Research & Development in phase 2 trials for hodgkin lymphoma and diffuse large B-cell lymphoma, aimed at CD19 and CD20.Open in Atlas onco.cc
JNJ-90301900phase-3: JNJ-90301900 is an experimental radioenhancer nanoparticle from Johnson & Johnson Enterprise Innovation in phase 3 trials for head and neck squamous cell carcinoma, with its target not yet stated publicly.Open in Atlas onco.cc
JS105phase-3: JS105 is an experimental small-molecule drug from Risen (Suzhou) Pharma Tech in phase 3 trials for HR-positive / HER2-negative breast cancer, with its target not yet stated publicly.Open in Atlas onco.cc
JS108historic: JS108 is an experimental TROP-2 antibody-drug conjugate whose first clinical study was terminated.Open in Atlas onco.cc
JS111phase-2: JS111 is an experimental small-molecule drug from Suzhou Junjing BioSciences in phase 2 trials for non-small-cell lung cancer, aimed at EGFR and MET.Open in Atlas onco.cc
JSKN003phase-3: JSKN003 is an experimental investigational agent whose form is not stated in the registry from Jiangsu Alphamab Biopharmaceuticals in phase 3 trials for HR-positive / HER2-negative breast cancer and HER2-positive breast cancer, with its target not yet state...Open in Atlas onco.cc
JSKN016phase-3: JSKN016 is an experimental drug that targets two proteins on cancer cells and carries chemotherapy. It has reached phase 3 testing; earlier response findings do not prove comparative benefit.Open in Atlas onco.cc
JYP0015phase-2: JYP0015 is an experimental small-molecule drug from Guangzhou JOYO Pharma in phase 2 trials for pancreatic ductal adenocarcinoma, non-small-cell lung cancer and colorectal cancer, aimed at KRAS.Open in Atlas onco.cc

K

KC1036phase-3: KC1036 is an experimental small-molecule drug from Beijing Konruns Pharmaceutical in phase 3 trials for oesophageal cancer, ewing sarcoma and thymoma and thymic carcinoma, with its target not yet stated publicly.Open in Atlas onco.cc
KH815phase-1: An experimental antibody drug that carries two cancer-killing payloads to cells carrying TROP2. A first human study is registered but is still listed as not yet recruiting in an older record.Open in Atlas onco.cc
KL-A167phase-3: KL-A167 is an experimental investigational agent whose form is not stated in the registry from Sichuan Kelun-Biotech Biopharmaceutical in phase 3 trials for nasopharyngeal carcinoma and non-small-cell lung cancer, with its target not yet stated publicly.Open in Atlas onco.cc
KN026phase-3: KN026 is an experimental monoclonal antibody from Shanghai JMT-Bio in phase 3 trials for HER2-positive breast cancer and HR-positive / HER2-negative breast cancer, aimed at HER2.Open in Atlas onco.cc
KRT-232phase-2: KRT-232 is an experimental small-molecule drug from Kartos Therapeutics in phase 2 trials for myeloproliferative neoplasms, diffuse large B-cell lymphoma and chronic lymphocytic leukaemia, aimed at MDM2 and TP53.Open in Atlas onco.cc

L

LAM561phase-3: LAM561 is an experimental small-molecule drug from Laminar Pharmaceuticals in phase 3 trials for glioma & glioblastoma, aimed at MET.Open in Atlas onco.cc
Lapatinibapproved: Lapatinib was the first HER2-blocking pill (2007) and is now mostly a comparator arm and a late-line option, displaced by tucatinib and ADCs.Open in Atlas onco.cc
Larotrectinibapproved: The first drug approved for a gene fusion regardless of where the cancer started; it works in about 75% of NTRK-fusion cancers, from infant fibrosarcoma to salivary and thyroid cancers.Open in Atlas onco.cc
Lazertinibapproved: A third-generation EGFR pill used together with amivantamab as the first regimen to beat osimertinib in EGFR-mutant lung cancer.Open in Atlas onco.cc
LB1410phase-2: LB1410 is an experimental bispecific antibody from L & L Bio, Ningbo, China in phase 2 trials, aimed at PD-1 and TIM-3.Open in Atlas onco.cc
LB4330phase-2: LB4330 is an experimental fusion protein from L & L Bio, Ningbo, China in phase 2 trials, aimed at Claudin 18.2.Open in Atlas onco.cc
LCB02Aphase-2: LCB02A is an experimental monoclonal antibody from LigaChem Biosciences in phase 2 trials, aimed at Claudin 18.2.Open in Atlas onco.cc
LCB84phase-2: LCB84 is an experimental antibody-drug conjugate from LigaChem Biosciences. It links an antibody aimed at TROP2 to an MMAE prodrug and is being studied in a phase 1/2 trial.Open in Atlas onco.cc
Lenalidomideapproved: Lenalidomide is a thalidomide descendant that glues the proteins IKZF1 and IKZF3 to cereblon so the cell destroys them, killing plasma cells and rousing T cells. It is the backbone of myeloma treatment and maintenance, also used in mantle cell and follicula...Open in Atlas onco.cc
Lenograstimestablished: Lenograstim is Europe's and Japan's glycosylated form of G-CSF, given after chemotherapy to shorten the period of dangerously low neutrophils and to mobilise stem cells for transplant; it does the same job as filgrastim.Open in Atlas onco.cc
Lenvatinibapproved: An oral anti-angiogenic pill that matched sorafenib in liver cancer with higher response rates, and partners with pembrolizumab in kidney and endometrial cancer.Open in Atlas onco.cc
Lenzilumabphase-2: Lenzilumab is an antibody that soaks up GM-CSF, a growth signal that chronic myelomonocytic leukaemia cells with RAS mutations are unusually sensitive to. It is being tested with azacitidine in this leukaemia.Open in Atlas onco.cc
Lerociclibphase-3: Lerociclib is a CDK4/6 inhibitor from G1 Therapeutics developed in China by Genor Biopharma, in a phase 3 trial with letrozole for hormone receptor-positive breast cancer.Open in Atlas onco.cc
Lerotinibphase-3: Lerotinib is an experimental small-molecule drug from Sunshine Lake Pharma in phase 3 trials for oesophageal cancer, with its target not yet stated publicly.Open in Atlas onco.cc
Letetresgene autoleucelphase-2: Letetresgene autoleucel is a second engineered T-cell receptor therapy for sarcoma, targeting NY-ESO-1 in synovial sarcoma and myxoid/round cell liposarcoma; a BLA is expected by the end of 2026.Open in Atlas onco.cc
Letrozole (and other aromatase inhibitors)approved: Daily pills that stop the body making oestrogen after menopause, the backbone of hormone therapy for most breast cancers.Open in Atlas onco.cc
Leucovorin (folinic acid)established: Leucovorin is not a cancer drug in itself: it rescues normal tissue after high-dose methotrexate and, given with fluorouracil, makes that chemotherapy work better, which is why it appears in FOLFOX, FOLFIRI and FOLFIRINOX.Open in Atlas onco.cc
Leuprolide (leuprorelin) and GnRH agonistsapproved: Leuprolide is the injectable that shuts off testosterone production, the foundation of hormone therapy for prostate cancer since the 1980s; it is also used for ovarian suppression in premenopausal breast cancer.Open in Atlas onco.cc
Lifileucelapproved: Lifileucel was the first approved TIL therapy: the patient's own tumour-fighting immune cells are expanded to billions and given back.Open in Atlas onco.cc
Limertinibapproved: Limertinib is Aosaikang's third-generation EGFR inhibitor, approved in China in 2024 for lung cancer with the T790M resistance mutation after earlier EGFR drugs, and in phase 3 trials for first-line use.Open in Atlas onco.cc
Linperlisibapproved: Linperlisib is Shanghai Yingli's PI3K-delta inhibitor, approved in China in 2022 for relapsed or refractory follicular lymphoma after two or more lines.Open in Atlas onco.cc
Linvoseltamabapproved: Linvoseltamab is Regeneron's BCMA bispecific, approved in July 2025 with the highest complete-response rate of the class in its pivotal study.Open in Atlas onco.cc
Lipegfilgrastimapproved: Lipegfilgrastim (Lonquex) is a once-per-chemotherapy-cycle white cell booster used in Europe, similar to pegfilgrastim, for adults and children from two years old.Open in Atlas onco.cc
Liposomal irinotecanapproved: Irinotecan wrapped in a fat bubble so it circulates longer. It is approved for pancreatic cancer, and in bile duct and gallbladder cancer one Korean trial found it helped as second-line treatment while a German trial did not.Open in Atlas onco.cc
Lirafugratinibapproved: An oral FGFR2 inhibitor approved in September 2026 for bile duct cancer whose tumour carries an FGFR2 fusion or rearrangement, after earlier treatment.Open in Atlas onco.cc
Lisocabtagene maraleucelapproved: Lisocabtagene maraleucel is the only CAR-T approved for chronic lymphocytic leukaemia, for patients whose disease has outrun both BTK and BCL-2 inhibitors.Open in Atlas onco.cc
Livmoniplimabphase-3: Livmoniplimab is an experimental investigational agent whose form is not stated in the registry from AbbVie in phase 3 trials for hepatocellular carcinoma, non-small-cell lung cancer and bladder & urothelial cancer, with its target not yet stated publicly.Open in Atlas onco.cc
LM-108phase-3: LM-108 is an experimental monoclonal antibody from Chia Tai Tianqing Pharmaceutical Nanjing Shunxin Pharmaceutical in phase 3 trials for pancreatic ductal adenocarcinoma and gastric & gastro-oesophageal junction cancer, with its target not yet stated publicly.Open in Atlas onco.cc
LM-302phase-3: LM-302 is an experimental antibody-drug conjugate from LaNova Medicines Zhejiang in phase 3 trials for gastric & gastro-oesophageal junction cancer, aimed at Claudin 18.2.Open in Atlas onco.cc
LNS8801phase-3: LNS8801 is an experimental investigational agent whose form is not stated in the registry from Linnaeus Therapeutics in phase 3 trials for melanoma, aimed at Estrogen receptor (ERα).Open in Atlas onco.cc
Locametz (kit for Ga-68 gozetotide)approved: Novartis' gallium PSMA scan kit, approved the same day as Pluvicto as the test that qualifies men for that radioactive drug.Open in Atlas onco.cc
Lomustine (CCNU)standard-of-care: An old chemotherapy pill used when glioblastoma comes back, and the control arm most new glioblastoma drugs must beat.Open in Atlas onco.cc
Loncastuximab tesirineapproved: Loncastuximab tesirine (Zynlonta) is a CD19 ADC with a DNA-crosslinking payload for relapsed large B-cell lymphoma.Open in Atlas onco.cc
Lorigerlimabphase-2: Lorigerlimab is an experimental bispecific antibody from MacroGenics in phase 2 trials for ovarian cancer, vulvar cancer and cervical cancer, aimed at PD-1 and CTLA-4.Open in Atlas onco.cc
Lorlatinibapproved: An ALK inhibitor with the longest disease control ever recorded for a targeted lung cancer pill: 60% progression-free at five years.Open in Atlas onco.cc
LP-184phase-2: LP-184 is a small-molecule inhibitor from Lantern Pharma Inc., in registered phase 2 trials for triple-negative breast cancer, non-small-cell lung cancer, pancreatic ductal adenocarcinoma.Open in Atlas onco.cc
Lunit INSIGHT MMGapproved: A Korean AI mammography reader used in screening programmes in Sweden and Australia and cleared in the US and Europe.Open in Atlas onco.cc
Lurbinectedinapproved: A marine-derived chemotherapy that jams cancer's gene-reading machinery, approved for relapsed small-cell lung cancer and, since 2025, as first-line maintenance with atezolizumab.Open in Atlas onco.cc
Luspaterceptapproved: An injection that helps the marrow finish making red cells, reducing or removing the need for transfusions in lower-risk MDS and beta-thalassaemia.Open in Atlas onco.cc
Lutetium-177 dotatateapproved: Lutetium-177 dotatate was the first modern radioligand therapy (2018), for neuroendocrine tumours, and is now used in first line.Open in Atlas onco.cc
Lutetium-177 vipivotide tetraxetanapproved: A radioactive drug that seeks out PSMA on prostate cancer cells; the best-selling radiopharmaceutical ever.Open in Atlas onco.cc
Luveltamab tazevibulinphase-3: A folate-receptor ADC designed to work across low and high receptor levels, in a pivotal ovarian cancer trial.Open in Atlas onco.cc
LVGN6051phase-2: LVGN6051 is a monoclonal antibody from Lyvgen Biopharma Holdings Limited, in registered phase 2 trials for head and neck squamous cell carcinoma.Open in Atlas onco.cc

M

M108phase-3: M108 is an experimental monoclonal antibody from FutureGen Biopharmaceutical (Beijing) in phase 3 trials for gastric & gastro-oesophageal junction cancer, aimed at Claudin 18.2.Open in Atlas onco.cc
M701phase-3: M701 is Wuhan YZY Biopharma's EpCAM-CD3 bispecific antibody infused into the abdomen to control malignant ascites, in a phase 3 trial in China.Open in Atlas onco.cc
Magrolimabwithdrawn: The first 'don't eat me' signal blocker. Gilead paid $4.9B for it; it was stopped in 2024 after trials showed more deaths, not fewer.Open in Atlas onco.cc
MammaPrint (70-gene signature)established: A 70-gene test that tells whether an early breast cancer is genomically low or high risk, used to decide who can skip chemotherapy.Open in Atlas onco.cc
Margetuximabapproved: A trastuzumab look-alike with an engineered tail that binds immune cells more tightly; approved in 2020 but rarely used after ADCs arrived.Open in Atlas onco.cc
Masofanitenwithdrawn: A drug designed to block the part of the androgen receptor that resistant variants keep; its phase 2 was stopped for futility and development ended.Open in Atlas onco.cc
Mavorixaforapproved: Mavorixafor is a once-daily tablet that blocks CXCR4, a receptor that traps white cells in the bone marrow. It is approved for the rare immunodeficiency WHIM syndrome and is being tested in Waldenström macroglobulinaemia, where CXCR4 mutations blunt the res...Open in Atlas onco.cc
Mavrostobartphase-2: Mavrostobart is an experimental monoclonal antibody from Phanes Therapeutics in phase 2 trials for non-small-cell lung cancer and pancreatic ductal adenocarcinoma, aimed at CD73 / adenosine axis.Open in Atlas onco.cc
MCLA-129phase-2: MCLA-129 is an experimental bispecific antibody from Betta Pharmaceuticals in phase 2 trials for non-small-cell lung cancer, head and neck squamous cell carcinoma and colorectal cancer, aimed at EGFR and MET.Open in Atlas onco.cc
Mebendazolephase-2: Mebendazole is a human worm medicine that has been through two very small cancer trials: a dose-finding study in brain tumours found a tolerable dose, and a study in advanced bowel and stomach cancers saw every patient's cancer keep growing.Open in Atlas onco.cc
Mecapegfilgrastimapproved: Mecapegfilgrastim is Hengrui's long-acting G-CSF, approved in China in 2018 to prevent chemotherapy-induced neutropenia.Open in Atlas onco.cc
Mechlorethamine (chlormethine)approved: Mechlorethamine, or nitrogen mustard, was the first chemotherapy ever used, in 1940s Hodgkin lymphoma. Today its main use is as a skin gel (Valchlor in the US, Ledaga in Europe) for early cutaneous T-cell lymphoma.Open in Atlas onco.cc
Megestrol acetateapproved: Megestrol acetate is a hormone tablet used to ease advanced breast and womb cancer, and as a liquid to improve appetite and weight in people with cancer or AIDS-related wasting.Open in Atlas onco.cc
Melphalan (including hepatic delivery system)approved: The myeloma chemotherapy that is also the standard high-dose conditioning before autologous transplant, and, delivered directly into the liver's blood supply or the eye, treats uveal melanoma metastases and retinoblastoma.Open in Atlas onco.cc
Melphalan flufenamidewithdrawn: A myeloma drug given accelerated approval in 2021 and withdrawn in the US months later when its confirmatory trial suggested it shortened survival.Open in Atlas onco.cc
Melphalan hepatic delivery systemapproved: High-dose melphalan pumped through the liver's own blood supply while the blood leaving the liver is filtered, the first approved treatment for uveal melanoma that has spread to the liver.Open in Atlas onco.cc
Memantineapproved: Memantine is an Alzheimer's drug taken during whole-brain radiotherapy to protect memory. With hippocampal-sparing radiotherapy it has become the standard way to limit the thinking problems the treatment causes.Open in Atlas onco.cc
MEN1703phase-2: MEN1703 is an experimental small molecule (kinase inhibitor) from Ryvu Therapeutics in phase 2 trials for hodgkin lymphoma, aimed at FLT3.Open in Atlas onco.cc
Mercaptopurineapproved: Mercaptopurine is a daily tablet, or a liquid for children, that keeps acute lymphoblastic leukaemia in remission during the long maintenance phase of treatment.Open in Atlas onco.cc
Merestinibphase-2: Merestinib is an oral kinase inhibitor from Eli Lilly and Company, in registered phase 2 trials for metastatic cancer.Open in Atlas onco.cc
Mesnaapproved: Mesna is given with the chemotherapy ifosfamide (and high-dose cyclophosphamide) to stop its breakdown products from burning the bladder lining and causing bleeding.Open in Atlas onco.cc
Methotrexateapproved: The 1948 antifolate that produced the first chemotherapy remissions in childhood leukaemia and the first cure of a solid tumour; still essential in ALL, lymphoma, osteosarcoma and CNS lymphoma.Open in Atlas onco.cc
Methoxsalen (extracorporeal photopheresis)established: Uvadex is the drug used in photopheresis, where a patient's white cells are drawn off, treated with methoxsalen and ultraviolet light, and returned; it is approved for the skin symptoms of cutaneous T-cell lymphoma and widely used for graft-versus-host dise...Open in Atlas onco.cc
Methyl aminolevulinateestablished: Methyl aminolevulinate is a cream applied to sun-damaged skin or a superficial basal cell carcinoma and then activated with red light, clearing precancerous and early skin cancers with better cosmetic results than surgery or freezing.Open in Atlas onco.cc
Methylnaltrexoneapproved: Methylnaltrexone (Relistor) is an injection or tablet that relieves the severe constipation caused by strong painkillers in people with advanced cancer, without blocking the pain relief itself.Open in Atlas onco.cc
Metyraponeestablished: Metyrapone is an older tablet that blocks cortisol production in the adrenal glands. It is used to bring cortisol down quickly in Cushing's disease before or after pituitary surgery, and in the United States mainly as a diagnostic test.Open in Atlas onco.cc
Mevrometostatphase-3: An epigenetic drug that may re-sensitise prostate cancer to hormone therapy, in three phase 3 trials with enzalutamide.Open in Atlas onco.cc
Mezigdomidephase-3: Mezigdomide is the most potent oral cereblon modulator, producing responses in about 40% of triple-class-refractory myeloma with dexamethasone alone.Open in Atlas onco.cc
MHB036Cphase-2: MHB036C is an antibody-drug conjugate from Minghui Pharmaceutical (Hangzhou) Ltd, in registered phase 2 trials for metastatic cancer.Open in Atlas onco.cc
MHB039Aphase-2: MHB039A is a bispecific antibody from Minghui Pharmaceutical (Hangzhou) Ltd, in registered phase 2 trials for metastatic cancer.Open in Atlas onco.cc
MI Cancer Seekapproved: The first FDA-approved test that sequences all of a tumour's genes and gene activity at once, used to match patients to several targeted drugs.Open in Atlas onco.cc
Mia (Mammography Intelligent Assessment)established: A London-built breast screening AI trialled across NHS sites as a second reader, now folded into RadNet's DeepHealth after a 2024 acquisition.Open in Atlas onco.cc
Midostaurinapproved: The first drug to improve survival in FLT3-mutated AML, added to standard chemotherapy: median survival went from about two years to more than six.Open in Atlas onco.cc
Mifamurtideapproved: An immune-activating drug approved in Europe for osteosarcoma after a trial suggested it improved survival; the FDA never approved it, and it remains one of oncology's transatlantic disagreements.Open in Atlas onco.cc
Mifepristonenegative: Mifepristone, best known as an abortion pill and a treatment for Cushing's syndrome, blocks progesterone receptors that most meningiomas carry. A large phase 3 trial found it did not slow inoperable meningiomas.Open in Atlas onco.cc
Mirdametinibapproved: Mirdametinib (Gomekli in the US, Ezmekly in Europe) is a MEK-blocking capsule or dispersible tablet for adults and children with neurofibromatosis type 1 whose plexiform neurofibromas cannot be removed surgically; it is the first such drug approved for adults.Open in Atlas onco.cc
Mirvetuximab soravtansineapproved: Mirvetuximab soravtansine (Elahere) is the first ADC for ovarian cancer, for tumours with high folate receptor alpha.Open in Atlas onco.cc
Mitazalimabphase-2: Mitazalimab is an antibody-drug conjugate from Alligator Bioscience AB, in registered phase 2 trials for pancreatic ductal adenocarcinoma.Open in Atlas onco.cc
Mitobronitolhistoric: Mitobronitol was a Hungarian-developed oral tablet used in Europe from the 1960s to control chronic myeloid leukaemia and polycythaemia, an alternative to busulfan that disappeared once hydroxycarbamide, interferon and imatinib took over.Open in Atlas onco.cc
Mitomycin Capproved: The chemotherapy given with radiation to cure anal cancer without surgery, used as a bladder instillation after tumour resection, and since 2020-25 in gel form for upper-tract and recurrent bladder cancers.Open in Atlas onco.cc
Mitotaneapproved: A relative of the insecticide DDT that is the only drug specific to adrenal cortex cancer; it needs blood-level monitoring and permanent steroid replacement.Open in Atlas onco.cc
Mitoxantroneapproved: Mitoxantrone is a blue chemotherapy infusion used with cytarabine for acute myeloid leukaemia and, historically, to relieve pain in advanced prostate cancer; it is also licensed for multiple sclerosis.Open in Atlas onco.cc
MK-1045phase-3: MK-1045 is an experimental investigational agent whose form is not stated in the registry from Merck Sharp & Dohme in phase 3 trials for acute lymphoblastic leukaemia, follicular lymphoma and hodgkin lymphoma, aimed at CD19.Open in Atlas onco.cc
Mobocertinibwithdrawn: Mobocertinib was the first oral drug for EGFR exon 20 insertion lung cancer, approved in 2021 and withdrawn in 2023-24 after its confirmatory trial failed.Open in Atlas onco.cc
Mogamulizumabapproved: Mogamulizumab is an antibody that clears cancerous T cells from the blood in mycosis fungoides and Sézary syndrome, the leukaemic form of skin lymphoma.Open in Atlas onco.cc
Momelotinibapproved: Momelotinib is the JAK inhibitor designed for anaemic myelofibrosis patients: it can improve haemoglobin while shrinking the spleen.Open in Atlas onco.cc
Monalizumabphase-3: Monalizumab is an experimental investigational agent whose form is not stated in the registry from AstraZeneca in phase 3 trials for non-small-cell lung cancer and head and neck squamous cell carcinoma, with its target not yet stated publicly.Open in Atlas onco.cc
Mosunetuzumabapproved: Mosunetuzumab is a fixed-duration CD20 bispecific approved for follicular lymphoma and studied with polatuzumab in large B-cell lymphoma.Open in Atlas onco.cc
Motixafortideapproved: Motixafortide is an injection given with G-CSF before stem cell collection in people with multiple myeloma, approved in the United States in 2023, so that enough stem cells for an autologous transplant can be harvested in one or two sessions.Open in Atlas onco.cc
Moxetumomab pasudotoxwithdrawn: An immunotoxin for hairy cell leukaemia that produced lasting remissions in relapsed patients but was withdrawn from sale in 2023 for commercial reasons.Open in Atlas onco.cc
MRG002phase-3: MRG002 is an experimental investigational agent whose form is not stated in the registry from Shanghai Miracogen in phase 3 trials for gastric & gastro-oesophageal junction cancer and bladder & urothelial cancer, with its target not yet stated publicly.Open in Atlas onco.cc
MRG003phase-3: MRG003 is an experimental antibody-drug conjugate from Lepu Biopharma in phase 3 trials for head and neck squamous cell carcinoma and nasopharyngeal carcinoma, with its target not yet stated publicly.Open in Atlas onco.cc
MRTX1133phase-1: MRTX1133 was the first potent chemical tool against KRAS G12D, and proved the mutation could be drugged even though it lacks the reactive handle G12C has.Open in Atlas onco.cc
MT-302phase-1: MT-302 programs myeloid immune cells inside the body to recognise TROP-2-bearing cancers. It is an experimental treatment in an early clinical trial.Open in Atlas onco.cc
myChoice CDxapproved: A tumour test that measures DNA-repair scarring so that women with ovarian cancer beyond BRCA carriers can benefit from PARP inhibitors.Open in Atlas onco.cc

N

Nab-paclitaxelapproved: Paclitaxel bound to albumin so it needs no solvent and no steroid premedication. Adding it to gemcitabine and cisplatin looked promising in a small study of bile duct and gallbladder cancer but did not lengthen life in the 452-patient SWOG S1815 trial.Open in Atlas onco.cc
Nabiloneestablished: Nabilone is a synthetic cannabinoid capsule approved in 1985 for chemotherapy-induced nausea and vomiting that standard drugs cannot control; like dronabinol it is a later-line option because of its effects on mood and balance.Open in Atlas onco.cc
Nadofaragene firadenovecapproved: Nadofaragene firadenovec is the first gene therapy for bladder cancer: a virus that makes bladder cells produce interferon for weeks, given once every three months.Open in Atlas onco.cc
NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV)approved: NALIRIFOX is a version of FOLFIRINOX using a liposome-wrapped irinotecan, approved in 2024 as a first-line option for metastatic pancreatic cancer.Open in Atlas onco.cc
Napabucasinnegative: Napabucasin, an oral drug marketed as a cancer stemness inhibitor, was tested in 1,134 people with untreated metastatic pancreatic cancer on top of nab-paclitaxel and gemcitabine; survival was identical and the trial was stopped for futility.Open in Atlas onco.cc
Naporafenibphase-3: Naporafenib is an experimental small-molecule drug from Erasca in phase 3 trials for melanoma, with its target not yet stated publicly.Open in Atlas onco.cc
Navitoclaxphase-3: Navitoclax is an experimental small-molecule drug from AbbVie in phase 3 trials for myeloproliferative neoplasms, with its target not yet stated publicly.Open in Atlas onco.cc
Navlimetostatphase-3: Navlimetostat is an experimental small-molecule drug from Bristol-Myers Squibb in phase 3 trials for non-small-cell lung cancer and pancreatic ductal adenocarcinoma, aimed at PRMT5 (MTAP-deleted cancers).Open in Atlas onco.cc
Naxitamabapproved: Naxitamab is a humanised anti-GD2 antibody from Memorial Sloan Kettering, given as an outpatient with GM-CSF for relapsed neuroblastoma in bone or marrow.Open in Atlas onco.cc
NB003phase-3: NB003 is an experimental small-molecule drug from Ningbo Newbay Technology Development in phase 3 trials for gastrointestinal stromal tumour, with its target not yet stated publicly.Open in Atlas onco.cc
NBTXR3 (hafnium oxide nanoparticles)phase-3: NBTXR3 is Nanobiotix's radioenhancer: a single injection of hafnium oxide nanoparticles that makes ordinary radiotherapy hit harder inside the tumour. It carries a European CE mark for soft-tissue sarcoma and is in a phase 3 trial in head and neck cancer wi...Open in Atlas onco.cc
NDI-219216phase-2: NDI-219216 is an experimental small-molecule drug from Nimbus Wadjet in phase 2 trials, aimed at WRN helicase (MSI-high cancers).Open in Atlas onco.cc
Necitumumabapproved: Necitumumab (Portrazza) is an antibody added to gemcitabine and cisplatin as first treatment for squamous non-small cell lung cancer that has spread; the benefit is modest and it is little used.Open in Atlas onco.cc
Nedaplatinestablished: Nedaplatin is a Japanese platinum drug, approved there in 1995, used for head and neck, oesophageal, lung, cervical and other squamous cancers as a gentler alternative to cisplatin on the kidneys; it has never been approved in the West.Open in Atlas onco.cc
Neladalkibphase-3: A fourth-generation ALK pill that works after lorlatinib and avoids the TRK-related brain side effects; under FDA priority review with a decision due 27 November 2026.Open in Atlas onco.cc
Nelarabineapproved: Nelarabine (Arranon) is an infusion for T-cell acute lymphoblastic leukaemia and lymphoma that has come back after at least two other treatments; it is now also added to first-line therapy for children with T-cell leukaemia.Open in Atlas onco.cc
Nemtabrutinibphase-3: Nemtabrutinib is Merck's reversible BTK blocker, active against the C481S escape mutation, being tested against ibrutinib and acalabrutinib in first-line CLL.Open in Atlas onco.cc
NeoVaxphase-1: NeoVax is a made-to-order vaccine: a patient's tumour is sequenced, the mutations most likely to be seen by the immune system are turned into peptides, and these are injected to train T cells against that tumour alone. Early trials in melanoma and glioblast...Open in Atlas onco.cc
Neratinibapproved: A pill taken for a year after trastuzumab to further reduce recurrence in HER2-positive, hormone-positive breast cancer, limited by severe diarrhoea.Open in Atlas onco.cc
Netupitant and palonosetronapproved: Akynzeo combines two anti-sickness drugs in one capsule or infusion taken once before chemotherapy, so a single dose plus dexamethasone protects against both immediate and delayed vomiting.Open in Atlas onco.cc
Nicotinamideestablished: Nicotinamide is a cheap over-the-counter form of vitamin B3. Taken twice a day it cuts the number of new skin cancers in people who have already had several, by helping skin cells repair sun damage.Open in Atlas onco.cc
Nilotinibapproved: Nilotinib is a second-generation CML pill that produces deeper responses faster than imatinib, at the cost of cardiovascular and metabolic side effects.Open in Atlas onco.cc
Nilutamideapproved: Nilutamide (Nilandron) is an older antiandrogen tablet started on the day of surgical castration for metastatic prostate cancer; it is rarely used now because of lung and eye side effects.Open in Atlas onco.cc
Nimorazoleestablished: Nimorazole is the one hypoxic radiosensitiser in routine use: given with radiotherapy for head and neck cancer in Denmark since the DAHANCA 5 trial improved control, and tested across Europe in patients whose tumours carry a hypoxia gene signature.Open in Atlas onco.cc
Nimotuzumabestablished: Nimotuzumab is a Cuban-developed antibody against EGFR approved in India, China, Cuba and other countries for head and neck cancer, nasopharyngeal cancer and brain tumours, usually with radiotherapy; it causes far less rash than cetuximab but has never been...Open in Atlas onco.cc
Nintedanibapproved: Nintedanib is a triple angiokinase inhibitor pill (VEGFR, FGFR, PDGFR) approved for pulmonary fibrosis and, in the EU, for second-line lung adenocarcinoma with docetaxel. In mesothelioma the phase 2 part of LUME-Meso suggested slower progression in epitheli...Open in Atlas onco.cc
Niraparibapproved: Niraparib is a DNA-repair inhibitor used after chemotherapy for selected ovarian cancers and with hormone treatment for selected BRCA-mutated prostate cancers.Open in Atlas onco.cc
Nirogacestatapproved: Nirogacestat is the first approved medicine for desmoid tumours, locally invasive growths that do not spread but can be crippling; it works by blocking Notch signalling.Open in Atlas onco.cc
Nivolumabapproved: Nivolumab was the second PD-1 blocker and is often combined with ipilimumab. Long-term data show about half of advanced melanoma patients alive at 10 years on the combination.Open in Atlas onco.cc
NMS-03305293phase-2: NMS-03305293 is an experimental pill being studied to block a DNA-repair enzyme in cancer cells.Open in Atlas onco.cc
Nogapendekin alfa inbakiceptapproved: Nogapendekin alfa inbakicept is an engineered version of the immune-boosting protein IL-15, given with BCG into the bladder, approved in 2024 for early bladder cancer that BCG alone no longer controls.Open in Atlas onco.cc
Nonavalent HPV vaccineapproved: A vaccine against nine HPV types that prevents about 90% of cervical cancers, and now works with a single dose.Open in Atlas onco.cc
NP137phase-2: NP137 is a monoclonal antibody from NETRIS Pharma, in registered phase 2 trials for endometrial cancer, cervical cancer.Open in Atlas onco.cc
NUV-1511phase-2: NUV-1511 is a small-molecule inhibitor from Nuvation Bio Inc., in registered phase 2 trials for prostate cancer, pancreatic ductal adenocarcinoma, ovarian cancer.Open in Atlas onco.cc
NXC-201 CAR-Tphase-2: NXC-201 CAR-T is an experimental CAR-T cell therapy from Nexcella in phase 2 trials, aimed at BCMA.Open in Atlas onco.cc

O

Obecabtagene autoleucelapproved: A CD19 CAR-T built to grip and release quickly, which cut severe side effects and gave adults with relapsed ALL a real chance at durable remission.Open in Atlas onco.cc
OBI-902phase-2: OBI-902 is an antibody-drug conjugate from OBI Pharma, Inc, in registered phase 2 trials for metastatic cancer.Open in Atlas onco.cc
OBI-992phase-2: OBI-992 is an antibody-drug conjugate from OBI Pharma, Inc, in registered phase 2 trials for metastatic cancer.Open in Atlas onco.cc
Obinutuzumabapproved: Obinutuzumab is a glycoengineered CD20 antibody that recruits immune cells and kills B cells more directly than rituximab. Paired with venetoclax for a fixed 12 months in chronic lymphocytic leukaemia, it keeps over half of patients treatment-free six years...Open in Atlas onco.cc
Obrixtamigphase-3: Obrixtamig is an antibody with two arms: one grabs DLL3, a protein on the surface of most neuroendocrine carcinomas, and the other grabs a T cell, pulling the killer cell onto the cancer. It is in a phase 3 trial for neuroendocrine carcinomas outside the lung.Open in Atlas onco.cc
Odronextamabapproved: Odronextamab is Regeneron's CD20 bispecific, approved in Europe for lymphoma and in the US for follicular lymphoma after earlier FDA rejections over confirmatory-trial enrolment.Open in Atlas onco.cc
Ofatumumabapproved: Ofatumumab (Arzerra) is a fully human anti-CD20 antibody for chronic lymphocytic leukaemia, used with chlorambucil in untreated patients or alone after other drugs have failed; the same molecule is sold as Kesimpta for multiple sclerosis.Open in Atlas onco.cc
Olaparibapproved: Olaparib was the first PARP inhibitor, and turned an inherited BRCA mutation from a risk factor into a drug target, including after surgery in breast cancer.Open in Atlas onco.cc
Olaratumabwithdrawn: Olaratumab was approved in 2016 with doxorubicin for soft tissue sarcoma after a small trial suggested it added almost a year of life, but the large confirmatory trial found no benefit and it was withdrawn in 2019, a warning case for accelerated approvals.Open in Atlas onco.cc
Oleclumabphase-3: Oleclumab is an experimental investigational agent whose form is not stated in the registry from AstraZeneca in phase 3 trials for non-small-cell lung cancer, triple-negative breast cancer and colorectal cancer, with its target not yet stated publicly.Open in Atlas onco.cc
Olmutinibwithdrawn: Olmutinib was a Korean-developed EGFR pill approved in South Korea in 2016 for lung cancers that had developed the T790M resistance mutation, the same niche as osimertinib; severe skin reactions and osimertinib's success ended its development.Open in Atlas onco.cc
Olomorasibphase-3: Olomorasib is Lilly's KRAS G12C pill, designed to combine safely with immunotherapy in first-line lung cancer.Open in Atlas onco.cc
Olutasidenibapproved: Olutasidenib is a second IDH1 inhibitor for relapsed AML, with a higher response rate in its pivotal cohort than ivosidenib had in its own.Open in Atlas onco.cc
Olverembatinibapproved: Olverembatinib is Ascentage Pharma's third-generation BCR-ABL inhibitor, approved in China in 2021 for chronic myeloid leukaemia carrying the T315I mutation, and now in global phase 3 trials against the established drugs; it was the one China-only approval...Open in Atlas onco.cc
Olvimulogene nanivacirepvecphase-3: Olvimulogene nanivacirepvec is an experimental oncolytic virus from Genelux in phase 3 trials for ovarian cancer and non-small-cell lung cancer, with its target not yet stated publicly.Open in Atlas onco.cc
Omacetaxine mepesuccinateapproved: Omacetaxine (Synribo) is a twice-daily injection under the skin for chronic myeloid leukaemia that has stopped responding to at least two tyrosine kinase inhibitor pills.Open in Atlas onco.cc
Omidubicelapproved: An expanded umbilical cord blood graft that shortens the dangerous wait for neutrophils to return after a transplant for blood cancer, the first cell therapy approved to speed engraftment.Open in Atlas onco.cc
Oncodetectemerging: Exact Sciences' entry into the leftover-cancer blood test market, launched in 2025 for bowel cancer follow-up.Open in Atlas onco.cc
Oncomine Dx Target Testapproved: The first FDA-approved gene panel that could match one biopsy to several different lung cancer drugs at once.Open in Atlas onco.cc
Oncotype DXestablished: A 21-gene test that tells most women with early hormone-positive breast cancer whether they can safely skip chemotherapy.Open in Atlas onco.cc
Oncotype DX Genomic Prostate Scoreestablished: A 17-gene biopsy test that helps men with newly diagnosed low-risk prostate cancer decide whether to watch or treat.Open in Atlas onco.cc
Ondansetronapproved: Ondansetron (Zofran) was the drug that made cisplatin-type chemotherapy bearable. It blocks the serotonin signal that triggers vomiting and is now a cheap generic tablet, dissolving wafer or injection used across cancer care.Open in Atlas onco.cc
Onvansertibphase-2: Onvansertib is an oral serine/threonine kinase inhibitor from Cardiff Oncology, in registered phase 2 trials for colorectal cancer.Open in Atlas onco.cc
Opevesostatphase-3: Opevesostat is an experimental small-molecule drug from Merck Sharp & Dohme in phase 3 trials for prostate cancer, with its target not yet stated publicly.Open in Atlas onco.cc
Oprelvekinwithdrawn: Oprelvekin was the first drug approved, in 1997, to prevent the severe platelet falls that chemotherapy causes, but fluid retention and heart rhythm problems limited it and it was withdrawn in 2011; thrombopoietin agonists took over the problem.Open in Atlas onco.cc
Optellum Virtual Nodule Clinicapproved: The first AI cleared to estimate how likely a lung nodule on a CT scan is to be cancer, helping doctors decide who needs a biopsy and who can wait.Open in Atlas onco.cc
Optune / Optune Pax (TTFields)approved: Optune is a wearable device delivering electric fields that disrupt cell division. It is approved for glioblastoma and, in 2026, pancreatic cancer.Open in Atlas onco.cc
OR502phase-2: OR502 is a monoclonal antibody from OncoResponse, Inc., in registered phase 2 trials for metastatic cancer, melanoma, non-small-cell lung cancer.Open in Atlas onco.cc
Oregovomabphase-3: Oregovomab is an experimental monoclonal antibody from CanariaBio in phase 3 trials for ovarian cancer, with its target not yet stated publicly.Open in Atlas onco.cc
Orelabrutinibapproved: Orelabrutinib is InnoCare's BTK-blocking pill for chronic lymphocytic leukaemia and mantle cell lymphoma, approved in China in 2020.Open in Atlas onco.cc
Orteronelwithdrawn: A more selective version of abiraterone that was meant to avoid the need for steroids. It delayed the cancer on scans but did not help men live longer, and was abandoned.Open in Atlas onco.cc
OSE2101phase-3: OSE2101 is an experimental cancer vaccine from OSE Immunotherapeutics in phase 3 trials for non-small-cell lung cancer, aimed at HER2 and CEACAM5.Open in Atlas onco.cc
Osilodrostatapproved: Osilodrostat is a twice-daily tablet that stops the adrenal glands making cortisol. It controls Cushing's disease caused by a pituitary tumour when surgery has failed or is not possible, normalising cortisol in most patients.Open in Atlas onco.cc
Osimertinibapproved: Osimertinib (Tagrisso) is the standard pill for EGFR-mutant lung cancer, now also given after surgery and with chemotherapy or after chemoradiation.Open in Atlas onco.cc
Oxaliplatinapproved: The platinum drug that works in bowel cancer where cisplatin does not, the 'OX' in FOLFOX and CAPOX; its cost is nerve damage in hands and feet.Open in Atlas onco.cc

P

Paclitaxel / nab-paclitaxelapproved: A microtubule poison discovered in the Pacific yew tree, among the most used chemotherapies in breast, lung, and ovarian cancer.Open in Atlas onco.cc
Pacritinibapproved: The JAK inhibitor for myelofibrosis patients whose platelet counts are too low for ruxolitinib.Open in Atlas onco.cc
Padeliporfinapproved: Tookad is a light-activated drug for men with low-risk prostate cancer in one side of the prostate. It is infused and then switched on with laser fibres placed in the gland, destroying the cancer-bearing tissue as an alternative to watchful waiting.Open in Atlas onco.cc
Pafolacianineapproved: An injected dye that makes ovarian and lung cancer deposits glow during surgery so surgeons can find lesions they would otherwise miss.Open in Atlas onco.cc
Paige Prostate Detectapproved: The first AI for reading biopsy slides authorised by the FDA, which points pathologists to prostate cancer they might otherwise miss.Open in Atlas onco.cc
Palacaparibphase-2: Palacaparib is an experimental DNA-repair inhibitor designed to reach the brain and selectively block PARP1.Open in Atlas onco.cc
Palbociclibapproved: Palbociclib was the first CDK4/6 inhibitor (2015), and in 2026 became the first approved as maintenance in HER2-positive, hormone-positive breast cancer.Open in Atlas onco.cc
Paliferminapproved: Palifermin (Kepivance) is a growth factor injected for three days before and after high-dose chemotherapy and stem cell rescue to reduce the severe mouth ulcers (mucositis) that this treatment causes in people with blood cancers.Open in Atlas onco.cc
Palonosetronapproved: Palonosetron (Aloxi) is a long-acting anti-sickness injection given once before chemotherapy; a single dose covers both the first day and the delayed nausea that follows.Open in Atlas onco.cc
Paltusotineapproved: Paltusotine is the first somatostatin-type drug that works as a once-daily pill instead of a monthly injection. It was approved in 2025 for acromegaly and is being tested for the flushing and diarrhoea of carcinoid syndrome from small-bowel neuroendocrine t...Open in Atlas onco.cc
Pamidronateapproved: Pamidronate (Aredia) is a bisphosphonate infusion approved in 1991 for dangerously high blood calcium in cancer and later for bone damage from myeloma and breast cancer, where it roughly halved skeletal complications. Its two-hour infusion, against fifteen...Open in Atlas onco.cc
Pamiparibphase-3: Pamiparib is an oral parp inhibitor from BeiGene, in registered phase 3 trials for ovarian cancer.Open in Atlas onco.cc
Pamrevlumabnegative: Pamrevlumab targeted the scar-like tissue around pancreatic tumours; its phase 3 LAPIS trial in locally advanced disease did not lengthen survival.Open in Atlas onco.cc
Pancrelipase (pancreatic enzyme replacement therapy)established: Enzyme capsules taken with every meal replace the digestive enzymes a pancreas blocked or removed by cancer no longer delivers; NICE says to offer them to everyone with unresectable pancreatic cancer and to consider them around surgery.Open in Atlas onco.cc
Panitumumabapproved: Panitumumab is a fully human EGFR antibody, the preferred first-line partner for chemotherapy in left-sided, RAS-normal bowel cancer after the PARADIGM trial.Open in Atlas onco.cc
Panobinostatwithdrawn: An HDAC inhibitor for relapsed myeloma approved in 2015 and withdrawn in 2021 after its confirmatory trial was never completed.Open in Atlas onco.cc
Parsaclisibphase-2: Parsaclisib is an oral pi3k inhibitor from Incyte Corporation, in registered phase 2 trials for diffuse large B-cell lymphoma.Open in Atlas onco.cc
Pasireotideapproved: Pasireotide is a second-generation somatostatin analogue that hits more receptor types than octreotide. It is approved for Cushing's disease and acromegaly caused by pituitary tumours when surgery has not cured them, at the cost of frequent high blood sugar.Open in Atlas onco.cc
Pasritamigphase-3: Pasritamig is Johnson & Johnson's bispecific T-cell engager that binds KLK2 on prostate cancer cells and CD3 on T cells, with a deliberately low-affinity CD3 arm. In phase 1 about 40% of patients had a PSA50 response with far less cytokine release syndrome...Open in Atlas onco.cc
Patidegibphase-3: Patidegib is a hedgehog-pathway blocker made into a skin gel. It is being tested in people with Gorlin syndrome, who grow dozens of basal cell carcinomas, to prevent new tumours without the hair loss, muscle cramps and taste loss that the oral drugs cause.Open in Atlas onco.cc
Patritumab deruxtecanphase-3: A HER3-directed ADC with Enhertu's payload, active in lung and all subtypes of breast cancer, but with a bumpy regulatory road.Open in Atlas onco.cc
Pazopanibapproved: Pazopanib is the only multi-kinase inhibitor approved for soft-tissue sarcoma (excluding fat-derived tumours), used after chemotherapy fails.Open in Atlas onco.cc
PBP1510phase-2: PBP1510 is a monoclonal antibody from Prestige Biopharma Limited, in registered phase 2 trials for pancreatic ductal adenocarcinoma.Open in Atlas onco.cc
PD-L1 IHC 22C3 pharmDxapproved: The 22C3 pharmDx assay is the PD-L1 stain tied to pembrolizumab since 2015 and the source of the combined positive score (CPS). The cut-off differs by cancer: 1% of tumour cells in lung cancer, CPS 1 in gastric, cervical and head and neck cancer, CPS 10 in...Open in Atlas onco.cc
Pegfilgrastimapproved: Pegfilgrastim (Neulasta) is a long-acting form of the growth factor G-CSF, given once per chemotherapy cycle to speed white cell recovery and prevent febrile neutropenia; one dose replaces about eleven daily filgrastim injections. Biosimilars have been sold...Open in Atlas onco.cc
Pegilodecakinnegative: Pegilodecakin, a long-acting interleukin-10 meant to expand tumour-killing T cells, added nothing to FOLFOX in the phase 3 SEQUOIA trial of second-line pancreatic cancer, and Eli Lilly dropped it.Open in Atlas onco.cc
Peginterferon alfa-2bestablished: Peginterferon alfa-2b, a long-acting interferon, was approved in 2011 as Sylatron for melanoma that had spread to lymph nodes and been removed, to delay recurrence; checkpoint inhibitors have since replaced it in that role.Open in Atlas onco.cc
Pegulicianineapproved: A cavity-imaging dye used during breast lumpectomy to spot leftover tumour before the operation ends; in its main trial it spared a second operation for 9 of 62 patients whose margins were positive.Open in Atlas onco.cc
Pegvisomantapproved: Pegvisomant is a daily injection that blocks growth hormone at its receptor. It normalises the downstream hormone IGF-1 in most people with acromegaly whose tumours were not cured by surgery, although it does not shrink the tumour itself.Open in Atlas onco.cc
Pegvorhyaluronidase alfanegative: PEGPH20 was designed to break down the hyaluronan that stiffens pancreatic tumours and let chemotherapy in; in the phase 3 HALO-301 trial it raised response rates but not survival, and Halozyme stopped developing it in 2019.Open in Atlas onco.cc
Pegylated liposomal doxorubicinapproved: Doxorubicin wrapped in a fatty bubble so it reaches tumours with less heart damage; a workhorse of relapsed ovarian cancer.Open in Atlas onco.cc
Pelabresibphase-3: Pelabresib is an experimental small-molecule drug from Novartis Pharmaceuticals in phase 3 trials, with its target not yet stated publicly.Open in Atlas onco.cc
Peluntamigphase-2: Peluntamig is an experimental bispecific antibody from Phanes Therapeutics in phase 2 trials for non-small-cell lung cancer and neuroendocrine tumours, aimed at CD47 and DLL3.Open in Atlas onco.cc
Pembrolizumabapproved: Pembrolizumab is a PD-1 blocking antibody approved in more than 40 settings, from melanoma and lung cancer to the first tumour-agnostic approval for mismatch-repair-deficient tumours in 2017, and before and after surgery in triple-negative breast cancer. A...Open in Atlas onco.cc
Pemetrexedapproved: Pemetrexed is the chemotherapy that, with a platinum drug, became the first approved treatment for mesothelioma in 2004, and is still the backbone today.Open in Atlas onco.cc
Pemigatinibapproved: Pemigatinib was the first targeted therapy for bile duct cancer, for tumours with an FGFR2 gene fusion.Open in Atlas onco.cc
Penpulimabapproved: Penpulimab is a Chinese PD-1 antibody approved in the US in 2025 for nasopharyngeal carcinoma, the second after toripalimab.Open in Atlas onco.cc
Pentostatinapproved: An intravenous drug given every other week that produces long remissions in hairy cell leukaemia by poisoning the leukaemic lymphocytes' purine metabolism; cladribine is the one-week alternative.Open in Atlas onco.cc
Pertuzumabapproved: A second HER2 antibody that binds a different spot from trastuzumab, blocking HER2 from pairing with HER3; together they extended survival by 16 months in CLEOPATRA.Open in Atlas onco.cc
Petosemtamabphase-3: A two-armed antibody that blocks EGFR while gripping LGR5, a marker of cancer stem cells, so it hits the cells that regrow tumours.Open in Atlas onco.cc
Pevonedistatnegative: Pevonedistat was a first-in-class drug that jammed part of the cell's protein-disposal system. Promising with azacitidine in a mid-stage trial for higher-risk myelodysplastic syndromes, it failed to beat azacitidine alone in the phase 3 PANTHER trial in 2021.Open in Atlas onco.cc
Pexidartinibapproved: Pexidartinib is the first drug for tenosynovial giant cell tumour, a benign but destructive joint tumour; it is effective but has liver toxicity that requires a restricted programme.Open in Atlas onco.cc
PF-06664178historic: This early TROP-2 antibody-drug conjugate was tested in a study that stopped before completing development.Open in Atlas onco.cc
PF-07248144phase-3: PF-07248144 is an experimental small-molecule drug from Pfizer in phase 3 trials for HR-positive / HER2-negative breast cancer, prostate cancer and non-small-cell lung cancer, with its target not yet stated publicly.Open in Atlas onco.cc
PF-08046054phase-3: PF-08046054 is an experimental antibody-drug conjugate from Pfizer in phase 3 trials for non-small-cell lung cancer, aimed at PD-L1.Open in Atlas onco.cc
PF-08634404phase-3: PF-08634404 is an experimental investigational agent whose form is not stated in the registry from Pfizer in phase 3 trials for colorectal cancer, gastric & gastro-oesophageal junction cancer and oesophageal cancer, with its target not yet stated publicly.Open in Atlas onco.cc
Phosphorus-32 (radiophosphorus)historic: Radiophosphorus was one of the first treatments for polycythaemia vera, from the 1940s: a radioactive phosphate injection that quietened the overactive bone marrow for a year or more. It was abandoned when trials showed it raised the risk of leukaemia.Open in Atlas onco.cc
Piflufolastat F-18 / Pylarify TruVuapproved: Piflufolastat F-18 (Pylarify) is the leading PSMA PET tracer for prostate cancer, with a new formulation approved in March 2026.Open in Atlas onco.cc
Pilocarpineapproved: Pilocarpine tablets are approved to treat the dry mouth that follows head and neck radiotherapy; they help when some gland tissue is left, at the cost of sweating and other cholinergic side effects.Open in Atlas onco.cc
Pimicotinibphase-2: Pimicotinib is an oral kinase inhibitor from Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, in registered phase 2 trials for tenosynovial giant cell tumour.Open in Atlas onco.cc
Pipobromanhistoric: Pipobroman was an oral tablet approved in 1966 for polycythaemia vera, the blood disorder that makes too many red cells, and for chronic myeloid leukaemia; it was discontinued after studies showed it raised the risk of leukaemia compared with hydroxycarbamide.Open in Atlas onco.cc
Pirarubicinestablished: Pirarubicin is a doxorubicin relative developed in Japan and used there and in China for breast cancer, lymphoma, bladder cancer and other tumours, including instillation into the bladder after tumour resection.Open in Atlas onco.cc
Pirtobrutinibapproved: A BTK blocker that works after the older ones stop, because it grips a different part of the enzyme. Fully approved for CLL in December 2025.Open in Atlas onco.cc
Pivekimab sunirineapproved: Pivekimab sunirine is an antibody-drug conjugate against CD123, approved in 2026 for blastic plasmacytoid dendritic cell neoplasm as the second targeted drug for this rare cancer.Open in Atlas onco.cc
Pixantronewithdrawn: Pixantrone is an anthracycline-like drug engineered to spare the heart. The European Union authorised it in 2012 as a single agent for adults with aggressive B-cell lymphoma that had relapsed several times; the authorisation expired in June 2024 when the co...Open in Atlas onco.cc
Platinum + etoposide (EP / CE)standard-of-care: Platinum plus etoposide has been the chemotherapy backbone of small-cell lung cancer for over 40 years, and is now given with immunotherapy.Open in Atlas onco.cc
Plerixaforapproved: Plerixafor (Mozobil) is an injection given with G-CSF to flush stem cells out of the bone marrow into the blood so that enough can be collected for an autologous transplant in myeloma or lymphoma.Open in Atlas onco.cc
Plicamycinhistoric: Plicamycin, approved in 1970, was a chemotherapy for testicular cancer that fell out of use as cisplatin arrived, and was kept for treating dangerously high calcium levels caused by cancer until it was discontinued in 2000.Open in Atlas onco.cc
Plitidepsinestablished: Plitidepsin is a chemotherapy derived from a Mediterranean sea squirt, approved in Australia in 2018 with dexamethasone for multiple myeloma after several other treatments; the European regulator refused it, and it drew attention in 2021 as a possible COVID...Open in Atlas onco.cc
PM8002phase-3: PM8002 is an experimental bispecific antibody from Biotheus in phase 3 trials for small-cell lung cancer, triple-negative breast cancer and neuroendocrine tumours, aimed at PD-L1 and VEGF / VEGFR.Open in Atlas onco.cc
Polatuzumab vedotinapproved: Polatuzumab vedotin is an ADC against CD79b that, swapped into the classic R-CHOP regimen, became the first improvement on frontline lymphoma therapy in twenty years.Open in Atlas onco.cc
Pomalidomideapproved: The third-generation thalidomide analogue for myeloma that has failed lenalidomide, and since 2020 the first new drug for Kaposi sarcoma in two decades.Open in Atlas onco.cc
Ponatinibapproved: Ponatinib is the only BCR::ABL1 inhibitor that covers the T315I resistance mutation. In 2024 it became the preferred pill for newly diagnosed Ph-positive ALL.Open in Atlas onco.cc
Ponsegromabphase-3: Ponsegromab is a monoclonal antibody from Pfizer, in registered phase 3 trials for pancreatic ductal adenocarcinoma.Open in Atlas onco.cc
Porfimer sodiumestablished: Porfimer sodium is the drug half of photodynamic therapy: injected, it gathers in tumours, and a laser passed through an endoscope two days later activates it to burn away oesophageal and lung tumours that block the airway or gullet.Open in Atlas onco.cc
Poziotinibnegative: Poziotinib was a tablet designed to fit the awkward shape of HER2 and EGFR exon 20 mutations in lung cancer. It shrank tumours in some patients but caused severe rash and diarrhoea, and the FDA declined to approve it in 2022.Open in Atlas onco.cc
Pralatrexateapproved: Pralatrexate was the first drug approved specifically for relapsed peripheral T-cell lymphoma; about a third of patients respond.Open in Atlas onco.cc
Pralsetinibapproved: Pralsetinib is the second selective RET pill for lung cancer, less used than selpercatinib after a change of owner and label.Open in Atlas onco.cc
Precemtabart tocentecanphase-3: Precemtabart tocentecan is an experimental antibody-drug conjugate from EMD Serono Research & Development Institute in phase 3 trials for colorectal cancer, aimed at CEACAM5.Open in Atlas onco.cc
Prednisoneapproved: Prednisone is the everyday steroid tablet in cancer care. It is the P in CHOP and MOPP for lymphoma, part of childhood leukaemia treatment, and taken with abiraterone in prostate cancer.Open in Atlas onco.cc
Procarbazineapproved: Procarbazine (Matulane) is an old chemotherapy capsule from the MOPP regimen for Hodgkin lymphoma; it is now used mainly in the PCV combination for certain brain tumours.Open in Atlas onco.cc
ProFound AI (iCAD)approved: The first AI cleared for 3D mammography in the US, now part of RadNet's imaging network.Open in Atlas onco.cc
Progestins (megestrol acetate, medroxyprogesterone, levonorgestrel IUD)approved: Progesterone-like hormones that can reverse early endometrial cancer in women who want to keep their uterus, and control advanced hormone-sensitive disease.Open in Atlas onco.cc
Prolarisestablished: A gene test on a prostate biopsy that estimates how aggressive the cancer is, to help decide between active surveillance and treatment.Open in Atlas onco.cc
Propranolol (Hemangeol)established: Hemangeol is a liquid form of the blood-pressure drug propranolol approved to shrink infantile haemangiomas, the common benign blood-vessel tumours of babies, replacing steroids and surgery for most children who need treatment.Open in Atlas onco.cc
Prosigna (PAM50)approved: A 50-gene test run in local hospital laboratories that estimates the ten-year risk of a hormone-positive breast cancer coming back.Open in Atlas onco.cc
PROSTVACwithdrawn: A vaccine made from two viruses carrying the PSA gene, meant to teach the immune system to attack prostate cancer. The big trial found it did nothing at all.Open in Atlas onco.cc
PRTX007phase-2: PRTX007 is a small-molecule inhibitor from Primmune Therapeutics, Inc., in registered phase 2 trials for melanoma.Open in Atlas onco.cc
PSMA-1007 F-18phase-3: PSMA-1007 is a fluorine-18 PSMA PET tracer from ABX in Germany, widely used in Europe for prostate cancer staging because little of it reaches the bladder, and in a phase 3 trial registered by its maker.Open in Atlas onco.cc
Pucotenlimabapproved: Pucotenlimab is Lepu Biopharma's PD-1 antibody, approved in China in 2022 for mismatch-repair-deficient solid tumours and for melanoma, and in a phase 3 trial in colorectal cancer.Open in Atlas onco.cc
Purinostatphase-3: Purinostat is an experimental investigational agent whose form is not stated in the registry from Chengdu Zenitar Biomedical Technology in phase 3 trials for diffuse large B-cell lymphoma and multiple myeloma, with its target not yet stated publicly.Open in Atlas onco.cc
Puxitatug samrotecanphase-2: Puxitatug samrotecan is a B7-H4 ADC targeting a checkpoint-like protein enriched in breast, ovarian, and endometrial cancers.Open in Atlas onco.cc
Pyrotinibapproved: Pyrotinib is an irreversible pan-ErbB kinase inhibitor pill (EGFR, HER2, HER4) from Jiangsu Hengrui, approved in China since 2018 but not in the US or EU. It is the standard HER2 pill there, given with capecitabine after trastuzumab, and the comparator that...Open in Atlas onco.cc

Q

QL1706phase-3: QL1706 is an experimental small-molecule drug from Qilu Pharmaceutical in phase 3 trials for non-small-cell lung cancer and colorectal cancer, with its target not yet stated publicly.Open in Atlas onco.cc
QL2107phase-3: QL2107 is an experimental investigational agent whose form is not stated in the registry from Qilu Pharmaceutical in phase 3 trials for non-small-cell lung cancer, with its target not yet stated publicly.Open in Atlas onco.cc
QLC5508phase-3: QLC5508 is an experimental antibody-drug conjugate from Qilu Pharmaceutical in phase 3 trials for oesophageal cancer, prostate cancer and non-small-cell lung cancer, aimed at B7-H3.Open in Atlas onco.cc
QLH12016phase-2: QLH12016 is an experimental protein degrader from Qilu Pharmaceutical in phase 2 trials for prostate cancer, aimed at Androgen receptor.Open in Atlas onco.cc
QLS31905phase-3: QLS31905 is an experimental investigational agent whose form is not stated in the registry from Qilu Pharmaceutical in phase 3 trials for pancreatic ductal adenocarcinoma, with its target not yet stated publicly.Open in Atlas onco.cc
QLS32015phase-3: QLS32015 is an experimental investigational agent whose form is not stated in the registry from Qilu Pharmaceutical in phase 3 trials for multiple myeloma, with its target not yet stated publicly.Open in Atlas onco.cc
Quemliclustatphase-3: Quemliclustat is an experimental investigational agent whose form is not stated in the registry from Arcus Biosciences in phase 3 trials for pancreatic ductal adenocarcinoma and non-small-cell lung cancer, with its target not yet stated publicly.Open in Atlas onco.cc
Quizartinibapproved: Quizartinib is a more selective FLT3 blocker that, added to chemotherapy, roughly doubled median survival in the highest-risk FLT3 subtype.Open in Atlas onco.cc

R

RaDaRestablished: NeoGenomics' personalised blood test for tiny amounts of leftover cancer, tracking up to 48 mutations from the patient's own tumour.Open in Atlas onco.cc
Radioactive iodine (I-131)approved: The original targeted radiotherapy: thyroid cells soak up iodine, so radioactive iodine destroys leftover thyroid tissue and metastases while sparing everything else.Open in Atlas onco.cc
Radium-223 dichlorideapproved: Radium-223 was the first alpha-emitting drug ever approved (2013). It homes to bone like calcium and treats prostate cancer that has spread only to bone.Open in Atlas onco.cc
Radotinibphase-3: Radotinib is an oral kinase inhibitor from Il-Yang Pharm. Co., Ltd., in registered phase 3 trials for chronic myeloid leukaemia.Open in Atlas onco.cc
Raloxifeneapproved: Raloxifene (Evista) is an osteoporosis tablet that also lowers the chance of developing invasive breast cancer in postmenopausal women at higher risk, with fewer womb-cancer problems than tamoxifen.Open in Atlas onco.cc
Raltitrexedestablished: Raltitrexed is a three-weekly intravenous antifolate used in Europe, Canada and Australia for advanced bowel cancer, and with cisplatin for mesothelioma, in patients who cannot take fluorouracil.Open in Atlas onco.cc
Raludotatug deruxtecanphase-3: Raludotatug deruxtecan is a CDH6 ADC in phase 3 for platinum-resistant ovarian cancer.Open in Atlas onco.cc
Ramucirumabapproved: An antibody that blocks the VEGF receptor, approved in liver cancer only for patients with a high AFP blood level, the first biomarker-selected HCC drug.Open in Atlas onco.cc
Rasburicaseapproved: Rasburicase (Elitek) is an enzyme infusion that rapidly dissolves the uric acid released when large numbers of leukaemia or lymphoma cells die at the start of treatment, protecting the kidneys from tumour lysis syndrome.Open in Atlas onco.cc
Ravulizumabestablished: Ravulizumab is an eight-weekly infusion that blocks the complement system; it treats paroxysmal nocturnal haemoglobinuria, a clonal bone marrow disorder managed by haematologists alongside aplastic anaemia and myelodysplasia.Open in Atlas onco.cc
RC118-ADCphase-2: RC118-ADC is an experimental antibody-drug conjugate from RemeGen in phase 2 trials, aimed at Claudin 18.2.Open in Atlas onco.cc
RC148phase-3: RC148 is an experimental investigational agent whose form is not stated in the registry from RemeGen in phase 3 trials for non-small-cell lung cancer and HR-positive / HER2-negative breast cancer, with its target not yet stated publicly.Open in Atlas onco.cc
Recombinant human endostatinapproved: Endostar is Simcere's recombinant endostatin, approved in China in 2005 with chemotherapy for advanced non-small-cell lung cancer, one of the first angiogenesis inhibitors approved anywhere.Open in Atlas onco.cc
REGN7075phase-2: REGN7075 is a bispecific antibody from Regeneron Pharmaceuticals, in registered phase 2 trials for non-small-cell lung cancer, small-cell lung cancer.Open in Atlas onco.cc
Regorafenibapproved: A sorafenib successor that became the first second-line drug proven to prolong life in liver cancer (2017).Open in Atlas onco.cc
Relacorilantapproved: A first-in-class drug that blocks cortisol signalling in tumour cells, approved in 2026 for platinum-resistant ovarian cancer with chemotherapy.Open in Atlas onco.cc
Relatlimab + nivolumabapproved: Opdualag combines relatlimab, the first drug targeting the LAG-3 immune brake, with nivolumab for melanoma.Open in Atlas onco.cc
Relmacabtagene autoleucelapproved: Relma-cel was the first CAR-T therapy developed and made in China to be approved, for large B-cell lymphoma that has come back after two treatments.Open in Atlas onco.cc
Relugolixapproved: Relugolix is the first hormone-suppressing pill for prostate cancer, working within days and wearing off quickly when stopped.Open in Atlas onco.cc
REM-422phase-2: REM-422 is a small-molecule inhibitor from Remix Therapeutics, in registered phase 2 trials for salivary gland cancers.Open in Atlas onco.cc
Remestemcel-Lapproved: Donor bone marrow stromal cells given to children whose acute graft-versus-host disease no longer responds to steroids, the first mesenchymal stromal cell therapy approved in the United States.Open in Atlas onco.cc
Repotrectinibapproved: A ROS1 and NTRK pill that also works after other ROS1 drugs fail, with dizziness as its signature side effect.Open in Atlas onco.cc
Resminostat: Resminostat is an oral drug of the HDAC inhibitor class, proposed for advanced mycosis fungoides and Sézary syndrome, two cutaneous T-cell lymphomas. Europe's medicines committee said no to it in May 2025, so it is not authorised.Open in Atlas onco.cc
Resolution ctDx FIRSTapproved: A blood test approved with adagrasib to find the KRAS G12C mutation in lung cancer when a tissue biopsy is not possible.Open in Atlas onco.cc
Retifanlimabapproved: Retifanlimab is a PD-1 antibody approved for Merkel cell carcinoma and, with chemotherapy, as the first immunotherapy standard for advanced anal cancer.Open in Atlas onco.cc
Retlirafusp alfaphase-3: Retlirafusp alfa is Hengrui's PD-L1 and TGF-beta bifunctional antibody, in phase 3 trials with chemotherapy in gastric cancer after the Western class leader bintrafusp alfa failed.Open in Atlas onco.cc
Revumenibapproved: Revumenib (Revuforj) is the first menin inhibitor (2024), for acute leukaemias with KMT2A rearrangements or NPM1 mutations.Open in Atlas onco.cc
Rezvilutamideapproved: Rezvilutamide is Hengrui's androgen receptor blocker, approved in China in 2022 for high-volume metastatic hormone-sensitive prostate cancer on the CHART trial, where it improved survival over bicalutamide.Open in Atlas onco.cc
Ribociclibapproved: Ribociclib is the CDK4/6 inhibitor with the most consistent survival benefit, approved for a broad population of early breast cancer patients since 2024.Open in Atlas onco.cc
Rilvegostomigphase-2: Rilvegostomig is an experimental bispecific antibody from AstraZeneca in phase 2 trials for non-small-cell lung cancer, aimed at PD-1 and TIGIT.Open in Atlas onco.cc
Rinatabart sesutecanphase-3: Rinatabart sesutecan is a next-generation folate-receptor ADC with a topoisomerase payload that responds in both ovarian and endometrial cancer regardless of receptor level.Open in Atlas onco.cc
Rindopepimutnegative: Rindopepimut is a peptide vaccine against EGFRvIII, a mutant protein found only on some glioblastomas. After a phase 2 that beat historical controls, the 745-patient double-blind phase 3 ACT IV found no benefit in 2016, and tumours in both arms had lost EGF...Open in Atlas onco.cc
Rinzimetostatphase-3: Rinzimetostat is an experimental small-molecule drug from ORIC Pharmaceuticals in phase 3 trials for prostate cancer, with its target not yet stated publicly.Open in Atlas onco.cc
Ripretinibapproved: A fourth-line GIST drug that locks KIT in an off state regardless of which resistance mutation the tumour has acquired.Open in Atlas onco.cc
Rituximabapproved: Rituximab was the first antibody ever approved for cancer (1997). It made chemoimmunotherapy the CLL standard for a decade, and biosimilars keep it cheap and everywhere.Open in Atlas onco.cc
Rivoceranib (apatinib)approved: Apatinib, sold as rivoceranib outside China, was the first pill of its kind approved for stomach cancer and is now the partner of camrelizumab in first-line liver cancer.Open in Atlas onco.cc
RNK05047phase-2: RNK05047 is a targeted protein degrader from Ranok Therapeutics (Hangzhou) Co., Ltd., in registered phase 2 trials for metastatic cancer.Open in Atlas onco.cc
RO7771950phase-3: RO7771950 is an experimental small-molecule drug from Hoffmann-La Roche in phase 3 trials for HER2-positive breast cancer and HR-positive / HER2-negative breast cancer, aimed at HER2.Open in Atlas onco.cc
Rocbrutinibphase-3: Rocbrutinib is an experimental small-molecule drug from Guangzhou Lupeng Pharmaceutical in phase 3 trials for mantle cell lymphoma, chronic lymphocytic leukaemia and diffuse large B-cell lymphoma, with its target not yet stated publicly.Open in Atlas onco.cc
Roginolisibphase-2: Roginolisib is an oral pi3k inhibitor from iOnctura, in registered phase 2 trials for non-small-cell lung cancer, small-cell lung cancer.Open in Atlas onco.cc
Rolapitantapproved: Rolapitant (Varubi) is a long-lasting anti-sickness tablet taken once before chemotherapy, alongside a 5-HT3 blocker and dexamethasone, to prevent nausea and vomiting in the days after treatment.Open in Atlas onco.cc
Romidepsinapproved: Romidepsin is an epigenetic drug for T-cell lymphomas of the skin and lymph nodes; its US lymph-node indication was withdrawn when a confirmatory trial failed.Open in Atlas onco.cc
Romiplostimestablished: Romiplostim is a weekly injection that tells the bone marrow to make more platelets; it is approved for immune thrombocytopenia and for radiation injury, and is being tested for the low platelets that chemotherapy causes.Open in Atlas onco.cc
Rondecabtagene autoleucelphase-3: Rondecabtagene autoleucel is an experimental CAR-T cell therapy from Lyell Immunopharma in phase 3 trials for diffuse large B-cell lymphoma and hodgkin lymphoma, aimed at CD19 and CD20.Open in Atlas onco.cc
Ropeginterferon alfa-2bapproved: Ropeginterferon alfa-2b is a long-acting interferon for polycythaemia vera that, unlike hydroxyurea, can shrink the mutant clone over years.Open in Atlas onco.cc
Rovalpituzumab tesirinewithdrawn: Rovalpituzumab tesirine (Rova-T) was the first drug against DLL3 in small-cell lung cancer. AbbVie bought it for $5.8B and abandoned it after two failed phase 3 trials. The target later worked with a different weapon.Open in Atlas onco.cc
RPH-051phase-3: RPH-051 is an experimental monoclonal antibody from R-Pharm in phase 3 trials for HR-positive / HER2-negative breast cancer and HER2-positive breast cancer, aimed at HER2.Open in Atlas onco.cc
Rucaparibapproved: Rucaparib is a DNA-repair inhibitor for selected BRCA-mutated ovarian and prostate cancers. Its prostate indication received regular US approval in December 2025.Open in Atlas onco.cc
Rusfertideapproved: Rusfertide is the first drug to control polycythaemia vera's excess red cells by restricting iron, sparing patients repeated blood removal.Open in Atlas onco.cc
Ruxolitinibapproved: Ruxolitinib was the first JAK inhibitor: it shrinks the spleen and relieves symptoms in myelofibrosis and controls blood counts in polycythaemia vera, without eliminating the disease clone.Open in Atlas onco.cc
RV001Vphase-2: RV001V is a cancer vaccine from RhoVac APS, in registered phase 2 trials for prostate cancer.Open in Atlas onco.cc
RVU120phase-2: RVU120 is a small-molecule inhibitor from Ryvu Therapeutics SA, in registered phase 2 trials for acute myeloid leukaemia.Open in Atlas onco.cc

S

Sabatolimabphase-2: Sabatolimab is a monoclonal antibody from Novartis Pharmaceuticals, in registered phase 2 trials for myelodysplastic syndromes / neoplasms.Open in Atlas onco.cc
Sacituzumab govitecanapproved: Sacituzumab govitecan carries chemotherapy to cancer cells bearing TROP2. It is FDA-approved for specific advanced breast-cancer settings, including two first-line triple-negative indications.Open in Atlas onco.cc
Sacituzumab tirumotecanapproved: Sacituzumab tirumotecan is a TROP2 antibody-drug conjugate approved for specific advanced breast- and lung-cancer settings in China. It remains investigational in the United States.Open in Atlas onco.cc
Safusidenibphase-3: Safusidenib is an experimental small molecule inhibitor from Nuvation Bio in phase 3 trials for glioma & glioblastoma, aimed at IDH1 / IDH2.Open in Atlas onco.cc
Samarium-153 lexidronamapproved: Quadramet (samarium-153 lexidronam) is a radioactive bone-seeking injection that lodges in bone metastases and irradiates them from inside, approved in 1997 to relieve pain from prostate, breast and other cancers spread to bone. Most patients get relief wit...Open in Atlas onco.cc
Samuraciclibphase-2: Samuraciclib is an oral cdk inhibitor from Pfizer, in registered phase 2 trials for metastatic cancer, HR-positive / HER2-negative breast cancer.Open in Atlas onco.cc
Sapanisertibphase-2: Sapanisertib is an experimental small-molecule drug from Faeth Therapeutics in phase 2 trials for HR-positive / HER2-negative breast cancer and endometrial cancer, aimed at mTOR.Open in Atlas onco.cc
Sargramostimestablished: Sargramostim is a lab-made version of GM-CSF, the signal that tells bone marrow to make white cells; approved in 1991, it shortens the dangerous low-count period after leukaemia chemotherapy and stem cell transplants.Open in Atlas onco.cc
Saruparibphase-3: Saruparib is an experimental DNA-repair inhibitor in advanced trials for selected breast and prostate cancers. It selectively blocks PARP1.Open in Atlas onco.cc
Sasanlimabphase-3: Sasanlimab is an experimental monoclonal antibody from Pfizer in phase 3 trials for bladder & urothelial cancer, aimed at PD-1 and PD-L1.Open in Atlas onco.cc
Satricabtagene autoleucelapproved: Satricabtagene autoleucel (satri-cel) is the first CAR-T therapy approved for a solid tumour (gastric cancer), in China.Open in Atlas onco.cc
Savolitinibapproved: Savolitinib is a Chinese-discovered pill that blocks the MET growth signal, approved in China for lung cancers with a MET exon 14 mutation and being tested worldwide with osimertinib.Open in Atlas onco.cc
SCTB14phase-3: SCTB14 is an experimental investigational agent whose form is not stated in the registry from Sinocelltech in phase 3 trials for non-small-cell lung cancer, with its target not yet stated publicly.Open in Atlas onco.cc
SCTB35phase-3: SCTB35 is an experimental investigational agent whose form is not stated in the registry from Sinocelltech in phase 3 trials for diffuse large B-cell lymphoma and follicular lymphoma, with its target not yet stated publicly.Open in Atlas onco.cc
SCTB41phase-3: SCTB41 is an experimental investigational agent whose form is not stated in the registry from Sinocelltech in phase 3 trials for non-small-cell lung cancer, with its target not yet stated publicly.Open in Atlas onco.cc
SCTC21Cphase-3: SCTC21C is an experimental investigational agent whose form is not stated in the registry from Sinocelltech in phase 3 trials for multiple myeloma, with its target not yet stated publicly.Open in Atlas onco.cc
Selicrelumabphase-2: Selicrelumab is a monoclonal antibody from Hoffmann-La Roche, in registered phase 2 trials for metastatic cancer.Open in Atlas onco.cc
Selinexorapproved: Selinexor is a first-in-class pill that traps tumour-suppressor proteins inside the nucleus; approved in myeloma, it failed its endometrial cancer test in 2026.Open in Atlas onco.cc
Selpercatinibapproved: Selpercatinib is a selective RET inhibitor approved for any tumour with a RET fusion, with a further label update in July 2026.Open in Atlas onco.cc
Selumetinibapproved: Selumetinib (Koselugo) is the first medicine for children and adults with neurofibromatosis type 1 whose plexiform neurofibromas, benign but disfiguring and painful nerve tumours, cannot be removed by surgery.Open in Atlas onco.cc
Senaparib (IMP4297)phase-3: Senaparib is an oral PARP inhibitor from IMPACT Therapeutics tested as maintenance treatment after first-line chemotherapy for advanced ovarian cancer. On 17 September 2026 the EMA's medicines committee recommended EU approval under the name Sepalna; the Eu...Open in Atlas onco.cc
Serabelisibphase-2: Serabelisib is an experimental small-molecule drug from Faeth Therapeutics in phase 2 trials for HR-positive / HER2-negative breast cancer and endometrial cancer, aimed at PIK3CA / PI3K-alpha.Open in Atlas onco.cc
Serplulimabapproved: Serplulimab is a Chinese PD-1 antibody with the largest survival gain of any first-line small-cell lung cancer immunotherapy trial, approved in China, Europe, and the UK but not yet the US.Open in Atlas onco.cc
Setidegrasibphase-3: Setidegrasib is an experimental investigational agent whose form is not stated in the registry from Astellas Pharma Global Development in phase 3 trials for pancreatic ductal adenocarcinoma and non-small-cell lung cancer, aimed at KRAS.Open in Atlas onco.cc
Setmelanotideapproved: Setmelanotide is a daily injection that switches back on the brain's fullness signal. It is approved for rare genetic causes of obesity and, since March 2026 in the United States, for the continuous weight gain that follows damage to the hypothalamus from a...Open in Atlas onco.cc
Sevabertinibapproved: Sevabertinib is an oral HER2 inhibitor for lung cancers with HER2 mutations, approved in November 2025 as an alternative to Enhertu and zongertinib.Open in Atlas onco.cc
SG301phase-3: SG301 is an experimental investigational agent whose form is not stated in the registry from Hangzhou Sumgen Biotech in phase 3 trials for multiple myeloma, aimed at CD38.Open in Atlas onco.cc
SGM-101phase-3: SGM-101 is an experimental monoclonal antibody from Surgimab in phase 3 trials for colorectal cancer, aimed at CEACAM5.Open in Atlas onco.cc
Shieldapproved: The first FDA-approved blood test for colorectal cancer screening (2024), now optionally reporting other cancers too.Open in Atlas onco.cc
SHR-1501phase-3: SHR-1501 is an experimental investigational agent whose form is not stated in the registry from Suzhou Suncadia Biopharmaceuticals in phase 3 trials for bladder & urothelial cancer, with its target not yet stated publicly.Open in Atlas onco.cc
SHR-8068phase-3: SHR-8068 is an experimental investigational agent whose form is not stated in the registry from Suzhou Suncadia Biopharmaceuticals in phase 3 trials for biliary tract cancer, non-small-cell lung cancer and cervical cancer, with its target not yet stated pub...Open in Atlas onco.cc
SHR-A1912phase-3: SHR-A1912 is an experimental investigational agent whose form is not stated in the registry from Suzhou Suncadia Biopharmaceuticals in phase 3 trials for diffuse large B-cell lymphoma, with its target not yet stated publicly.Open in Atlas onco.cc
SHR-A1921phase-3: SHR-A1921 is an experimental drug that delivers chemotherapy to TROP2-bearing cells. Early solid-tumor findings are distinct from the later trials testing its comparative benefit.Open in Atlas onco.cc
SHR-A2009phase-3: SHR-A2009 is an experimental investigational agent whose form is not stated in the registry from Shanghai Hengrui Pharmaceutical in phase 3 trials for non-small-cell lung cancer, with its target not yet stated publicly.Open in Atlas onco.cc
SHR-A2102phase-3: SHR-A2102 is an experimental investigational agent whose form is not stated in the registry from Shanghai Hengrui Pharmaceutical in phase 3 trials for cervical cancer, non-small-cell lung cancer and head and neck squamous cell carcinoma, with its target not...Open in Atlas onco.cc
SI-B001phase-3: SI-B001 is an experimental investigational agent whose form is not stated in the registry from Sichuan Baili Pharmaceutical in phase 3 trials for non-small-cell lung cancer and head and neck squamous cell carcinoma, with its target not yet stated publicly.Open in Atlas onco.cc
Signateraestablished: Signatera is Natera's tumour-informed blood test that tracks 16 mutations from each patient's own tumour to detect residual or returning cancer after surgery. Medicare covers it in colorectal, breast, bladder, lung and ovarian cancer and for immunotherapy m...Open in Atlas onco.cc
Silevertinibphase-2: Silevertinib is an experimental small-molecule drug from Black Diamond Therapeutics in phase 2 trials for non-small-cell lung cancer, aimed at EGFR.Open in Atlas onco.cc
Siltuximabapproved: Siltuximab (Sylvant) is an antibody that neutralises the inflammatory messenger interleukin-6. It is the only approved treatment for multicentric Castleman disease, a rare lymph node disorder, in people without HIV or HHV-8 infection.Open in Atlas onco.cc
SIM0270phase-3: SIM0270 is an experimental investigational agent whose form is not stated in the registry from Jiangsu Simcere Pharmaceutical in phase 3 trials for HR-positive / HER2-negative breast cancer, with its target not yet stated publicly.Open in Atlas onco.cc
SimpleScreen CRCapproved: The second FDA-approved blood test for bowel cancer screening, from Freenome, sold by Abbott from late 2026.Open in Atlas onco.cc
Sintilimabapproved: Sintilimab is Innovent's PD-1 antibody, approved in China since 2018 for Hodgkin lymphoma and then, on the ORIENT trials, for first-line lung, liver, oesophageal and stomach cancer. In 2022 the FDA rejected its lung cancer application because a China-only t...Open in Atlas onco.cc
Sipuleucel-Tapproved: Sipuleucel-T was the first therapeutic cancer vaccine approved (2010): it lengthened survival in metastatic prostate cancer by about four months without shrinking tumours or lowering PSA.Open in Atlas onco.cc
Sirolimusapproved: Sirolimus is an anti-rejection tablet taken after an organ transplant. Switching to it from a calcineurin inhibitor roughly halves the number of new skin squamous cell carcinomas in people who have already had one, at the cost of more side effects and a qua...Open in Atlas onco.cc
Sirolimus protein-bound particlesapproved: Fyarro is an infusion of the transplant drug sirolimus packaged in albumin particles. It is the first approved treatment for malignant PEComa, a rare soft-tissue tumour driven by loss of the TSC genes.Open in Atlas onco.cc
Sitneprotafibphase-3: Sitneprotafib is an experimental small-molecule drug from Allist Pharmaceuticals in phase 3 trials for non-small-cell lung cancer, colorectal cancer and pancreatic ductal adenocarcinoma, with its target not yet stated publicly.Open in Atlas onco.cc
SKB105phase-2: SKB105 is an antibody-drug conjugate from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., in registered phase 2 trials for metastatic cancer.Open in Atlas onco.cc
SNV1521phase-1: SNV1521 is an experimental pill being studied to block a DNA-repair enzyme in cancer cells.Open in Atlas onco.cc
Socazolimabphase-3: Socazolimab is Lee's Pharmaceutical's PD-L1 antibody, in phase 3 trials in China for extensive-stage small cell lung cancer and recurrent cervical cancer.Open in Atlas onco.cc
Sodium thiosulfate (otoprotectant)approved: An old antidote proven in two paediatric trials to halve permanent hearing loss from cisplatin, and approved in 2022 as the first drug to prevent a chemotherapy side effect in children.Open in Atlas onco.cc
Sofetabart Mipitecanphase-3: Sofetabart Mipitecan is an experimental antibody-drug conjugate from Eli Lilly and in phase 3 trials for ovarian cancer, aimed at Folate receptor alpha.Open in Atlas onco.cc
Somatostatin analogues (octreotide, lanreotide)approved: Monthly injections of a synthetic hormone that both quiets tumour hormone symptoms and slows tumour growth, the first treatment for most neuroendocrine tumours.Open in Atlas onco.cc
Sonesitatug vedotinphase-3: Sonesitatug vedotin is a Claudin 18.2 ADC in phase 3 for gastric cancer, licensed by AstraZeneca from KYM Biosciences.Open in Atlas onco.cc
Sonidegibapproved: Sonidegib (Odomzo) is the second hedgehog inhibitor for locally advanced basal cell carcinoma, similar in effect and side effects to vismodegib.Open in Atlas onco.cc
Sonrotoclaxapproved: Sonrotoclax is a more potent, shorter-acting successor to venetoclax. It was approved for mantle cell lymphoma in May 2026 and is in late-stage trials with zanubrutinib for CLL.Open in Atlas onco.cc
Soquelitinibphase-3: Soquelitinib is an experimental small-molecule drug from Corvus Pharmaceuticals in phase 3 trials for peripheral T-cell lymphomas, with its target not yet stated publicly.Open in Atlas onco.cc
Sorafenibapproved: The first drug ever to extend life in advanced liver cancer (2007), now mostly a comparator arm that newer combinations are measured against.Open in Atlas onco.cc
Sotevtamabphase-2: Sotevtamab is a monoclonal antibody from Alethia Biotherapeutics, in registered phase 2 trials for colorectal cancer.Open in Atlas onco.cc
Sotorasibapproved: Sotorasib (Lumakras) was the first drug to hit KRAS, approved in 2021 after four decades of failure.Open in Atlas onco.cc
Spartalizumabphase-2: Spartalizumab is a monoclonal antibody from Novartis Pharmaceuticals, in registered phase 2 trials for myelodysplastic syndromes / neoplasms.Open in Atlas onco.cc
Spevatamigphase-2: Spevatamig is an experimental bispecific antibody from Phanes Therapeutics in phase 2 trials for gastric & gastro-oesophageal junction cancer, pancreatic ductal adenocarcinoma and biliary tract cancer, aimed at Claudin 18.2 and CD47.Open in Atlas onco.cc
SPH4336phase-3: SPH4336 is an experimental small-molecule drug from Shanghai Pharmaceuticals in phase 3 trials for HR-positive / HER2-negative breast cancer, with its target not yet stated publicly.Open in Atlas onco.cc
SSGJ-612phase-2: SSGJ-612 is an experimental monoclonal antibody from Shenyang Sunshine Pharmaceutical in phase 2 trials, aimed at HER2.Open in Atlas onco.cc
SSGJ-705phase-2: SSGJ-705 is an experimental monoclonal antibody from Shenyang Sunshine Pharmaceutical in phase 2 trials, aimed at PD-1 and HER2.Open in Atlas onco.cc
SSGJ-706phase-2: SSGJ-706 is an experimental bispecific antibody from Shenyang Sunshine Pharmaceutical in phase 2 trials for non-small-cell lung cancer, aimed at PD-1 and PD-L1.Open in Atlas onco.cc
STI-3258historic: The first registered STI-3258 TROP-2 study was withdrawn before enrolling any participants.Open in Atlas onco.cc
STI-6129phase-2: STI-6129 is an experimental antibody-drug conjugate from Zhejiang ACEA Pharmaceutical in phase 2 trials for multiple myeloma, aimed at CD38.Open in Atlas onco.cc
STP938phase-2: STP938 is a small-molecule inhibitor from Step Pharma, SAS, in registered phase 2 trials for non-Hodgkin lymphoma.Open in Atlas onco.cc
Streptozocinestablished: Streptozocin is a chemotherapy drug that seeks out pancreatic islet cells, approved in 1982 for the rare tumours that arise from them; the same selectivity makes it the standard way to induce diabetes in laboratory animals.Open in Atlas onco.cc
Sugemalimabapproved: Sugemalimab is CStone's PD-L1 antibody, approved in China for first-line lung cancer with chemotherapy and after chemoradiotherapy in stage III disease, and the first China-developed PD-L1 antibody to win European approval.Open in Atlas onco.cc
Sunitinibapproved: Sunitinib is an anti-angiogenic pill approved for pancreatic neuroendocrine tumours, kidney cancer and GIST.Open in Atlas onco.cc
Sunvozertinibapproved: An oral drug for EGFR exon 20 insertion lung cancer that succeeded where mobocertinib failed; approved in China (2023) and the US (2025).Open in Atlas onco.cc
Surufatinibapproved: Surufatinib is HUTCHMED's angio-immuno kinase inhibitor, approved in China in 2020 for non-pancreatic and in 2021 for pancreatic neuroendocrine tumours.Open in Atlas onco.cc
Synthetic hypericinphase-3: HyBryte is an ointment containing synthetic hypericin, the active pigment of St John's wort. Rubbed on patches of cutaneous T-cell lymphoma and switched on with ordinary visible light, it kills the lymphoma cells in the skin without ultraviolet light.Open in Atlas onco.cc
SYS6010phase-3: SYS6010 is an experimental investigational agent whose form is not stated in the registry from CSPC Megalith Biopharmaceutical in phase 3 trials for non-small-cell lung cancer and head and neck squamous cell carcinoma, with its target not yet stated publicly.Open in Atlas onco.cc
SYS6023phase-2: SYS6023 is an experimental antibody-drug conjugate from CSPC Megalith Biopharmaceutical in phase 2 trials for HR-positive / HER2-negative breast cancer, aimed at HER3.Open in Atlas onco.cc

T

T3011phase-2: T3011 is an experimental small-molecule drug from ImmVira Pharma in phase 2 trials for melanoma, head and neck squamous cell carcinoma and sarcomas, aimed at PD-1 and PD-L1.Open in Atlas onco.cc
Tabelecleucelapproved: Tabelecleucel is a bank of donor T cells trained against Epstein-Barr virus, approved in Europe in 2022 as the first off-the-shelf T-cell therapy, for EBV-driven lymphoma after transplant when rituximab has failed.Open in Atlas onco.cc
TAC01-CLDN18.2phase-2: TAC01-CLDN18.2 is an experimental TCR-T cell therapy from Triumvira Immunologics in phase 2 trials, aimed at Claudin 18.2.Open in Atlas onco.cc
Tacquell (autologous melanoma-derived tumour-infiltrating lymphocytes): Tacquell is a tumour-infiltrating lymphocyte therapy for melanoma developed by the Netherlands Cancer Institute, the academic group whose randomised trial first showed TIL therapy could beat ipilimumab. Europe's medicines committee gave it a negative opinio...Open in Atlas onco.cc
Tafasitamabapproved: A CD19 antibody given with lenalidomide for lymphoma patients who cannot have a transplant; in 2026 it showed the first frontline gain over R-CHOP in high-risk disease.Open in Atlas onco.cc
Tagraxofuspapproved: Tagraxofusp is a fusion of the growth factor IL-3 with a bacterial toxin that homes to CD123 on a rare, aggressive blood cancer.Open in Atlas onco.cc
TAK-928phase-3: TAK-928 is an experimental bispecific antibody from Takeda in phase 3 trials for non-small-cell lung cancer, aimed at PD-1 and CD25 (IL-2 receptor alpha).Open in Atlas onco.cc
Talazoparibapproved: Talazoparib is a DNA-repair inhibitor for selected inherited-BRCA breast cancers and, with hormone treatment, selected advanced prostate cancers.Open in Atlas onco.cc
Talc (intrapleural)approved: Sterile talc is puffed or instilled into the chest cavity after fluid is drained to make the lung stick to the chest wall, stopping cancer-related fluid (malignant pleural effusion) from building up again.Open in Atlas onco.cc
Taletrectinibapproved: A ROS1 lung-cancer pill approved in 2025 that works in the brain and after crizotinib, with fewer dizziness-type side effects than repotrectinib.Open in Atlas onco.cc
Talicabtagene autoleucelapproved: India's first home-grown CAR-T cell therapy, approved in 2023 for relapsed leukaemia and lymphoma, made in Mumbai for roughly a tenth of what the same kind of treatment costs in the US.Open in Atlas onco.cc
Talimogene laherparepvecapproved: Talimogene laherparepvec (T-VEC, Imlygic) was the first approved oncolytic virus (2015), injected into melanoma skin lesions.Open in Atlas onco.cc
Talquetamabapproved: Talquetamab is the first drug against GPRC5D, a second myeloma target used after BCMA therapies stop working; taste and skin side effects are its signature.Open in Atlas onco.cc
Tamoxifenapproved: The original targeted cancer drug (1977): a pill that blocks oestrogen's effect on breast cancer and halves recurrence, still essential for premenopausal women.Open in Atlas onco.cc
TAR-210phase-3: TAR-210 is an experimental small molecule (intravesical drug-releasing system) from Janssen Research & Development in phase 3 trials for bladder & urothelial cancer, aimed at FGFR2.Open in Atlas onco.cc
TARA-002phase-3: TARA-002 is an experimental cell therapy whose type is not stated from Protara Therapeutics in phase 3 trials for bladder & urothelial cancer, with its target not yet stated publicly.Open in Atlas onco.cc
Tarlatamabapproved: The first T-cell engager to improve survival in a common solid tumour, small-cell lung cancer.Open in Atlas onco.cc
Tasonerminapproved: Beromun is a recombinant form of the immune protein TNF-alpha, pumped with the chemotherapy melphalan through the isolated blood supply of an arm or leg to shrink soft-tissue sarcomas so that the limb can be saved rather than amputated.Open in Atlas onco.cc
Tasquinimodwithdrawn: An oral drug aimed at the tissue around the tumour rather than the cancer cells. It held the cancer back on scans and, if anything, shortened life.Open in Atlas onco.cc
Tazemetostatwithdrawn: Tazemetostat was the first EZH2 inhibitor, approved for epithelioid sarcoma and follicular lymphoma in 2020 and withdrawn worldwide in 2026 after secondary blood cancers.Open in Atlas onco.cc
TBI-1301phase-3: TBI-1301 is an experimental investigational agent whose form is not stated in the registry from Takara Bio in phase 3 trials for sarcomas, with its target not yet stated publicly.Open in Atlas onco.cc
TBI-1501phase-2: TBI-1501 is an experimental CAR-T cell therapy from Takara Bio in phase 2 trials for acute lymphoblastic leukaemia, aimed at CD19.Open in Atlas onco.cc
TC011phase-2: TC011 is an experimental CAR-T cell therapy from TICAROS in phase 2 trials for diffuse large B-cell lymphoma and follicular lymphoma, aimed at CD19.Open in Atlas onco.cc
Tebentafuspapproved: The first drug to improve survival in metastatic uveal melanoma, and the first TCR-based bispecific.Open in Atlas onco.cc
Technetium Tc-99m sulfur colloidestablished: Technetium sulfur colloid is the radioactive tracer injected around a breast cancer or melanoma before surgery so the surgeon can find the first lymph node the tumour drains to and remove only that node instead of the whole basin.Open in Atlas onco.cc
Technetium-99m tilmanoceptapproved: The purpose-built tracer for sentinel lymph node mapping in breast cancer, melanoma and oral cancer, replacing off-label sulfur colloid.Open in Atlas onco.cc
Teclistamabapproved: Teclistamab was the first off-the-shelf bispecific for multiple myeloma, and is now approved after just one prior line of therapy.Open in Atlas onco.cc
Tegafur, gimeracil and oteracil (S-1)approved: Teysuno (S-1) is an oral chemotherapy combining a fluorouracil pro-drug with two protectors. It is a standard in Japan and approved in Europe for stomach cancer with cisplatin and for bowel cancer when other fluoropyrimidines cause hand-foot syndrome or hea...Open in Atlas onco.cc
Telisotuzumab adizutecanphase-3: Telisotuzumab adizutecan is an experimental antibody-drug conjugate from AbbVie in phase 3 trials for colorectal cancer and non-small-cell lung cancer, with its target not yet stated publicly.Open in Atlas onco.cc
Telisotuzumab vedotinapproved: Telisotuzumab vedotin (Emrelis) is the first c-MET-directed ADC, approved in 2025 for lung cancer with high c-MET protein.Open in Atlas onco.cc
Telotristat ethylapproved: Telotristat ethyl (Xermelo) is a tablet that cuts the serotonin that neuroendocrine tumours pour out, easing the constant diarrhoea of carcinoid syndrome when somatostatin analogue injections are not enough.Open in Atlas onco.cc
Temoporfinapproved: Foscan is a light-activated drug used in Europe to shrink advanced head and neck cancers that have failed other treatments and cannot be operated on, irradiated or given chemotherapy, to relieve symptoms.Open in Atlas onco.cc
Temozolomidestandard-of-care: The only chemotherapy proven to extend life in glioblastoma, given during and after radiation. It works best when the tumour has switched off a repair gene called MGMT.Open in Atlas onco.cc
Tempus xT CDxapproved: Tempus's tumour-and-normal gene panel, FDA-approved in 2023 as a companion test for EGFR antibodies in bowel cancer.Open in Atlas onco.cc
Temsirolimusapproved: A weekly infusion that was the first drug to extend survival in poor-risk kidney cancer (2007), and in 2024 the first targeted drug to improve outcomes in childhood rhabdomyosarcoma.Open in Atlas onco.cc
Tenalisibphase-2: Tenalisib is an oral pi3k inhibitor from Rhizen Pharmaceuticals SA, in registered phase 2 trials for triple-negative breast cancer.Open in Atlas onco.cc
Teniposideestablished: Teniposide is a close relative of etoposide approved in the United States in 1992 for children whose acute lymphoblastic leukaemia has come back after induction, and used in Europe for childhood brain tumours and neuroblastoma.Open in Atlas onco.cc
Tepotinibapproved: Tepotinib is a once-daily targeted pill for lung cancers driven by a MET exon 14 skipping mutation, and the MET inhibitor NICE funds in England.Open in Atlas onco.cc
Tersolisibphase-3: Tersolisib is an experimental small-molecule drug from Eli Lilly and in phase 3 trials for HR-positive / HER2-negative breast cancer, aimed at PIK3CA / PI3K-alpha.Open in Atlas onco.cc
TGRX-326phase-3: TGRX-326 is an experimental small-molecule drug from Shenzhen TargetRx in phase 3 trials for non-small-cell lung cancer, with its target not yet stated publicly.Open in Atlas onco.cc
Thalidomideapproved: Thalidomide is the drug behind the 1960s birth-defect tragedy, rehabilitated as the first immunomodulatory myeloma drug and the parent of lenalidomide and pomalidomide.Open in Atlas onco.cc
THEO-260phase-2: THEO-260 is an oncolytic virus from Theolytics Limited, in registered phase 2 trials for ovarian cancer.Open in Atlas onco.cc
therascreen companion diagnostic kits (KRAS, EGFR, PIK3CA, FGFR, BRAF)approved: A family of quick single-gene tests that decide who can have several bowel, lung, breast and bladder cancer drugs.Open in Atlas onco.cc
Thioguanineapproved: Thioguanine (Tabloid) is an oral chemotherapy tablet used in some regimens to induce and consolidate remission in acute myeloid leukaemia; long-term use is avoided because it damages the liver.Open in Atlas onco.cc
Thiotepaapproved: Thiotepa is an old chemotherapy with a modern job: at high doses it prepares patients for stem cell transplants, and it is still instilled into the bladder or body cavities for superficial bladder cancer and malignant effusions.Open in Atlas onco.cc
Thyrotropin alfaapproved: Thyrogen is an injected version of thyroid-stimulating hormone that lets people with thyroid cancer have radioiodine treatment and follow-up blood tests without stopping their thyroid hormone tablets and suffering weeks of hypothyroidism.Open in Atlas onco.cc
Tilatamig samrotecanphase-2: AstraZeneca's EGFR×c-MET bispecific ADC, the most advanced in the most crowded next-generation ADC target pair.Open in Atlas onco.cc
TILT-123phase-2: TILT-123 is an oncolytic virus from TILT Biotherapeutics Ltd., in registered phase 2 trials for ovarian cancer.Open in Atlas onco.cc
Tinengotinibphase-3: A next-generation FGFR inhibitor designed to work after pemigatinib or futibatinib stop working, now in a global phase 3.Open in Atlas onco.cc
Tiragolumabnegative: An immune-brake blocker that looked excellent in a phase 2 lung cancer trial and then failed every phase 3.Open in Atlas onco.cc
Tisagenlecleucelapproved: Tisagenlecleucel was the first CAR-T therapy ever approved (2017), for children and young adults whose leukaemia had come back after everything else.Open in Atlas onco.cc
Tislelizumabapproved: A Chinese-developed PD-1 blocker, engineered to avoid a side-channel that may blunt other PD-1 drugs, now approved in the US and EU for oesophageal and stomach cancer.Open in Atlas onco.cc
Tisotumab vedotinapproved: Tisotumab vedotin is an ADC against tissue factor, the first to show a survival benefit in recurrent cervical cancer.Open in Atlas onco.cc
Tivozanibapproved: Tivozanib is a VEGF-receptor pill that hits VEGFR1 to 3 with little off-target kinase activity, so it is better tolerated than other anti-angiogenic pills, though hypertension and fatigue remain common. It is approved for kidney cancer after two or more pri...Open in Atlas onco.cc
TK216phase-2: TK216 was an attempt to hit the fusion protein that causes Ewing sarcoma directly, something long thought impossible for a transcription factor. In early trials with vincristine it produced a few responses but not enough to carry the drug forward.Open in Atlas onco.cc
TNG260phase-2: TNG260 is a small-molecule inhibitor from Tango Therapeutics, Inc., in registered phase 2 trials for non-small-cell lung cancer, small-cell lung cancer.Open in Atlas onco.cc
TNG456phase-2: TNG456 is an experimental small-molecule drug from Tango Therapeutics in phase 2 trials for non-small-cell lung cancer and glioma & glioblastoma, aimed at PRMT5 (MTAP-deleted cancers).Open in Atlas onco.cc
TNG462phase-2: TNG462 is an experimental small-molecule drug from Tango Therapeutics in phase 2 trials for pancreatic ductal adenocarcinoma and non-small-cell lung cancer, aimed at PRMT5 (MTAP-deleted cancers).Open in Atlas onco.cc
TNO155phase-2: TNO155 is a small-molecule inhibitor from Novartis Pharmaceuticals, in registered phase 2 trials for non-small-cell lung cancer, small-cell lung cancer.Open in Atlas onco.cc
Tocilizumabapproved: Tocilizumab (Actemra) is a rheumatoid arthritis antibody that has become the rescue drug for cytokine release syndrome, the fever and blood-pressure crash that CAR-T cells and bispecific antibodies can trigger. Every CAR-T centre must have it on hand.Open in Atlas onco.cc
Topotecanapproved: Topotecan is the long-standing second-line chemotherapy for relapsed small-cell lung cancer, and now the comparator that new drugs must beat.Open in Atlas onco.cc
Toremifeneapproved: Toremifene (Fareston) is a tamoxifen-like tablet for postmenopausal women with hormone-sensitive breast cancer that has spread.Open in Atlas onco.cc
Toripalimabapproved: A Chinese-developed PD-1 blocker that became the first immunotherapy approved in the US for nasopharyngeal cancer.Open in Atlas onco.cc
Tovecimigphase-3: Tovecimig is an experimental bispecific antibody from Compass Therapeutics in phase 3 trials for biliary tract cancer and bladder & urothelial cancer, aimed at VEGF / VEGFR.Open in Atlas onco.cc
Tovorafenibapproved: Tovorafenib is a pill for the most common childhood brain tumour, low-grade glioma driven by BRAF changes, approved in 2024.Open in Atlas onco.cc
TQ-B3234phase-3: TQ-B3234 is an experimental small-molecule drug from Chia Tai Tianqing Pharmaceutical in phase 3 trials for rare cancers of childhood, with its target not yet stated publicly.Open in Atlas onco.cc
TQB2102phase-3: TQB2102 is an experimental antibody-drug conjugate from Chia Tai Tianqing Pharmaceutical Nanjing Shunxin Pharmaceutical in phase 3 trials for HR-positive / HER2-negative breast cancer, HER2-positive breast cancer and biliary tract cancer, aimed at HER2.Open in Atlas onco.cc
TQB2450phase-3: TQB2450 is an experimental monoclonal antibody from Chia Tai Tianqing Pharmaceutical in phase 3 trials for renal cell carcinoma and non-small-cell lung cancer, aimed at PD-L1 and PD-1.Open in Atlas onco.cc
TQB2825phase-2: TQB2825 is an experimental bispecific antibody from Chia Tai Tianqing Pharmaceutical in phase 2 trials for diffuse large B-cell lymphoma, aimed at CD20 and CD3.Open in Atlas onco.cc
TQB2868phase-2: TQB2868 is a bispecific antibody from Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., in registered phase 2 trials for pancreatic ductal adenocarcinoma.Open in Atlas onco.cc
TQB2922phase-2: TQB2922 is an experimental bispecific antibody from Chia Tai Tianqing Pharmaceutical Nanjing Shunxin Pharmaceutical in phase 2 trials for colorectal cancer, aimed at EGFR and MET.Open in Atlas onco.cc
TQB2930phase-2: TQB2930 is an experimental bispecific antibody from Chia Tai Tianqing Pharmaceutical in phase 2 trials for HR-positive / HER2-negative breast cancer, aimed at HER2 and EGFR.Open in Atlas onco.cc
TQB3454phase-3: TQB3454 is an experimental small-molecule drug from Chia Tai Tianqing Pharmaceutical in phase 3 trials for biliary tract cancer, aimed at IDH1 / IDH2.Open in Atlas onco.cc
TQB3616phase-3: TQB3616 is an experimental small-molecule drug from Chia Tai Tianqing Pharmaceutical in phase 3 trials for HR-positive / HER2-negative breast cancer, aimed at CDK4/6.Open in Atlas onco.cc
TQB3702phase-2: TQB3702 is a small-molecule inhibitor from Chia Tai Tianqing Pharmaceutical Group Co., Ltd., in registered phase 2 trials for non-Hodgkin lymphoma.Open in Atlas onco.cc
TQB3909phase-2: TQB3909 is a small-molecule inhibitor from Chia Tai Tianqing Pharmaceutical Group Co., Ltd., in registered phase 2 trials for metastatic cancer.Open in Atlas onco.cc
TQB6411phase-2: TQB6411 is an experimental antibody-drug conjugate from Chia Tai Tianqing Pharmaceutical in phase 2 trials for non-small-cell lung cancer and oesophageal cancer, aimed at EGFR and MET.Open in Atlas onco.cc
Trabectedinapproved: A chemotherapy derived from a sea squirt, used with liposomal doxorubicin in relapsed ovarian cancer in Europe and for sarcomas.Open in Atlas onco.cc
Trabedersenphase-3: Trabedersen is an experimental investigational agent whose form is not stated in the registry from Oncotelic in phase 3 trials for pancreatic ductal adenocarcinoma, with its target not yet stated publicly.Open in Atlas onco.cc
Trametinibapproved: Trametinib (Mekinist) blocks MEK, the protein one step below BRAF in the growth-signal chain. Paired with dabrafenib it treats BRAF-mutant melanoma, lung, thyroid and other cancers, including brain tumours in children.Open in Atlas onco.cc
Transparaapproved: The breast screening AI tested in Sweden's MASAI trial, where AI-supported reading found more cancers and nearly halved the radiologists' workload.Open in Atlas onco.cc
Trastuzumabapproved: The first targeted antibody for a solid tumour (1998), which turned HER2-positive breast cancer from the worst subtype into one of the most treatable.Open in Atlas onco.cc
Trastuzumab biosimilarsapproved: Near-identical copies of Herceptin, approved since 2017, that cut the price of HER2 treatment and widened access worldwide.Open in Atlas onco.cc
Trastuzumab brengitecanphase-3: SystImmune's HER2 ADC, sharing its payload with iza-bren, now in a 1,450-patient trial to replace Kadcyla after surgery.Open in Atlas onco.cc
Trastuzumab deruxtecanapproved: Trastuzumab deruxtecan (Enhertu) is the most successful ADC ever. It redefined HER2 by working in tumours with only tiny amounts of the protein, and in 2026 moved into early-stage breast cancer.Open in Atlas onco.cc
Trastuzumab duocarmazinewithdrawn: A HER2 ADC with a DNA-alkylating payload that beat chemotherapy in a phase 3 trial yet never reached the market, because eye and lung toxicity and a stronger rival arrived first.Open in Atlas onco.cc
Trastuzumab emtansineapproved: Trastuzumab emtansine (Kadcyla, T-DM1) was the first ADC for a solid tumour (2013). It is still standard after surgery for HER2+ breast cancer patients whose tumour did not fully respond to pre-surgery treatment.Open in Atlas onco.cc
Trastuzumab pamirtecanphase-3: Trastuzumab pamirtecan is DualityBio and BioNTech's HER2 antibody-drug conjugate, in phase 3 trials in breast cancers with high and with modest HER2 expression and in HER2-expressing endometrial cancer.Open in Atlas onco.cc
Trastuzumab rezetecanapproved: Hengrui's HER2 ADC, approved in China for lung cancer and showing Enhertu-scale results in breast cancer, part of a wave of Chinese ADCs heading for global trials.Open in Atlas onco.cc
Tremelimumabapproved: Tremelimumab is AstraZeneca's CTLA-4 antibody, given as a single priming dose with durvalumab and chemotherapy in lung and liver cancer.Open in Atlas onco.cc
Treosulfanapproved: A conditioning chemotherapy given before donor stem-cell transplant in AML and MDS; it was long used in Europe and reached the US in 2025.Open in Atlas onco.cc
Tretinoin (all-trans retinoic acid, ATRA)approved: The vitamin-A derivative that made acute promyelocytic leukaemia the first cancer cured by differentiation therapy rather than by killing cells.Open in Atlas onco.cc
TRI-611phase-2: TRI-611 is an experimental protein degrader from TRIANA Biomedicines in phase 2 trials for non-small-cell lung cancer, aimed at ALK.Open in Atlas onco.cc
Trifluridine/tipiracilapproved: An oral chemotherapy pill for bowel cancer that has stopped responding to everything else; with bevacizumab it extends life by about three months.Open in Atlas onco.cc
Trilaciclibapproved: Trilaciclib is given as an infusion just before chemotherapy for small cell lung cancer to put the bone marrow's stem cells briefly to sleep, so fewer are killed and patients need fewer transfusions and growth factor injections.Open in Atlas onco.cc
Triptorelinapproved: Triptorelin (Trelstar) is a one-, three- or six-monthly injection that switches off testosterone production for men with advanced prostate cancer.Open in Atlas onco.cc
TRK-950phase-2: TRK-950 is an experimental investigational agent whose form is not stated in the registry from Toray Industries in phase 2 trials for gastric & gastro-oesophageal junction cancer and melanoma, aimed at NTRK.Open in Atlas onco.cc
TROP2 CAR/IL-15 cord-blood NK cellsphase-1: These experimental immune cells are designed to recognize TROP2 on cancer cells. Early trials are studying their safety and activity.Open in Atlas onco.cc
TruSight Oncology Comprehensiveapproved: A large gene panel hospitals can run themselves, approved by the FDA in 2024 as a companion diagnostic for the tumour-agnostic drug larotrectinib.Open in Atlas onco.cc
TST001phase-2: TST001 is a monoclonal antibody from Transcenta Therapeutics (Hangzhou) Co., Ltd., in registered phase 2 trials for metastatic cancer.Open in Atlas onco.cc
TST003phase-2: TST003 is a monoclonal antibody from Transcenta Therapeutics (Hangzhou) Co., Ltd., in registered phase 2 trials for colorectal cancer.Open in Atlas onco.cc
Tucatinibapproved: A HER2-selective pill that works in the brain, for HER2-positive breast cancer with brain metastases.Open in Atlas onco.cc
Tucidinostat (chidamide)approved: Chidamide, approved in 2014, was the first epigenetic cancer drug invented in China and the first oral drug of its kind anywhere, used for T-cell lymphoma and, with hormone therapy, for breast cancer.Open in Atlas onco.cc
Tunlametinibapproved: Tunlametinib is a Chinese MEK inhibitor approved in 2024 for advanced melanoma with an NRAS mutation, a group with no targeted therapy elsewhere in the world, and in phase 3 trials with vemurafenib for BRAF-mutant disease and for colorectal cancer.Open in Atlas onco.cc
Tusamitamab ravtansinewithdrawn: Tusamitamab ravtansine was Sanofi's ADC against the classic CEA tumour marker, stopped for futility in lung cancer in 2023.Open in Atlas onco.cc
Tuspetinibphase-2: Tuspetinib is an oral kinase inhibitor from Aptose Biosciences Inc., in registered phase 2 trials for myelodysplastic syndromes / neoplasms, chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms.Open in Atlas onco.cc
TY-9591phase-3: TY-9591 is an experimental small-molecule drug from TYK Medicines in phase 3 trials for non-small-cell lung cancer, with its target not yet stated publicly.Open in Atlas onco.cc
TYRA-300phase-2: TYRA-300 is an experimental small-molecule drug from Tyra Biosciences in phase 2 trials for bladder & urothelial cancer, aimed at FGFR2.Open in Atlas onco.cc

U

Ubamatamabphase-2: Ubamatamab (REGN4018) is Regeneron's investigational MUC16×CD3 bispecific antibody, in phase 1/2 and phase 2 trials for ovarian and endometrial cancer.Open in Atlas onco.cc
UCART22phase-2: UCART22 is an experimental allogeneic CAR T-cell therapy from Cellectis S.A. in phase 2 trials for acute lymphoblastic leukaemia, aimed at CD22.Open in Atlas onco.cc
UGN-103phase-3: UGN-103 is an experimental chemotherapy (mitomycin) delivered via hydrogel from UroGen Pharma in phase 3 trials for bladder & urothelial cancer, with its target not yet stated publicly.Open in Atlas onco.cc
UGN-104phase-3: UGN-104 is an experimental chemotherapy (mitomycin) delivered via hydrogel from UroGen Pharma in phase 3 trials for bladder & urothelial cancer, with its target not yet stated publicly.Open in Atlas onco.cc
Uliledlimabphase-3: Uliledlimab is an experimental investigational agent whose form is not stated in the registry from TJ Biopharma in phase 3 trials for non-small-cell lung cancer, with its target not yet stated publicly.Open in Atlas onco.cc
Umbralisibwithdrawn: A PI3K inhibitor for marginal zone and follicular lymphoma approved in 2021 and withdrawn in 2022 after the UNITY-CLL trial suggested more deaths.Open in Atlas onco.cc
Upifitamab rilsodotinphase-2: Upifitamab rilsodotin is an antibody-drug conjugate from Mersana Therapeutics, in registered phase 2 trials for ovarian cancer, non-small-cell lung cancer.Open in Atlas onco.cc
Uracil mustardhistoric: Uracil mustard was an oral alkylating agent approved in 1962 for chronic lymphocytic leukaemia and lymphomas, one of the early nitrogen mustard tablets, and long since discontinued.Open in Atlas onco.cc
Uridine triacetateapproved: Uridine triacetate (Vistogard) is an oral antidote for fluorouracil or capecitabine overdose, or for dangerously early severe toxicity from these drugs, and must be started within four days of the chemotherapy.Open in Atlas onco.cc
UroVysion Bladder Cancer Kitapproved: A urine test that looks for chromosome changes in shed bladder cells, approved for people with blood in the urine and for follow-up after bladder cancer.Open in Atlas onco.cc
Utideloneapproved: Utidelone is Biostar Pharmaceuticals' epothilone chemotherapy, approved in China in 2021 with capecitabine for advanced breast cancer after anthracyclines and taxanes.Open in Atlas onco.cc
Utomilumabphase-3: Utomilumab is a monoclonal antibody from Pfizer, in registered phase 3 trials for ovarian cancer.Open in Atlas onco.cc

V

Vactosertibphase-2: Vactosertib is an oral serine/threonine kinase inhibitor from MedPacto, Inc., in registered phase 2 trials for osteosarcoma.Open in Atlas onco.cc
Valrubicinapproved: Valrubicin (Valstar) is a chemotherapy washed into the bladder for carcinoma in situ that has not responded to BCG, in patients who cannot yet have their bladder removed.Open in Atlas onco.cc
Vandetanibapproved: Vandetanib was the first drug approved for medullary thyroid cancer (2011), now largely replaced by RET-selective selpercatinib.Open in Atlas onco.cc
Varegacestatphase-3: Varegacestat is an experimental small-molecule drug from Immunome in phase 3 trials for desmoid tumour, with its target not yet stated publicly.Open in Atlas onco.cc
Varlitinibhistoric: A pill that blocked the HER family of growth receptors, tested with capecitabine as second-line treatment for bile duct and gallbladder cancer. It did not beat capecitabine alone in the TreeTopp trial and development stopped.Open in Atlas onco.cc
Varnimcabtagene autoleucelapproved: India's second approved CAR-T therapy, a Bengaluru-made version of a Spanish hospital's academic CD19 cell therapy, for lymphoma that has come back after other treatments.Open in Atlas onco.cc
VB15010phase-2: VB15010 is an experimental pill targeting the PARP1 DNA-repair enzyme.Open in Atlas onco.cc
VBC103phase-1: VBC103 is an experimental drug designed to recognize two proteins on cancer cells. Its early trial is testing safety and activity.Open in Atlas onco.cc
VC004phase-3: VC004 is an experimental small-molecule drug from Jiangsu vcare pharmaceutical technology co. in phase 3 trials, with its target not yet stated publicly.Open in Atlas onco.cc
Vebreltinibapproved: Vebreltinib is a Chinese MET inhibitor approved in 2023 for lung cancers with a MET exon 14 skipping mutation, and the first drug tested in a phase 3 trial for glioblastomas carrying a PTPRZ1-MET fusion.Open in Atlas onco.cc
Veliparibnegative: Veliparib is a PARP inhibitor that AbbVie tested with chemotherapy in breast cancer. It added nothing to carboplatin before surgery (BrighTNess) and lengthened progression-free but not overall survival with carboplatin and paclitaxel in inherited BRCA advan...Open in Atlas onco.cc
Velzatinibphase-3: Velzatinib is an experimental investigational agent whose form is not stated in the registry from GlaxoSmithKline in phase 3 trials for gastrointestinal stromal tumour, with its target not yet stated publicly.Open in Atlas onco.cc
Vemurafenibapproved: Vemurafenib was the first BRAF inhibitor (2011); it shrank melanomas in weeks and proved that a single mutation could be drugged in a solid tumour.Open in Atlas onco.cc
Venetoclaxapproved: A pill that removes the survival shield from leukaemia cells, enabling chemotherapy-free, time-limited treatment for CLL.Open in Atlas onco.cc
VENTANA MMR RxDx Panelapproved: A four-stain test that shows whether a womb cancer has lost its DNA spell-checker, which makes immunotherapy likely to work.Open in Atlas onco.cc
VENTANA PD-L1 (SP142) Assayapproved: The PD-L1 stain that decides who can have atezolizumab, scored on immune cells rather than tumour cells in breast cancer.Open in Atlas onco.cc
VENTANA PD-L1 (SP263) Assayapproved: The VENTANA SP263 assay is an immunohistochemistry stain that measures PD-L1 on tumour cells. Approved in 2017 alongside durvalumab in bladder cancer, it became the companion test in 2021 for adjuvant atezolizumab in resected lung cancer with PD-L1 on at le...Open in Atlas onco.cc
Vepdegestrantapproved: Vepdegestrant is the first PROTAC ever approved (2026): a pill that tags the oestrogen receptor for destruction, for breast cancers with ESR1 mutations.Open in Atlas onco.cc
Vepugratinibphase-3: Vepugratinib is an experimental small-molecule drug from Eli Lilly and in phase 3 trials for bladder & urothelial cancer, with its target not yet stated publicly.Open in Atlas onco.cc
Vibostolimabphase-2: Vibostolimab is a monoclonal antibody from Merck Sharp & Dohme LLC, in registered phase 2 trials for non-small-cell lung cancer.Open in Atlas onco.cc
Vimseltinibapproved: Vimseltinib is a pill approved in February 2025 for tenosynovial giant cell tumour, a benign but destructive joint tumour, offering an alternative to repeated surgery.Open in Atlas onco.cc
Vinblastineapproved: Vinblastine is the vinca alkaloid in ABVD, the standard Hodgkin lymphoma regimen, and was formerly in the cisplatin combinations that first cured testicular cancer.Open in Atlas onco.cc
Vincristineapproved: A plant-derived chemotherapy from the Madagascar periwinkle that has been in almost every childhood leukaemia and lymphoma regimen since the 1960s.Open in Atlas onco.cc
Vindesineestablished: Vindesine is a vinca alkaloid, a semi-synthetic relative of vinblastine, used in Europe and elsewhere for acute lymphoblastic leukaemia and some solid tumours; it was never marketed in the United States.Open in Atlas onco.cc
Vinflunineapproved: Vinflunine (Javlor) is a chemotherapy infusion used in Europe as a second treatment for advanced bladder cancer after platinum chemotherapy has stopped working.Open in Atlas onco.cc
Vinorelbineapproved: Vinorelbine is a vinca chemotherapy for lung and breast cancer, available orally, and is now part of maintenance therapy that improved survival in childhood rhabdomyosarcoma.Open in Atlas onco.cc
Vismodegibapproved: Vismodegib was the first hedgehog-pathway drug, for basal cell carcinomas too advanced for surgery; it shrinks most tumours but muscle cramps, taste loss and hair loss make long-term use hard.Open in Atlas onco.cc
Vistusertibphase-2: Vistusertib is an oral serine/threonine kinase inhibitor from AstraZeneca, in registered phase 2 trials for non-small-cell lung cancer, small-cell lung cancer.Open in Atlas onco.cc
Visugromabphase-3: Visugromab is CatalYm's antibody against GDF-15, a tumour-made signal that both blocks immune cells and causes cancer wasting; it is in a phase 3 trial with PD-1 blockade after durable responses in patients whose cancers had stopped responding to checkpoint...Open in Atlas onco.cc
Vorasidenibapproved: The first targeted therapy for low-grade brain tumours, delaying the need for radiation and chemotherapy by years.Open in Atlas onco.cc
Vorinostatapproved: Vorinostat (Zolinza) was the first drug of its kind, a capsule that loosens the chemical packaging of DNA. It treats the skin disease of cutaneous T-cell lymphoma after two other treatments have failed.Open in Atlas onco.cc
Vorolanibapproved: Vorolanib is Betta Pharmaceuticals' oral VEGFR and PDGFR inhibitor, approved in China in 2023 with everolimus for advanced kidney cancer after a first kinase inhibitor has failed.Open in Atlas onco.cc
VRN110755phase-2: VRN110755 is an experimental small-molecule drug from Voronoi in phase 2 trials for non-small-cell lung cancer, aimed at EGFR.Open in Atlas onco.cc
VS-7375phase-2: VS-7375 is an experimental small-molecule drug from Verastem in phase 2 trials for pancreatic ductal adenocarcinoma, non-small-cell lung cancer and colorectal cancer, aimed at KRAS.Open in Atlas onco.cc
Vudalimabphase-2: Vudalimab is a bispecific antibody from Xencor, Inc., in registered phase 2 trials for ovarian cancer, endometrial cancer, cervical cancer.Open in Atlas onco.cc
Vusolimogene oderparepvecapproved: Vusolimogene oderparepvec is an engineered herpes virus injected into melanoma tumours, approved in August 2026 with nivolumab after immunotherapy failure.Open in Atlas onco.cc

W

WJB001phase-2: WJB001 is a small-molecule inhibitor from Wigen Biomedicine Technology (Shanghai) Co., Ltd., in registered phase 2 trials for metastatic cancer.Open in Atlas onco.cc

X

Xaluritamigphase-3: Xaluritamig is Amgen's T-cell engager for prostate cancer, now in two phase 3 trials, aiming to do for prostate cancer what tarlatamab did for small-cell lung cancer.Open in Atlas onco.cc
Xevinapantnegative: Xevinapant was a tablet meant to make head and neck cancer cells easier to kill with chemoradiation by removing the proteins that stop them dying. A promising mid-stage trial was followed by a phase 3 that was stopped in 2024 because it was not working.Open in Atlas onco.cc
XNW27011phase-2: XNW27011 is an experimental antibody-drug conjugate from Astellas Pharma Global Development in phase 2 trials for pancreatic ductal adenocarcinoma, non-small-cell lung cancer and ovarian cancer, aimed at Claudin 18.2.Open in Atlas onco.cc
XNW5004phase-2: XNW5004 is an experimental small-molecule drug from Evopoint Biosciences in phase 2 trials for follicular lymphoma and prostate cancer, aimed at EZH2.Open in Atlas onco.cc
XZP-3287phase-3: XZP-3287 is an experimental small-molecule drug from Sihuan Pharmaceutical in phase 3 trials for HR-positive / HER2-negative breast cancer, with its target not yet stated publicly.Open in Atlas onco.cc

Y

YL201phase-3: YL201 is an experimental antibody-drug conjugate from MediLink Therapeutics (Suzhou) in phase 3 trials for nasopharyngeal carcinoma, non-small-cell lung cancer and small-cell lung cancer, aimed at B7-H3.Open in Atlas onco.cc
YL202phase-3: YL202 is an experimental antibody-drug conjugate (ADC) from MediLink Therapeutics (Suzhou) in phase 3 trials for non-small-cell lung cancer, HR-positive / HER2-negative breast cancer and colorectal cancer, aimed at HER3.Open in Atlas onco.cc

Z

Zalifrelimabphase-2: Zalifrelimab is a monoclonal antibody from Nelum Corp, in registered phase 2 trials for pancreatic ductal adenocarcinoma.Open in Atlas onco.cc
Zamtocabtagene autoleucelphase-2: Zamtocabtagene autoleucel is an experimental CAR-T cell therapy from Miltenyi Biomedicine in phase 2 trials for diffuse large B-cell lymphoma, primary CNS lymphoma and mantle cell lymphoma, aimed at CD19 and CD20.Open in Atlas onco.cc
Zanidatamabapproved: Zanidatamab (Ziihera) is an antibody that grabs HER2 at two different spots, approved for HER2+ bile duct cancer.Open in Atlas onco.cc
Zanidatamab zovodotinphase-1: Zanidatamab zovodotin joined the two-armed HER2 antibody zanidatamab to a cell-killing payload. It was tested in early trials in HER2-expressing cancers; the plain antibody went on to approval, the conjugate did not progress beyond phase 1.Open in Atlas onco.cc
Zanubrutinibapproved: Zanubrutinib is the only BTK blocker to beat ibrutinib on both efficacy and safety in a head-to-head trial. It is now the most prescribed BTK inhibitor in CLL.Open in Atlas onco.cc
Zanzalintinibphase-3: Zanzalintinib is an experimental small-molecule drug from Exelixis in phase 3 trials for neuroendocrine tumours, head and neck squamous cell carcinoma and renal cell carcinoma, aimed at VEGF / VEGFR and MET.Open in Atlas onco.cc
Zelenectide pevedotinphase-2: A tiny peptide instead of an antibody carries the same payload as Padcev to Nectin-4, with far less rash and neuropathy in early data, but its developer stepped back in 2026.Open in Atlas onco.cc
ZEN-3694phase-2: ZEN-3694 is a BET inhibitor from Zenith Epigenetics being tested in NUT carcinoma, where the cancer's driving fusion is itself a BET protein, and in prostate and breast cancers.Open in Atlas onco.cc
Zenocutuzumabapproved: Zenocutuzumab is the first drug for cancers driven by NRG1 gene fusions, working by blocking HER3 from receiving its growth signal.Open in Atlas onco.cc
Zevorcabtagene autoleucelapproved: Zevor-cel is CARsgen's myeloma CAR-T, approved in China in 2024 for patients whose disease has come back after three or more treatments.Open in Atlas onco.cc
ZG006phase-3: ZG006 is an experimental investigational agent whose form is not stated in the registry from Suzhou Zelgen Biopharmaceuticals in phase 3 trials for non-small-cell lung cancer and neuroendocrine tumours, with its target not yet stated publicly.Open in Atlas onco.cc
Zibotentanwithdrawn: A drug blocking a signal that prostate cancer uses to grow in bone. Three trials in prostate cancer found no survival benefit and it was dropped.Open in Atlas onco.cc
Zidesamtinibapproved: A ROS1 inhibitor approved in July 2026 that works after other ROS1 drugs fail and avoids their brain side effects.Open in Atlas onco.cc
Ziftomenibapproved: Ziftomenib is the second menin inhibitor for leukaemia, approved in November 2025 as a once-daily pill for relapsed NPM1-mutated AML.Open in Atlas onco.cc
Zilovertamab vedotinphase-3: Zilovertamab vedotin is a ROR1-directed ADC in phase 3 for large B-cell lymphoma.Open in Atlas onco.cc
Zimberelimabapproved: Zimberelimab is a PD-1 antibody approved in China in 2021 for relapsed classical Hodgkin lymphoma, and the checkpoint partner in Arcus and Gilead's Western trials of the TIGIT antibody domvanalimab.Open in Atlas onco.cc
Zipalertinibphase-3: Zipalertinib is an experimental small-molecule drug from Taiho Oncology in phase 3 trials for non-small-cell lung cancer, aimed at EGFR.Open in Atlas onco.cc
Zirconium-89 girentuximabphase-3: Zirconium-89 girentuximab is Telix's PET scan that tells whether a kidney mass is clear cell renal cell carcinoma without a biopsy; the phase 3 ZIRCON trial met its endpoints in 2023 and the product is under regulatory review.Open in Atlas onco.cc
Ziv-afliberceptapproved: Ziv-aflibercept (Zaltrap) is a decoy receptor that soaks up the blood-vessel growth signal VEGF. It is added to the FOLFIRI chemotherapy combination for bowel cancer that has spread and progressed after oxaliplatin.Open in Atlas onco.cc
ZL-1310phase-3: ZL-1310 is an experimental antibody-drug conjugate from Zai Lab (Shanghai) in phase 3 trials for non-small-cell lung cancer, aimed at DLL3.Open in Atlas onco.cc
Zolbetuximabapproved: Zolbetuximab is the first drug against Claudin 18.2, a protein exposed on stomach cancer cells. Added to chemotherapy it extends survival by two to three months; nausea is the price.Open in Atlas onco.cc
Zoldonrasibphase-2: The first drug aimed specifically at KRAS G12D, the single most common mutation in pancreatic cancer. Early combination data in 2026 showed half of previously treated patients responding.Open in Atlas onco.cc
Zoledronic acidapproved: Zoledronic acid (Zometa) is a fifteen-minute infusion given every few weeks or months to strengthen bone and prevent fractures, spinal cord compression and the need for radiotherapy in people with myeloma or cancer that has spread to bone; it also treats da...Open in Atlas onco.cc
Zongertinibapproved: Zongertinib was the first oral HER2 inhibitor for lung cancer with HER2 mutations, approved in 2025 and moved to first line in 2026.Open in Atlas onco.cc
Zovegalisibphase-3: Zovegalisib is an experimental small-molecule drug from Relay Therapeutics in phase 3 trials for HR-positive / HER2-negative breast cancer, aimed at PIK3CA / PI3K-alpha.Open in Atlas onco.cc

#

131I-MIBG (iobenguane I-131) therapyestablished: High-dose radioactive MIBG delivers radiation from inside neuroblastoma cells that take up noradrenaline; used for relapsed disease and tested in upfront therapy. A branded high-specific-activity form, Azedra, was approved for phaeochromocytoma and paragang...Open in Atlas onco.cc
177Lu-edotreotidephase-3: A second lutetium radioligand for neuroendocrine tumours that beat the standard pill everolimus in a head-to-head trial and is awaiting an FDA decision.Open in Atlas onco.cc
177Lu-PSMA-I&Tphase-3: 177Lu-PSMA-I&T is a second PSMA radioligand, chemically different from Pluvicto, that has passed two phase 3 trials on progression but has not yet shown a survival benefit.Open in Atlas onco.cc
212Pb-DOTAMTATEphase-2: An alpha-particle version of neuroendocrine radioligand therapy that produced responses in over half of patients who had never had PRRT, with FDA Breakthrough designation.Open in Atlas onco.cc
5-Aminolevulinic acid (oral, for glioma surgery)approved: A drink taken before brain surgery that makes high-grade glioma glow under blue light, letting surgeons remove more tumour safely.Open in Atlas onco.cc
9MW2921phase-1: 9MW2921 is an experimental antibody-drug conjugate being studied in people with advanced cancer. Its benefit and safety are still being evaluated.Open in Atlas onco.cc